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Summary 
 
INTRODUCTION: The conventional treatment of cancer includes surgery, radiotherapy and 
chemotherapy alone or in combination. These treatment modalities are often accompanied 
with severe side effects and repeated treatments may significantly reduce quality of life. 
Photodynamic therapy (PDT) is commonly known as a treatment modality for skin disorders. 
Today, PDT has been approved for a broad spectrum of applications, such as the diagnosis of 
neoplastic lesions during surgery, the treatment of age related wet macular degeneration, as 
well as the treatment of various superficial cancer types.  
In this present work PDT effects mediated by two very potent photosensitizers, a liposomal 
mTHPC derivative (Foslipos®), the most powerful natural occurring photosensitizer hypericin 
and especially their 1:1 mixture in-vitro were examined. Different cell models were used to 
elucidate the photosensitizers- and PDT-mediated cellular effects. 
 
MATERIALS AND METHODS: Three different cell lines were used for this study: prostate 
carcinoma cell line PC-3, and the two head and neck squamous cell carcinoma cell lines 
UMB-SCC 745 and UMB-SCC 969. The physico-chemical properties of photosensitizers 
alone, and particularly in the mixture, were examined with different approaches. Furthermore 
uptake, distribution and intracellular localization of photosensitizers were examined with help 
of confocal microscopy. Photosensitizer-mediated cell viability in the dark and after 
illumination was monitored with cell viability assays. Morphological changes and death 
pathways were monitored with wide-field and confocal microscopy. In addition, DNA- and 
RNA damage was examined. Gene expression changes after PDT were followed by rtPCR 
(array systems or specific gene observations).  
 
RESULTS: The examination of photosensitizer physico-chemical properties correlated to the 
values found in the literature except for the singlet oxygen yield for hypericin which was 
found to be slightly lower as previously reported. Their combination in solution does not 
show any interaction effects aside from some prolonged photobleaching kinetics. ROS 
measurements after PDT indicated that hypericin and photosensitizer mixture treated cells 
accumulated the fluorescent CM-H2DCFDA dye while Foslipos® treated cells displayed some 
fluorescence, but only in the beginning. The observations made on photosensitizer uptake, 
distribution and localization showed that Foslipos® intracellular accumulation was continuous 
over 24 hours and was localised mainly in the cell cytoplasm, while hypericin achieved its 
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maximum after five hours of incubation with localization preferably in cellular membranes 
and perinuclearly. Total clearance of Foslipos® was not reached after 24 hours while 
intracellular hypericin remains after 24 hours were minimal. Photosensitizer mixture showed 
similar results as reported for single photosensitizer applications. The cell viability in the dark 
in photosensitizer mixture treated cells was not affected while Foslipos® and hypericin treated 
cells showed some dark toxicity for certain concentrations. Cell viability after illumination 
was highly decreased for all three cell lines and all applied photosensitizer applications. PDT 
induced processes had different kinetics and cell death outcomes dependent on cell lines and 
treatment protocols. Foslipos® treated cells displayed a necrotic, hypericin treated cells more 
apoptotic death outcome while photosensitizer mixture displayed features of both. 
Photosensitizer influence on molecular mechanisms showed DNA- and RNA damage in the 
dark and after illumination depending on cell line and applied photosensitizer. Changes in 
gene expression patterns in particular a high up-regulation of heat shock genes were detected 
for all cell lines used.  
 
CONCLUSIONS: Our study documents a highly responsiveness of the cell models used on 
PDT and it indicates an improvement of PDT effects if photosensitizer mixtures are applied. 
These results are the first emphasizing advantages of this simple but innovative PDT 
approach.  
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Zusammenfassung 
 
EINLEITUNG: Die konventionelle Krebstherapie umfasst Chirurgie, Radio- und 
Chemotherapie. Diese Behandlungsmethoden sind sehr oft von schwerwiegenden 
Nebenwirkungen begleitet, welche grossen Einfluss auf die Lebensqualität der behandelten 
Personen ausüben können. Die photodynamische Therapie (PDT) ist seit geraumer Zeit als 
Therapie für Hauterkrankungen bekannt. Sie ist heutzutage für ein breites Spektrum von 
medizinischen Anwendungen zugelassen, wie beispielsweise für die Diagnose von 
neoplastischen Läsionen während chirurgischen Eingriffen, Behandlung altersbedingter 
Makuladegeneration, sowie die Behandlung verschiedener oberflächlicher Krebsarten. 
In der vorliegenden Arbeit wurden in-vitro PDT Effekte untersucht, induziert durch zwei sehr 
starke Photosensitizer, zum Einen durch das liposomale mTHPC Derivat Foslipos®, zum 
Anderen den stärksten natürlich vorkommenden Photosensitizer Hypericin – jeweils einzeln 
und in einer 1:1-Kombination. Wir haben verschiedene Zellmodelle verwendet, um die 
Photosensitizer sowie der PDT induzierten Zelleffekte zu analysieren.  
 
MATERIALIEN AND METHODEN: In unserer Studie wurden drei verschiedene 
Zelllinien verwendet: die Prostatakarzinom Zelllinie PC-3 sowie zwei Plattenepithelkarzinom 
Zelllinien aus dem Kopf- und Halsbereich (UMB-SCC 745 und UMB-SCC 969). Die 
physikalisch-chemischen Eigenschaften der Photosensitizer wurden mit unterschiedlichen 
Methoden untersucht. Insbesondere die Eigenschaften betreffend ihrer Kombination waren 
von grossem Interesse. Zusätzlich haben wir die intrazelluläre Aufnahme, Distribution und die 
Lokalisation der jeweiligen Photosensitizer mittels konfokaler Mikroskopie untersucht. Die 
Zellviabilität wurde in Dunkelheit und nach Beleuchtung untersucht. Ebenso die 
morphologischen Veränderungen und der damit verbundene Zelltod wurden eingehend 
erläutert. Die DNA- und RNA-Schädigung sowie die Veränderung der Genexpression wurden 
mittels Arraysystemen oder durch die Untersuchung spezifischer Gene analysiert.  
 
RESULTATE: Die Untersuchungsresultate der physikalisch-chemischen Eigenschaften der 
Photosensitizer entsprachen den in der Fachliteratur aufgeführten Werten. Einzig die 
Ausbeute des Singulett-Sauerstoffs für Hypericin war etwas tiefer als von anderen 
Forschungsgruppen berichtet. Die beiden Photosensitizer in Kombination zeigten, ausser der 
etwas verlangsamten Photobleaching Kinetik, keine auffälligen Wechselwirkungen. ROS 
Messungen nach PDT zeigten, dass die Zellen, die mit Hypericin und Photosensitizer in 
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Kombination behandelt wurden, die fluoreszente Form des CM-H2DCFDA akkumulierten, 
während Foslipos® kein solches Verhalten aufzeigte. Die Studien betreffend Aufnahme, 
Verteilung und Lokalisation der Photosensitizer zeigten, dass die intrazelluläre Akkumulation 
mit Foslipos® über 24 Stunden kontinuierlich war und dessen Lokalisation sich auf das 
Zellzytoplasma beschränkte, ohne eine eindeutige Kolokalisation mit Zellorganellen 
aufzuweisen. Hypericin dagegen erreichte sein Akkumulationsmaximum nach 5 Stunden und 
wurde in Membransystemen, wie auch peri-nuklear aufgefunden. Die gesamte Beseitigung 
des Foslipos® wurde nicht nach 24 Sunden erreicht, während interzelluläre Hypericin-
Rückstände auf ein Minimum reduziert wurden. Die Photosensitizer in Kombination zeigten 
ähnliche Resultate wie die Einzelsubstanzen. Die Behandlung mit Photosensitizer in 
Kombination ohne Beleuchtung hatte keinen Einfluss auf die Zellviabilität, während mit 
Foslipos® und Hypericin behandelte Zellen eine Toxizität für gewisse Konzentrationen 
aufwiesen. Die Beleuchtung der Zellen in Abhängigkeit der angewendeten Photosensitizer 
führte zu einer signifikant tieferen Zellviabilität. Die PDT-induzierten Prozesse wiesen 
verschiedene Kinetiken und Zelltodwege auf, welche stark mit Zellmodellen und 
Behandlungsprotokollen zusammenhängen. Mit Foslipos® behandelte Zellen hatten 
nekrotische Eigenschaften, mit Hypericin behandelte Zellen die eines apoptotischen Zelltods. 
Die Behandlung mit den Photosensitizern in Kombination wiesen die Eigenschaften der 
Nekrose und Apoptose auf. Einfluss der Photosensitizer auf die molekularen Mechanismen 
zeigten DNA- und RNA- Schädigung auch ohne Beleuchtung auf. Auch hier war das 
Ausmass abhängig vom Zellmodell und der verwendeten Photosensitizer. Der Effekt war 
stärker und ausgeprägter nach der Photodynamischen Therapie. Veränderungen in 
Genexpressionen, insbesondere heat shock Gene, konnten für alle Zellmodelle nachgewiesen 
werden.  
 
SCHLUSSFOLGERUNGEN: Unsere Studie belegt eine signifikante Empfindlichkeit 
verschiedener Zellmodelle auf PDT und deutet auf verbesserte PDT-Effekte bei der 
Anwendung der Photosensitizer in Kombination hin. Diese Resultate sind die Ersten, welche 
die Vorteile dieser simplen aber innovativen Behandlungsmethode hervorheben. 
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Aims and rational of the thesis 
 
Photodynamic therapy (PDT) is a recognised therapeutic strategy known for over a 
hundred years. It is used in different medical areas and it is well suitable for superficial skin 
disorders and age related macular degeneration. The modern age of PDT treatment has begun 
in 1903 with the first clinical application on basal cell carcinoma. Since then many studies on 
PDT-mediated cancer treatment have been performed. Additionally, new potent 
photosensitizers and optimised light devices have been developed. The relatively simple mode 
of PDT action - a short administration of photoactive substance, illumination with the 
appropriate wavelength and singlet oxygen and reactive oxygen species – mediated tumour 
destruction - makes this treatment very attractive for therapy of any cancer type, as long as the 
tumour does not exceed a certain size and has good accessibility. Tumour cells, when 
compared to normal cells, display higher photosensitizer uptake rates and, with illumination 
restricted to the desired area, tumour destruction with low side effects is achievable. 
The aim of this thesis was to test the applicability of Foslipos® and later hypericin and a 
1:1 mixture of both photosensitizers on three different cancer cell lines (see chapters 2-4).  
In the initial study (see chapter 2) the effects of novel second generation photosensitizer 
Foslipos® on prostate carcinoma cell line PC-3 were explored. The focus was on uptake 
kinetics and subsequent changes on DNA and RNA levels after PDT treatment.  
When studying the PC-3 cell line, further questions were raised, leading to the inclusion 
of two different HNSCC cell lines into the study. Additionally, the study of Schneider-Yin 
showed very interesting and promising results in optimization of PDT. The PDT effects 
resulted from treatment with combined photosensitizers. In the case of the above mentioned 
study, hypericin and 5-ALA showed a higher protoporphyrin IX (PpIX) production when 
compared to treatment with 5-ALA alone. Based on this knowledge, the questions of 
Foslipos®, hypericin and their 1:1 mixture uptake as well as distribution kinetics, localization 
and influence of photosensitizing agents in the dark were explored, as is shown in chapter 3. 
Chapter 4 is devoted to the prosecution of the study of HNSCC. In this chapter the focus is on 
PDT effects of applied photosensitizers and their mixture. The questions were related to 
singlet oxygen production, cell death mechanisms and PDT efficiency. In the chapter 5 the 
most important results were discussed. 
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In chapter 6 the establishment of three dimensional HNSCC cell culture protocols is 
described. This is the basis for further PDT investigations in multi-cellular and more complex 
systems which are closer to the morphological situation in vivo.  
Close collaboration with clinicians from the Cranio-Maxillo-Facial and the Oral surgery 
department of the University Hospital of Zurich encouraged us to expand PDT treatment on 
oral pathogens to treat local infections in oral region. Thus, in chapter 7 additional published 
studies performed as a part of the above mentioned work, including not only treatment of oral 
pathogens but also the development of novel silica carrier systems for photosensitizer 
encapsulation, are described.  
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1. General Introduction 
 
1.1 Photodynamic Therapy 
 
General information: Photodynamic therapy (PDT) was already known to the ancient 
Indians, Greeks, Incas, Mayas and Egyptians as a medication for skin disorders [1, 2]. This so 
called heliotherapy was used to treat psoriasis and vitiligo with psoralen-containing plant 
extracts [3]. Rebirth of modern PDT begun last century with Oscar Raab, one of the von 
Tappeiner’s medical students who observed that acridines showed toxic properties towards 
the protozoan paramecium if combined with illumination [4]. However, the first clinical PDT 
application was described by von Tappeiner and Jesionek in 1903 [5]. They applied eosin 
topically as a remedy for basal cell carcinoma. They were the first explaining dynamic 
interactions between light, photosensitizing agent and molecular oxygen which resulted in 
tissue destruction [6]. A few years later in 1913, Friedrich Meyer-Betz conducted a self-
experiment and adminstred 200 mg of hematoporphyrin (HpD) intravenously [7]. More than 
two months he suffered from extreme photosensitivity (fig. 1). 
 
 
 
Figure 1: Friedrich Meyer-Betz after intravenous injection of 200 mg of hematophophyrin and light exposure 
[8].  
 
 11
___________________________________________________________________________ General Introduction 
Sixty years later Dougherty et al. used HpD derivatives to treat different cutaneous diseases. 
HpD was chromatographically purified by Dougherty’s group to Photofrin, which is still the 
most widely used clinical PDT photosensitizer. For more information on detailed historical 
data refer to the table below from the review of Allison et al [9]. 
 
 
 
Table 1: A short overview of milestones in the development of PDT and photodiagnosis (PD). Table from [9]. 
 
Nowadays, there are many PDT application areas with novel photosensitizers and light 
sources being developed. Some of the photosensitizers are already clinically approved, others 
are still under investigation. Currently, PDT is food and drug administration (FDA) approved 
for treatment of different skin disorders such as actinic keratosis or acne vulgaris [10]. 
Further, one of the largest patient cohort belongs to treatment of age related wet macular 
degeneration [11]. Additionally, PDT is used for pre-cancerous diseases such as “Barrett’s 
Esophagus” and various cancer types e.g. advanced stage esophageal tumours, bladder cancer, 
prostate cancer, lung cancer or palliative treatment of head and neck cancers or as adjuvant 
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therapy for brain tumours [12-14]. In addition to skin disorders and cancer treatments PDT 
has shown very promising results in treatment of microorganisms such as antibiotic-resistant 
strains of methicillin-resistant Staphylococcus aureus (MRSA) [15] or oral pathogens such as 
Candida albicans or Streptotcoccus mutans and S. sobrinus [16]. 
Mechanisms of Action: PDT involves three per se non toxic key components: a 
photosensitizer, light (visible light or light with an appropriate wavelength) and molecular 
oxygen. In a simplified scheme (fig. 2) after photosensitizer administration, followed by its 
distribution and photosensitizer accumulation in the tumour, the desired area is illuminated 
with light of the appropriate wavelength resulting in production of singlet oxygen and other 
reactive oxygen species (ROS) subsequently leading to cellular and vascular damage and cell 
death.  
 
 
Figure 2: Schematic view of principles of PDT in cancer treatment. Photosensitizer administration occurs 
systemically or topically. After a period of the time systemic photosensitizer is distributed in the whole body 
with selective accumulation in dysplasia or tumours. Irradiation triggers a photochemical reaction resulting in 
production of singlet oxygen and other reactive species leading to irreparable cellular damage and cell death 
[14].  
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The processes behind PDT are called photochemical reactions or photosensitizations. 
Generally, the photosensitization is divided in to two major pathways: Type I and Type II 
reactions (fig.3).  
 
 
Figure 3: Schematic overview of photosensitization. IC: internal conversion, ISC: intersystem crossing, hν: 
electromagnetic energy, 1Psen: singlet photosensitizer in ground state, 1Psen*: singlet excited photosensitizer, 1Psen*-
: photosensitizer radical anion, substrate*+: substrate radical cations. 
 
The Type I reaction is characterised by the production of two types radicals, photosensitizer 
and substrate radicals. The substrate can transfer either an electron or a hydrogen atom to the 
excited state of the photosensitizer producing a photosensitizer°- radical anion and substrate°+ 
cations or free radicals (photosensitizer° and substrate°). Further, the radicals can react with 
oxygen or biomolecules generating a complex mixture of intermediates, which can be 
cytotoxic but which also can initiate a cascade of cytotoxic free processes as well. Type I 
reactions can additionally lead to formation of photosensitizer photoproducts (true 
photobleaching) which can be cytotoxic [17]. In Type II reactions excited photosensitizers 
transfer their energy via intersystem crossing (ISC) to long living triplet state photosensitizers 
and finally to molecular oxygen or other biomolecules such as electron-rich compounds, e.g. 
unsaturated fatty acids. Photochemical mechanisms are explained in a modified Jablonski 
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energy diagram depicted in figure 4 [18]. These energy transfers result in oxidation of 
biomolecules and in generation of singlet oxygen (1O2) and other ROSs leading to cell death.  
 
 
Figure 4: Modified Jablonski energy diagram [18] explaining photochemical mechanisms from photon 
absorption by photosensitizer to energy transfer and generation of singlet oxygen. 1Psen: singlet photosensitizer in 
ground state; 1Psen*: singlet excited photosensitizer; IC: internal conversion; ISC: intersystem crossing; 3Psen*: 
triplet excited photosensitizer; 3O2: oxygen in ground state; 1O2: singlet oxygen; S0: ground state; Sn: excited 
states with different vibrational sub-levels S’n.  
 
Absorption of light by 1Psen elevates an electron (e-) from the photosensitizer ground singlet 
state (S0) into an excited vibronic sub-levels S’n without changing the e- spin direction. The 
excited photosensitizer (1Psen*) can lose its energy by decaying (vibrational relaxation Æ 
energy dissipated as heat) through these sub-levels via IC to populate the first excited singlet 
state S1 (fluorescent state). The relaxation from S1 to S0 results in fluorescence. Alternatively, 
e- from excited fluorescent state (S1) may undergo spin inversion and populate lower – energy 
excited triplet state T1 via ISC. The decay processes from T1 to S0 have a longer lifetime and 
are called phosphorescence. Due to the longer lifetime and presence of unpaired valence e-, 
photosensitisation may be initiated. 
Photobleaching: Singlet oxygen and ROS production by photosensitizer have not only 
influence on cellular damage but also on the photodegradation of the photosensitizer itself. 
The degradation of the dye is called photobleaching and is defined as the loss of absorption or 
emission intensity caused by light [19]. In general, there are two different types of irreversible 
photosensitizer degradation: 
i) Photomodification: Here, a photosensitizer or chromophore is retained in a 
modified form but there is a loss of absorbance or fluorescence at some 
wavelengths.  
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ii) True photobleaching: In this case, chemically changed photosensitizer leads to 
molecular degradation, resulting in small fragments which have no absorption in 
visible light region. 
The pathways of photobleaching may have oxidative or reductive nature. Involvement of 
singlet oxygen enhances the photobleaching processes.  
Advantages and Disadvantages of PDT: Clinical application of PDT is nowadays 
considered to be a new and very promising treatment [20] but its full potential has not been 
exploited yet. PDT treatment is still restricted to dermatological oncology and 
ophthalomology. Despite many advantages [21] of PDT, such as low side effects, no further 
cell mutations as observed in radiation therapy, no cellular resistance as well as high treatment 
repeatability or activation of immune response [22] in contrast to chemotherapy and 
noteworthy possible combination with other conventional treatments [23, 24] there is 
resistance from the clinical side to this new approach. The costs for the establishment of PDT 
centres and lack of convenient and inexpensive light sources are major resistance reasons. 
Nevertheless, progress is slow but steady. Unfortunately, there are only randomised clinical 
trials at the moment and the PDT treatments do not outperform conventional therapies yet.  
Besides general scepticism there are three major drawbacks in PDT: prolonged skin 
photosensitivity, low tumor selectivity and limited tissue penetration which restrict this 
therapy to superficial treatment modality only. However, the success of PDT is unstoppable 
and new photosensitizers with higher tumor selectivity and cheaper light delivery sources are 
under development. 
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1.2 Photosensitizers 
 
PDT efficacy is mainly dependent on the photosensitizing agent and applied light dose. An 
ideal photosensitizer should be a pure compound with minimal systemic toxicity, high singlet 
and/ or ROS quantum yield, high tumour selectivity, an absorption wavelength > 650 nm and 
low manufacturing costs [21]. So far, there are many different photosensitizers which are 
clinically approved and widely used such as Photofrin (porphyrin sodium) or under current 
investigations such as different formulations of mTHPC (Foslip®, Fospeg®). In general, 
photosensitizers can be classified in to porphyrin and non-porphyrin photosensitizers [13]. 
Furthermore, porphyrin-derived photosensitizers are classified in first, second or third 
generation (conjugations with antibodies) of photosensitizers (fig. 5).  
 
 
Figure 5: Classification of photosensitizers a) porphyrins-derived and b) non-porphyrin derived photosensitizers 
[13].  
 
Taken together, development of photosensitizers is focusing on increasing PDT efficacy and 
tumour selectivity while minimizing systemic toxicity. This work is ongoing in many research 
groups around the globe [25].  
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1.2.1 Hypericin 
 
General Information: Common St. John’s Wort is a perennial plant with golden yellow 
flowers (fig. 6 A and B) that can be found in sunny and dry places all over Europe, Western 
Asia, Northern Africa and America. This plant has been known since ancient time and has a 
long history. It was used as a analgesic in wound healing or against mild depressions [26, 27]. 
The use of the plant originates in Greece in the 1st century A.C. described by the herbologists 
Dioscorides and Plenius but its therapeutic potential was already mentioned in the 5th century 
B.C. by the father of Medicine, Hippocrates.  
 
                                     A B C 
 
Figure 6: Showed in A is Hypericum perforatum flower with typical golden yellow blossom (found on 
University of Zurich campus, Irchel). Hypericin (10, 11-dimethyl -1, 3, 4, 6, 8, 13-hexahydroxynaphtho-
dianthrone) and his congener pseudo-hypericin are located in dark granulates on the leafs and plant buds (B). In 
C is depicted chemical structure of hypericin.  
 
Hypericin is a major active constituent of the plants of the genus Hypericum. This substance 
is known for its strong photo-activity and - if taken in larger amounts - it can cause serious 
non pigmented skin burnings associated with oedema (hypericism). In contrast to the light 
exposition hypericin shows very low cell toxicity if applied in the dark. Sanochemia 
Pharmazeutica AG has applied PVP-hypericin with the trade name Vidon® for diagnostic 
purposes in superficial bladder cancer. Currently they are in phase IIb clinical trials and 
ongoing results are outstanding but compared to Hexvex (hexaminolevulinate), the only 
clinical approved photosensitizer for photodynamic diagnosis (PDD), they seem to be much 
more advantageous for patients.   
Physicochemical properties: Hypericin [28] (10,11-dimethyl-1, 3, 4, 6, 8, 13 – 
hexahydroxynaphthodianthrone, Mw = 504.45 g/ mol) (fig. 6 C) is a red, non planar aromatic 
polycyclic substance belonging to the chemical class of antraquinones. It shows low solubility 
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in water or organic solvents, but is well soluble in polar organic solvents such as dimethyl 
sulfoxid, tetrahydrofurane and ethanol with a pH ranging between 4 and 11. In physiological 
conditions hypericin is present as monosodium salt. In water, these monosodium salts form 
non-fluorescent aggregates (stacked and planar associations) [29]. Hypericin salts produce 
wine-red coloured solutions with a maximal absorption wavelength at 548 nm and 593 nm. 
Emitted fluorescence has its maxima at 594 nm and 642 nm. A very high triplet quantum 
yield and a high yield of singlet oxygen (Φt= 0.7; Φs= 0.7) as well as other reactive oxygen 
species (ROS) [30-32] characterise hypericin as a very promising photosensitizer. Besides the 
photoactive features, Kubin et al. [28] reported antineoplastic, antitumor and antiviral 
activities.  
Tumorotropic properties: Kamuhabwa et al. [33] have shown that in vitro uptake behaviour 
of hypericin in malignant and healthy cells is very similar to each other and no significant 
difference could be proven. Many in vitro studies showed that cellular hypericin uptake relies 
mainly on passive processes (diffusion) [34] and its preferential incorporation involves 
cellular membranous systems (cell and nuclear membranes, mitochondria, golgi apparatus, 
endoplasmatic reticulum and lysosomes) [35]. In contrast, in vivo studies showed that 
hypericin preferentially accumulates in tumour tissue. This tumorotropic behaviour can be 
explained by hypericin’s preferable lipoprotein interactions (low und high density 
lipoproteins) [36, 37]. This is not only an important carrier system in vivo but it is also 
responsible for receptor-mediated internalisation. The uptake could also be supported by the 
enhanced permeability and retention (EPR) effect in tumor tissues. Van de Putte et al. [38] 
elaborated the tumoritropic principle of hypericin in subcutaneously growing mouse tumours. 
They found up to 16-fold higher concentration in tumour tissue compared to surrounding 
healthy tissue. This study suggested that the accumulation of hypericin is highly dependent on 
the extent of local blood perfusion and on the tumour size. Smaller tumours display a more 
homogeneous and functional vessel distribution lacking necrotic areas if compared to larger 
tumours. The permeability of the tumour vessels has as well an important influence on intra-
tumoural accumulation [39].  
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1.2.2 Foslipos® 
 
General information: Meso-tetrahydroxyphenyl chlorin (mTHPC or temoporfin, Mw = 
680.75 g/ mol) is a chemically derived substance and one of the most potent second 
generation photosensitizer [40, 41]. Based on clinical results it is 100-200 times more potent 
than Photofrin [42]. Nowadays, mTHPC is known under the trade name Foscan® (Biolitec 
AG, Jena, Germany). Foscan® is a non-aqueous formulation containing mTHPC in ethanol as 
a solvent and propylene glycol as a co-solvent. This mTHPC formulation is approved for 
palliative treatment of advanced head and neck cancer in Europe [43]. In order to enhance 
solubility and PDT efficacy of mTHPC Biolitec AG developed different liposomal 
formulations. The mTHPC loaded liposomes are based on dipalmitoyl-phosphatidylcholine 
(DPPC) with a small amount of dipalmitoylphosphatidylglycerol (DPPG) as physical 
liposome stabiliser (fig. 7 A and 7 B) [44].  
 
                B A C 
 
Figur 7: Liposomal mTHPC (5,10,15,20-Tetra(meso-hydroxyphenyl)chlorin) cryo electron microscopy pictures 
are shown In A [45] and in B schematic picture of a liposome [46]. mTHPC molecules are located between lipid 
bilayers. The chemical structure of mTHPC is shown in C.  
 
The chemically flexible and biotolerable DPPC/ DPPG liposomes are very useful carrier 
systems for substances which are normally not soluble or toxic in a biological environment. 
This flexibility of DPPC/ DPPG liposomes was used to produce different mTHPC 
formulations such as Foslip® or Foslipos®, which only differs in additional 5% glucose in the 
Foslip® solution. Another promising DPPC/ DPPG-based mTHPC formulation is Fospeg®. 
The liposomal surface modifications with PEG were shown to have much longer systemic 
persistence in vivo [47, 48]. All these novel formulations are improving PDT treatments and 
outcomes in patients. On one side photosensitivity could be minimized but at the same time 
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bio-distribution and its systemic clearance as well as tumor selectivity could be enormously 
enhanced.  
Physicochemical properties: Generally, mTHPC is a strongly hydrophobic substance and 
has low solubility in aqueous solvents. Additionally, it tends to aggregate in physiological 
solutions, leading to drastic decrease of fluorescence, limited photosensitizer transport, low 
uptake in tumours and extremely low PDT effects. Solubility of mTHPC is achieved in 
alcohol, acetone or in ethyl acetate. When dissolved, it displays a brown-reddish solution with 
maximal absorption wavelength at 417 nm and 651 nm. The emitted fluorescence has its 
maximum at 653 nm. The singlet oxygen yield is very high (Φt = 0.89; Φs = 0.59) if compared 
to other photosensitizers [49]. The size of liposomal formulations of mTHPC (in particular 
Foslip® and Foslipos®) measured by dynamic light scattering (DLS) in water was ~ 140 nm. 
The current drug loading (mTHPC) in DPPC/ DPPG liposomes is 8 mol%. 
Tumourotropic properties: Foscan® has been evaluated as a phototherapeutic agent against 
early head and neck cancer or as an adjuvant therapy in advanced head and neck cancer when 
conventional treatments (surgery, chemo- and radiation therapy) have failed. Dougherty et al. 
[12] reported that this chlorin photosensitizer appears to be one of the most potent 
photosensitizer to date requiring very low drug and light doses. Unfortunately Foscan® can 
render patients photosensitive up to 20 days after initial illumination [50]. Lassalle et al. [51] 
studied correlations between pharmacokinetics, intra-tumoural distribution and PDT 
efficiency of Foslip® in EMT6 xenografted nude mice. Time dependent observations showed 
that after a short time post incubation fluorescence was found in vessels, tumour and 
endothelial cells. 15 h post injection the fluorescence was predominately localised in the 
cytoplasm of tumour cells. Kiesslich and colleagues reported that Foscan® has enhanced light 
tissue penetration in treatment of cholangiocarcinoma and that Foscan®-mediated PDT cause 
tumour necrosis and has higher tumouricidal depth (>7-8 mm) than Photofrin. Further in vitro 
studies were performed on two different biliary tract cancers [52]. The results of these studies 
indicated that less differentiated cell lines tend to be more sensitive to mTHPC-mediated 
PDT. Based on these investigations cellular uptake, phototoxicity and photosensitizer release 
were performed on a large set of cell lines [53]. Localisation of mTHPC was found partly in 
mitochondria, lysosomes or perinuclearly but in general it was difficult to provide evidence 
for an organelle specific localization. Uptake and the related phototoxicity correlated directly. 
Our study with the prostate carcinoma cell line (PC-3) displayed increasing accumulation of 
Foslip® in the cytoplasm, especially in the vicinity of the nucleus [54].  
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1.3 Cancer  
 
General Information: According to the World Health Organisation (WHO) cancer is the 
leading cause of death worldwide (7.6 million deaths in 2008) [55, 56]. About 70 % of all 
cancer deaths occurred in developing countries and it is expected to rise to 11 million per 
annum in 2030. Table 2 illustrates worldwide statistics on cancer incidence and mortality. 
 
WORLD Male Female Both sexes 
Population (thousands) 
 
3’402’841 3’347’220 6’750’061 
Number of new cancer cases 
(thousands) 
6’617.8 6’044.7 12’662.6 
Age-standardised rate (W) 
 
203.8 165.1 181.6 
Risk of getting cancer before age 75 
(%) 
21.2 16.5 18.7 
Number of cancer deaths 
(thousands) 
4’219.6 3’345.2 7’564.8 
Age-standardised rate 
 
128.6 87.6 106.1 
Risk of dying from cancer before 
age 75 (%) 
13.4 9.1 11.2 
5 most frequent cancers  Lung 
Prostate 
Colorectum 
Stomach 
Liver 
Breast 
Colorectum 
Cervix uteri 
Lung 
Stomach 
Lung 
Breast 
Colorectum 
Stomach 
Prostate 
 
Table 2: Worldwide statistics summary on cancer incidence and mortality (GLOBOCAN 2008) [57]. Glossary: 
Age-standardised rate (W): A rate is the number of new cases or deaths per 100’000 persons per year. An age-
standardised rate is the rate that a population would have if it had a standard age structure. Standardization is 
necessary when comparing several populations that differ with respect to age because age has a powerful 
influence on the risk of cancer.  
Risk of getting or dying from the disease before age 75 (%): The probability or risk of individuals getting/ dying 
from cancer. It is expressed as the number of newborn children (out of 100) who would be expected to develop/ 
die from cancer before the age of 75 if they had cancer rates (in the absence of other causes of death). 
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The cancer incidence is increasing as a result of population’s aging and growth, cancer 
associated lifestyle such as smoking, alcohol consumption, physical inactivity, environmental 
conditions and nutrition. WHO advises that modifying and avoiding of risk factors may 
prevent more than 30 % of cancers. Additionally, evidence-based strategies for cancer 
prevention, early detection and management of patients with cancer can reduce the cancer 
mortality. Therefore, knowledge about cancer causes, which is molecularly seen as a 
multistep process is the first step in treating this complex disease. Hanahan and Weinberg [58] 
proposed six hallmarks (fig. 8) of cancer which are involved in transformation of normal to 
neoplastic and lastly to malignant cell state.  
 
 
 
Figur 8: Illustration of the six hallmark capabilities proposed by Hanahan and Weinberg 2011 [58] (originally 
proposed in 2000). 
 
They included the following biological capabilities:  
i) Sustained proliferative signalling – this fundamental trait of cancer cells involves 
deregulation of homeostasis of cell growth-promoting signals. Cancer cells 
become masters of their own destinies. The regulation mechanisms are still not 
understood in detail. 
ii) Evading growth suppressors – inactivation of dozens of tumour suppressor genes 
leads to deregulation of cell proliferation. Inactivation of cell-to-cell contacts 
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enables construction and maintenance of architecturally complex cancerogenous 
tissues. 
iii) Resisting cell death – programmed cell death by apoptosis as a natural barrier for 
cancer development is disturbed by the loss of tumour suppressor functions such 
as TP53 or by suppressing pro-apoptotic factors. The diversity of cell death 
avoiding mechanisms is enormous and it is dependent on the cancer cell as well as 
their evolution to the malignant state. 
iv) Enabling replicative immortality – Telomerase over-expression in cancer cells and 
therewith connected resistance to induction of cellular senescence and apoptosis.  
v) Inducing angiogenesis – Starting with a certain tumour volume the induction of 
neo-vascularization is inevitable for further tumour survival. The “angiogenic 
switch” involves up-regulation of signalling proteins such as vascular endothelial 
growth factor– A (VEGF-A) and thrombospondin- 1 (TSP- 1). 
vi) Activating Invasion and Metastasis – the responsible mechanisms were not known 
in 2000. This multistep process is termed the invasion-metastasis cascade and 
includes cell-biologic changes, local invasion, intravasation, transit of cancer cells 
to lymphatic and hematogenous systems, extravasation and colonisation. 
 
Development of cancer and the complex biology behind its pathogenesis provide a huge 
challenge in treating this disease. The six acquired capabilities are integral components of 
most cancer types and their better understanding is from immense importance in creating 
personalised treatment methods. Additionally, the complex morphology of cancer and 
microenvironments demand different treatment approaches. Hanahan and Weinberg described 
illustrative samples for treatment of each proposed cancer hallmark (fig. 9). In particular, they 
state that selective co-targeting of multiple pathways will result in more effective and durable 
therapies for cancer.  
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Figur 9: Illustrative examples of therapeutic targeting of the hallmarks of cancer used in clinics or in clinical 
trials [58]. 
 
The cancer treatment has to be a multiple step approach as it is its development. Introducing 
PDT as a supporting co-therapy can be very advantageous since the PDT mode of action is 
universal and independent from any hallmark of cancers. In the review of Firczuk et al. [21] 
was reported that combination of PDT with different established treatment modalities such as 
surgery, radiotherapy or chemotherapy provides significant improvement of treatment 
outcome.  
 
1.3.1 Prostate Carcinoma 
 
Background: Prostate cancer is the second most frequent cancer type and sixth leading cause 
of cancer death in male (app. 900’000 new cases per year worldwide) [56]. More than 70 % of 
cases are diagnosed in elderly men (prevalence rate in men ages 70-90 is 90 %) [59]. The 
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major risk factor for developing prostate cancer is age, followed by race, family history and 
high fat diet. The exact role of race remains unclear [60]. The autopsy data suggest that more 
man will die with than from prostate cancer. The early stage of this disease is asymptomatic 
and therefore is recommended to make a preventive prostate cancer screening (PSA 
screening, considered to be imperfect due to the non cancerous elevation of serum PSA or 
digital rectal exam) if one of the following statements are true: men with low risk from the 
age of 50 or men with high risk (relatives which have been diagnosed for prostate carcinoma) 
from the age of 40.  
The treatment options for prostate cancer are based on the cancer staging and include 
localized prostate cancer active surveillance, radical prostatectomy, external beam radiation 
therapy, brachytherapy and cryotherapy. The treatments for advanced prostate cancer are 
hormone and chemotherapy as well as some newly emerging therapies. Incidence of prostate 
cancer will continue to rise therefore new therapies and nursing research are necessary.  
 
1.3.2 Head and Neck Cancer 
 
Background: Head and neck squamous cell carcinoma (HNSCC) comprises a group of 
epithelial cancers that arises from e.g. the lips, the oral or nasal cavity, salivary glands, 
paranasal sinuses, pharynx or larynx [61]. With a worldwide incidence of more than 600’000 
new cases per year, HNSCC accounts for about 6 % of all malignant diseases diagnosed 
(http://globocan.iarc.fr). Almost 75 % are in men. Main risk factors for head and neck 
malignancies are tobacco and alcohol consumption but also low consumption of fruits and 
vegetables. If detected early, patients have cure rates of about 90 %. However, 60 % of 
patients present with advanced disease or loco-regional lymph node metastasis at the time of 
diagnosis and have a poor prognosis [62, 63]. Another reason for the poor prognosis is 
substantial risk of a second primary cancer which is higher at younger ages [64]. Differences 
in survival depend on sex, age and on socioeconomic status as well as on the site of origin of 
the cancer invasion [65]. It has also been shown that patients suffering from an infection with 
human papillomavirus (HPV) may have a different prognosis from those of non-HPV-related 
cancers [66]. 
Currently, treatment options for HNSCC patients include surgery, radiotherapy, 
chemotherapy or a combination of them [67, 68]. Due to the distinct localization of these 
tumours in regions with anatomic structures important to e.g. breathing, mastication, 
swallowing or phonation, invasive treatment regimes frequently leading to severe functional 
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impairments, - often accompanied by unfavorable cosmetic outcomes. This is true despite 
significant advancements made in the reconstructive abilities over the past two decades. 
Moreover, radiation may have long-term effects on surrounding healthy tissue structures such 
as parts of the brain, the spinal cord or salivary glands. However, while surgery or radiation 
therapy is local, chemotherapy is applied systemically and may thus result in severe adverse 
effects e.g. on blood cell production (anaemia, neutropenia or thrombopenia), the mucosa 
(mucositis), the auditory and vestibular system (ototoxicity) or the kidneys (nephrotoxicity). 
Despite this aggressive therapeutic regime, to date many patients with advanced disease 
cannot be cured and more then half of them die within five years [69-71]. HNSCC is thus 
currently the eighth leading cause of cancer death worldwide.  
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1.4 Cell Models 
 
Research on two dimensional cell cultures has been routinely performed within the last sixty 
years. Drug screenings and developmental biology rely on the cell culture systems. In the 
following we used three different cell lines in culture to test the applicability of PDT in vitro.  
 
1.4.1 Prostate Carcinoma Cell Line (PC-3) 
 
The PC-3 [72] cell line was isolated from a 62-year-old Caucasian (from lumbar vertebra) 
originally presented with urinary retention, weight loss and anemia. His prostate was small 
and hard but mobile, four months after diagnosis the symptoms worsened and despite 
cryotherapy the patient died. Autopsy revealed tumour metastasis in the bone marrow and in 
the adrenal glands. The established cells show a population doubling time of approximately 
33 hours. PC-3 cell line is aneuploid and tumourigenic. Colony forming in soft agar has an 
efficiency of 0.15 %.  
 
1.4.2 Head and Neck Squamous Cell Carcinoma Cell Lines (UMB-SCC 745 and UMB-
SCC 969) 
 
The squamous cell carcinoma cell lines were isolated from oropharynx (UMB-SCC 745) and 
tonsil (UMB-SCC 969) [73]. Isolation of UMB-SCC 745 resulted from the primary tumour 
site (T4N2M0, grading G2) of a 48-year-old male patient. UMB-SCC 969 cells were also 
isolated from the primary tumour site (T4N2M1, grading G2) of a 67-year-old male patient. 
Both cell lines have p53 mutations. The cells have a population doubling time of 
approximately 36h. No colony forming was observable.  
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2. Cellular and molecular effect of the liposomal mTHPC derivate Foslipos 
in prostate carcinoma cells in vitro 
 
The contributions of Emina Besic Gyenge to the study: „Cellular and molecular effect of the 
liposomal mTHPC derivate Foslipos® in prostate carcinoma cells in vitro” were the following: 
 
1. Cell culturing 
 
2. Time dependent uptake of Foslipos® experiment and collection of microscopic data, in 
particular figure 2 
 
3. Cell treatments with Foslipos® and subsequent RNA and DNA extractions  
 
4. Measurements of RNA quantity and quality, in particular figure 5 (RNA content in µg per 
100’00 cells after incubation) and figure 6 (RNA integrity measurements) 
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Summary
Background: Meso-tetra-hydroxyphenyl-chlorine (mTHPC) is among the most powerful photo-
sensitizers available for photodynamic therapy (PDT). However, the mechanisms leading to cell
death are poorly understood. We here focused on changes at DNA and RNA levels after treatment
with the liposomal mTHPC derivative Foslipos in vitro.
Methods: After determination of darktoxicity, laser conditions and uptake kinetics, PC-3
prostate carcinoma cells were subjected to PDT with Foslipos, followed by assessment of cell
numbers directly (TP0) or 1 h (TP1), 2 h (TP2), 5 h (TP5) and 24 h (TP24) after illumination.
Nucleic acids had been extracted for evaluation of RNA amounts and integrity as well as for
estimation of abasic sites as a measure for DNA damage. Furthermore, expression changes of 84
genes related to oxidative stress were investigated by quantitative polymerase chain reaction.
Results: Already at TP0, the number of dead cells was signiﬁcantly higher after PDT versus
controls and at TP24 more than 90% of cells had been destroyed. PDT resulted in a severe
damage of both RNA and DNA. Gene expression analyses revealed an impact of PDT on pathways
for oxidative and metabolic stress, heat shock, proliferation and carcinogenesis, growth arrest,
inﬂammation, DNA repair and apoptosis signaling.
Conclusions: Mechanisms of Foslipos-mediated PDT comprise a combination of acute and
delayed lethal effects in PC-3 cells. The latter may include death processes initiated by nucleic
acid damage, activation of stress and growth arrest genes in combination with a reduced capa-
bility to adequately cope with oxidative toxicity. Our results will help to better understand
molecular photodynamic effects.
© 2011 Elsevier B.V. All rights reserved.
∗ Corresponding author. Tel.: +41 44 6355338; fax: +41 44 6355702.
E-mail address: cmaake@anatom.uzh.ch (C. Maake).
1 These authors contributed equally to this work.
Introduction
Currently, one of the most powerful second-generation pho-
tosensitizers available for photodynamic therapy (PDT) is
meso-tetra-hydroxyphenyl-chlorine (mTHPC, Temoporﬁn), a
1572-1000/$ — see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.pdpdt.2011.02.001
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member of the chlorine family of photosensitizers. The
commercial product Foscan gained approval in the EC for
palliative PDT treatment of patients with recurrent or
refractory head and neck cancers, but it is also under
investigation as a promising therapeutic modality for early
cancers of the head and neck region, colon adenocarcinoma,
non-melanotic skin tumors, pleural mesothelioma, pancreas
cancer, hepatoma, carcinoma in situ of the vulva, malig-
nant brain tumors, ovarian neoplasms, and organ conﬁned
prostate cancer [1,2].
However, Foscan is highly hydrophobic and thus requires
the use of organic solvents like alcohols, acetone or ethyl
acetate. After intravenous injection in patients, mTHPC
molecules tend to aggregate and display very complex bioki-
netics, such as, e.g. a series of subsequent concentration
maxima in plasma or limitations in transportation and tumor-
uptake [3,4]. In recent years, these clinically unfavorable
characteristics prompted the development of new deriva-
tives of Temoporﬁn, including the liposomal formulations
Foslip and Fospeg (the latter being PEGylated). In addition
to the advantage of solvency in hydrophilic media, in ﬁrst
in vivo and in vitro studies liposome-incorporated mTHPC
had been shown to accumulate faster, selectively and with
higher ﬂuorescence in tumor tissues [5—8].
The cell death pathways evoked by oxidative damage in
mTHPC-mediated PDT are far from being clear and appear
to depend not only on cell type investigated but also on
PDT protocol. It had been reported that apoptotic pathways
may be initiated [9—12], however, autophagy or necrosis
[13] may prevail — especially if high PDT doses are applied
[14]. To date only a limited number of studies are available
that focus on the spectrum of signaling pathways affected in
the course of mTHPC-mediated PDT. Apparently, effects may
not only include activation of caspase cascades [10,11] but
also acute-phase response processes [15], and expression
changes of heat-shock proteins [16], hypoxia-markers [17],
matrix metalloproteinases [18] or cytokines [19]. Since some
of these cellular responses may modify, delay or even coun-
teract cell death mechanisms, detailed analyses are highly
needed.
With the aim to elucidate pathways leading to and/or
interfering with cell death in PDT procedures with liposomal
mTHPC we here focus on changes at the DNA and RNA level,
as well as on gene expression proﬁles, using the established
prostate carcinoma cell line PC-3 as model system.
Material and methods
Cell line and reagents
The androgen-independent human prostate carcinoma cell
line PC-3 was obtained from the European Collection
of Cell Cultures (ECACC). Cells were grown in DMEM+
(1:1 mixture of DMEM and Ham’s F-12, without phe-
nol red indicator and pyridoxal HCl, supplemented with
10% fetal calf serum and 1% Penicillin-Streptomycin,
10,000UI/ml, all purchased from Gibco, Basel, Switzerland)
at 37 ◦C and 5% CO2 in a humid environment. Cells
were passaged by trypsinization using 1× trypsin/EDTA
(Invitrogen, Basel, Switzerland). As photosensitizer, we
used mTHPC encapsulated into dipalmitoylphosphatidyl-
choline/dipalmitoylphosphatidylglycerol (DPPC/DPPG) lipo-
somes (Foslipos, Biolitec AG, Jena, Germany). Concentra-
tion of mTHPC in liposomes was 1.5mg/ml. Unless otherwise
stated, chemicals were purchased from Sigma, Buchs,
Switzerland.
Dark toxicity assay
PC-3 cells were plated at a density of 1000 cells per 60mm
Petri dish and allowed to attach for 24 h. Thereafter, Fosli-
pos was added to end concentrations of 0.1, 0.5, 1.0, 5.0,
and 10.0g/ml, respectively, and incubated for 5 h. Then
a colony forming assay was performed as described ear-
lier [20]. Brieﬂy, after treatment, cells were washed with
PBS and fresh DMEM+ was added. Cells were cultured for
another 10 days and colonies were ﬁxed, stained with azur-
methylenblue-Giemsa and counted, whereby only colonies
containing ≥50 cells were considered. Controls were run
under the same conditions, while Foslipos was omitted.
Selection of laser intensity
PC-3 cells were processed as for the dark toxicity assay
described above with the exception that cells were exposed
to laser light after the 5 h incubation period with Foslipos.
Laser intensities of 1, 3, and 5 J/cm2, respectively, were
applied, using a diode laser (Applied Optronics Corporation,
USA) at 652 nm and a powermeter (Lightwave OMM6810B,
GMP, Renens, Switzerland). After irradiation, colony forming
assays were carried out as described above.
Confocal laser scanning microscopy
PC-3 cells grown on cover slips were incubated with 5g/ml
Foslipos for 15min, and 1, 2, 3, 4, and 5 h, respectively.
After a buffer wash, cells were ﬁxed with 4% buffered
paraformaldehyde, again washed, coverslipped with Glyc-
ergel (Dako, Baar, Switzerland) and analyzed with a confocal
laser scanning microscope (SP2, Leica Microsystems, Heer-
brugg, Switzerland), using an excitation wavelength of
488 nm and detection wavelengths of 580—660 nm.
Cell culture treatment
PC-3 cells were plated on 60mm Petri dishes at a density
of 1× 106, allowed to recover for 24 h and treated with
Foslipos for 5 h at an end concentration of 5g/ml. Cells
were then exposed to 652 nm laser light reaching a dose of
1 J/cm2. This experimental setting was termed PDT. Three
series of controls were included: (1) omission of the photo-
sensitizer, i.e. replacement of the photosensitizer by buffer,
but inclusion of irradiation (IRR), (2) omission of the irradi-
ation and treatment with Foslipos (FOS) and (3) omission of
both photosensitizer and irradiation (CO).
After washing all samples with PBS, fresh DMEM+ medium
was added and the dishes were placed back in the incuba-
tor. Experiments were stopped immediately (i.e. after about
3—4min) or after 1, 2, 5, and 24 h, respectively, by 2× 3min
washing and 5min trypsinization. These ﬁve time points are
referred to as TP0, TP1, TP2, TP5 and TP24. After centrifu-
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gation at 1000 rpm for 5min, cell pellets were resuspended
in 1ml PBS and either directly used for cell counting or
frozen for later nucleic acid analyses.
Cell survival test
Resuspended cells (10l) from experimental settings
described in ‘‘cell culture treatment’’ were mixed with
equal volumes of trypan blue solution (0.5%, Serva, Buchs,
Switzerland) and cells (dead and alive) were immediately
counted in a Neubauer chamber.
Nucleic acid extractions and quality analyses
From the remainder of resuspended cells (i.e. 990l),
genomic DNA and total RNA was extracted with the Nucle-
oSpin RNA II kit in conjunction with the NucleoSpin RNA/DNA
buffer set (Macherey-Nagel, Oensingen, Switzerland), fol-
lowing the protocol of the manufacturer. The kit allows for
a sequential elution of DNA and RNA from the same cell
lysate using a silica membrane ﬁlter column and a set of
predesigned buffers. Final elution volumes per sample for
genomic DNA and total RNA were 100l and 60l, respec-
tively. Nucleic acid concentrations were determined with a
Nanodrop spectrophotometer (ND-1000, Wilmington, DE).
RNA quality was assessed by means of the Agilent 2100
Bioanalyzer equipped with the RNA integrity number (RIN)
software algorithm (Agilent, Waldbronn, Germany). For this
purpose, total RNA was assayed with the Eukaryote total RNA
Nano LabChip kit (Agilent) according to the manufacturer’s
instructions.
DNA quality was determined with the DNA Damage Quan-
tiﬁcation kit (MBL, Woburn, MA) that measures the number
of apurinic/apyrimidinic sites in DNA lesions. Following the
recommendations of the manufacturer, genomic DNA was
diluted to 100g/ml and labelled with the biotinylated alde-
hyde reactive probe provided with the kit. Tagged DNA and a
tagged standard (provided with the kit) were then bound to a
96-well microplate, followed by an avidin—biotin assay and
colorimetric detection at O.D460 nm. The number of abasic
sites within the genomic DNA was determined by comparison
with the standard curve.
Gene expression analyses
For gene expression analyses, the PAHS-003 RT2 Proﬁler PCR
array system was performed according to instructions of the
manufacturer (Human stress and toxicity pathways ﬁnder
array, SuperArray, Frederick, MD). Brieﬂy, 0.5g total RNA
each from samples TP1 (PDT and CO) and TP5 (PDT and CO)
were reverse transcribed with the RT2 First Strand kit (Super-
Array). Resulting cDNA was subjected to quantitative PCR
(qPCR) on an ABI 7500 sequence detection system (Applied
Biosystems, Rotkreuz, Switzerland) using the supplied 96-
well plate format with pre-dispensed speciﬁc primer sets
and the RT2 SYBR green/ROX qPCR master mix (SuperArray).
Cycling parameters were as follows: 1 cycle for 10min at
95 ◦C and 40 cycles of 15 sec at 95 ◦C and 1min at 60 ◦C. Both
threshold and baseline values were automatically obtained
by the SDS software (Applied Biosystems) and CTs for all
Figure 1 Dark toxicity in PC-3 cells: results of colony forming
assays after incubation without or with 0.1—10mg/ml Foslipos.
* p > 0.05%.
wells were exported to the company’s data analysis web tool
(www. superarray.com).
Statistical analyses
All experiments were carried out in triplicate. Statisti-
cal analyses were performed with the StatView software
(www.statview.com). All possible pairwise differences
between time points as well as between experimental condi-
tions were examined by Fisher’s Protected Least Signiﬁcant
Difference (PLSD) tests. p-Values less than 0.05 were con-
sidered signiﬁcant.
Results
Experimental conditions
With the aim to establish the appropriate experimental con-
ditions, we ﬁrst determined the maximal non-dark-toxic
concentration of Foslipos. We found that colony numbers
after treatment with 10g/ml Foslipos were signiﬁcantly
lower compared to untreated controls (p < 0.0001), while all
other concentrations of Foslipos used showed no statistically
signiﬁcant effects compared to controls (Fig. 1). We thus
decided to perform further experiments with 5g/ml Fosli-
pos end concentration in the medium. We next investigated
the conditions of light exposure with minimal lethal effect
at 5g/ml Foslipos. 1 J/cm2 showed the lowest phototoxic
effect (data not shown) and was thus choosen for our further
study.
Microscopy
Cellular uptake kinetics of Foslipos in PC-3 cells were eval-
uated on the basis of its intracellular ﬂuorescence (Fig. 2).
Already after 15min, a weak signal was detectable within
cells. The ﬂuorescence intensity increased steadily over
time, reaching a maximum at 4 h. It was always diffusely
distributed throughout the cytoplasm, with a tendency for
a higher signal accumulation in the vicinity of the nucleus.
However, the nuclear compartment itself always remained
non-ﬂuorescent (Fig. 2).
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Figure 2 Uptake of Foslipos into PC-3 cells after (A) 15min, (B) 1 h, (C) 2 h, (D) 3 h, (E) 4 h, and (F) 5 h incubation with photosen-
sitizer. Confocal laser scanning microscopy, bar denotes 20m.
PDT-effects on cell death
As shown in Fig. 3, up from the earliest time point investi-
gated (TP0), PDT samples contained statistically signiﬁcant
more dead cells than untreated controls (p = 0.0002), with
a death of about 43% of cells compared to CO. The number
of dead cells in PDT samples, however, remained constant
up to TP5, while in the TP24-samples this parameter signiﬁ-
cantly rose (p < 0.0001) compared to time points before. At
TP24, PDT samples contained only 9% of living cells found in
CO. The number of dead cells in IRR and FOS was uniformly
low and not statistically different from CO at all time points
investigated.
Figure 3 Effect of PDT with Foslipos on cell death: direct
counts after trypan blue staining directly (TP0) and 1 h (TP1),
2 h (TP2), 5 h (TP5) and 24 h (TP24) after light application. CO:
no treatment, IRR: with light application, FOS: with incubation
of Foslipos.
Effects on nucleic acid quantity and integrity
Genomic DNA damage was estimated by measuring the
amount of apurinic/apyrimidinic sites — a marker for oxida-
tive stress (Fig. 4). We found that at all time points measured
(TP0, TP1, TP24), the degree of oxidative DNA damage was
signiﬁcantly higher in PDT-treated cells compared to CO
samples (TP0, p < 0.0001; TP1, p < 0.0001; TP24, p < 0.0001).
DNA quality was also impaired in FOS and IRR samples (com-
pared to CO), however, the difference between PDT and FOS
or IRR was still statistically signiﬁcant at all time points mea-
sured (in all cases: p < 0.0001). Generally, DNA damage of
PDT-treated cells was always high, corresponding to an aver-
age of 22 abasic sites per 105 base pairs at TP0, 18 sites per
105 base pairs at TP1 and 16 sites per 105 base pairs at TP24.
Figure 4 Estimation of DNA lesions: binding of an aldehyde
reactive probe to DNA after PDT with Foslipos directly (TP0), 1 h
(TP1) and 24 h (TP24) after light application. CO: no treatment,
IRR: with light application, FOS: with incubation of Foslipos.
Measurements in arbitrary units at O.D460 nm
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Figure 5 RNA content in g per 100,000 cells after incubation
with Foslipos directly (TP0) and 1 h (TP1), 2 h (TP2), 5 h (TP5)
and 24 h (TP24) after light application (PDT). CO: no treatment,
IRR: with light application, FOS: with incubation of Foslipos.
At all time points investigated, absolute amounts of total
RNA in PDT samples were signiﬁcantly lower than in CO sam-
ples. Being stable until (and including) TP2, RNA amounts
in PDT samples signiﬁcantly decreased at TP5, followed by
an additional drop at TP24 (p = 0.0009 and 0.0097, respec-
tively). FOS samples contained RNA amounts comparable to
those of CO samples, while IRR samples had a signiﬁcantly
higher RNA content up from TP1 compared to CO. In all con-
trol reactions, signiﬁcant increases in total RNA amounts
were found between TP5 and TP24 (IRR: p < 0.0001; FOS:
p = 0.009; CO: p = 0.0065). When expressed as a ratio of RNA
per (living) cell, RNA content per PDT-treated cell was signif-
icantly lower compared to CO from TP0 on (p = 0.0248), but
then remained unchanged over all time points investigated
(Fig. 5). In CO and FOS the ratio of RNA per cell was compa-
rable and remained constant over time, while IRR samples
had signiﬁcantly more RNA per cell at TP5 compared to CO
(p < 0.0001, Fig. 5).
In contrast to all controls, RNA quality was clearly
affected by PDT treatment. A small, but statistically sig-
niﬁcant RNA degradation was already seen at TP0, while
RNA integrity was completely maintained under all con-
trol conditions (RNA integrity number, RIN, of CO versus
PDT: p = 0.0022; IRR versus PDT: p = 0.001; FOS versus PDT:
p = 0.001). In plus, RNA continued to signiﬁcantly deteriorate
over time after PDT, being signiﬁcantly worse compared to
controls at all time points measured (Fig. 6).
Effects on gene expression proﬁles
With the aim to further characterize the effects of Foslipos-
mediated PDT, we investigated the expression of 84 genes
involved in stress and toxicity pathways by qPCR at TP1
and TP5. Taken together, we found that roughly 57% of all
genes investigated changed at least two-fold in expression
after PDT. Of these, the majority showed reduced tran-
script numbers at TP1 (about 83%). Over time, most of
the regulated genes (about 54%) maintained their initially
changed expression levels. However, at TP5 versus TP1,
about 23% had been further downregulated (HSPA4, CCNC,
CCND1, E2F1, NFKB1, ATM, DDB1, BCL2L1, CASP8, CASP10,
FASLG), about 12% displayed an further upregulation (CRYAB,
DNAJB4, HSPA1A, HSPA1L, HSPA6), and about 10% showed
Figure 6 (A) Effect of Foslipos-mediated PDT on RNA integrity
directly (TP0) and 1 h (TP1), 2 h (TP2), 5 h (TP5) and 24 h (TP24)
after light application (PDT). CO: no treatment, IRR: with light
application, FOS: with incubation of Foslipos. Calculation of the
RNA integrity number (RIN), where 10 is intact and 1 is dis-
integrated. (B) Virtual electrophoresis of total RNA after PDT
with Foslipos directly after illumination (TP0) and 24 h after
light application (TP24). CO: no treatment, IRR: with light appli-
cation, FOS: with incubation of Foslipos, M: molecular weight
marker. Arrow and double arrow denote 28S rRNA and 18S rRNA,
respectively.
signs of recovery (GSTM3, HSPA2, ERCC3, RAD50, TNFRSF1A,
TNFSF10). Tables 1—7 summarize those genes whose expres-
sion changed more than twofold between CO versus PDT
and/or over time.
In addition, we found that the following genes are
expressed in PC-3 but do not appear to be regulated after
PDT: CYP2E1, GPX1, MT2A, PRDX1, DNAJA1, HSF1, HSPA8,
HSPB1, HSP90AA2, HSPH1, MIF, GADD45A, GDF15, TP53,
CSF2, IL1A, IL6, SERPINE1, CHEK2, ANXA5, and NFKBIA.
Genes not expressed in PC-3 cells (neither CO nor PDT) com-
prise: CRP1A1, CYP7A1, EGR1, EPHX2, FMO1, PTGS1, CCL3,
CCL4, CCL21, CXCL10, NOS2A, UGT1A4, CASP1, LTA, and TNF.
All gene names are designated according to the HUGO gene
name nomenclature (www.genenames.org).
Discussion
Several new strategies are currently under development
aiming to improve the efﬁciency and speciﬁcity of PDT.
In this context, liposomal photosensitizer preparations are
of interest mainly for two reasons: on the one hand they
may serve as useful carriers for hydrophobic photoactive
molecules in biosystems and on the other hand, they may
possess a high payload for targeting molecules. Among oth-
ers, the photosensitizer mTHPC had been incorporated into
different types of liposomes and successfully applied in PDT
protocols in vitro and in vivo [5,6,8,21—24]. However, the
lack of information on molecular effects prompted us to
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Table 1 List of genes involved in oxidative or metabolic stress with expression levels altered at least 2-fold in samples subjected
to Foslipos-mediated PDT versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change TP1 Fold change TP5
CAT Catalase Oxidative or metabolic stress −3.3 −3.5
CRYAB Crystallin, alpha B Oxidative or metabolic stress +6.8 +42.8
FMO5 Flavin containing monooxygenase 5 Oxidative or metabolic stress −5.5 −4.7
GSR Glutathione reductase Oxidative or metabolic stress −4.8 −4.5
GSTM3 Glutathione S-transferase mu 3 Oxidative or metabolic stress −3.0 −1.6
HMOX1 Heme oxygenase (decycling) 1 Oxidative or metabolic stress +4.6 +3.2
POR P450 (cytochrome) oxidoreductase Oxidative or metabolic stress −3.8 −4.7
PRDX2 Peroxiredoxin 2 Oxidative or metabolic stress −2.6 −3.3
SOD1 Superoxide dismutase 1, soluble Oxidative or metabolic stress −2.2 −2.2
SOD2 Superoxide dismutase 2, mitochondrial Oxidative or metabolic stress −2.7 −3.4
Table 2 List of heat shock genes with expression levels altered at least 2-fold in samples subjected to Foslipos-mediated PDT
versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change TP1 Fold change TP5
DNAJB4 DnaJ (Hsp40) homolog, subfamily B,
member 4
Heat shock −1.4 +3.3
HSPA1A Heat shock 70 kDa protein 1A Heat shock +6.5 +11.1
HSPA1L Heat shock 70 kDa protein 1-like Heat shock −1.2 +7.2
HSPA2 Heat shock 70 kDa protein 2 Heat shock −2.2 +1.3
HSPA4 Heat shock 70 kDa protein 4 Heat shock −5.4 −7.5
HSPA5 Heat shock 70 kDa protein 5
(glucose-regulated protein, 78 kDa)
Heat shock −5.6 −5.5
HSPA6 Heat shock 70 kDa protein 6 (HSP70B′) Heat shock +282.1 +1112.8
HSP90AB1 Heat shock protein 90 kDa alpha (cytosolic),
class B member 1
Heat shock −1.8 −2.2
HSPD1 Heat shock 60 kDa protein 1 (chaperonin) Heat shock −2.3 −1.7
HSPE1 Heat shock 10 kDa protein 1 (chaperonin 10) Heat shock −2.4 −2.1
Table 3 List of genes involved in proliferation and carcinogenesis with expression levels altered at least 2-fold in samples
subjected to Foslipos-mediated PDT versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change TP1 Fold change TP5
CCNC Cyclin C Proliferation and carcinogenesis −3.0 −5.2
CCND1 Cyclin D1 Proliferation and carcinogenesis −8.6 −15.0
CCNG1 Cyclin G1 Proliferation and carcinogenesis −4.0 −5.1
E2F1 E2F transcription factor 1 Proliferation and carcinogenesis −2.6 −6.6
PCNA Proliferating cell nuclear antigen Proliferation and carcinogenesis −4.3 −6.1
Table 4 List of genes involved in growth arrest and senescence with expression levels altered at least 2-fold in samples
subjected to Foslipos-mediated PDT versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change
TP1
Fold change
TP5
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) Growth arrest and senescence −2.0 −2.1
DDIT3 DNA-damage-inducible transcript 3 Growth arrest and senescence +10.3 +6.5
IGFBP6 Insulin-like growth factor binding protein 6 Growth arrest and senescence −8.5 −7.6
MDM2 Mdm2 p53 binding protein homolog (mouse) Growth arrest and senescence −5.3 −3.5
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Table 5 List of genes involved in inﬂammation with expression levels altered at least 2-fold in samples subjected to Foslipos-
mediated PDT versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change TP1 Fold change TP5
IL1B Interleukin 1, beta Inﬂammation −2.1 −3.1
IL18 Interleukin 18 (interferon-gamma-inducing
factor)
Inﬂammation −3.0 −3.5
NFKB1 Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1
Inﬂammation −2.1 −3.6
Table 6 List of genes involved in DNA damage and repair with expression levels altered at least 2-fold in samples subjected to
Foslipos-mediated PDT versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change TP1 Fold change TP5
ATM Ataxia telangiectasia mutated DNA damage and repair −4.0 −6.7
DDB1 Damage-speciﬁc DNA binding protein 1,
127 kDa
DNA damage and repair −2.7 −4.9
ERCC1 Excision repair cross-complementing rodent
repair deﬁciency, compl. group 1
DNA damage and repair −3.6 −3.5
ERCC3 Excision repair cross-complementing rodent
repair deﬁciency, compl. group 3
DNA damage and repair −7.2 −3.3
RAD23A RAD23 homolog A (S. cerevisiae) DNA damage and repair −2.3 −2.7
RAD50 RAD50 homolog (S. cerevisiae) DNA damage and repair −12.6 −3.9
UNG Uracil-DNA glycosylase DNA damage and repair −2.0 −3.4
XRCC1 X-ray repair complementing defective
repair in Chinese hamster cells 1
DNA damage and repair −2.3 −2.4
XRCC2 X-ray repair complementing defective
repair in Chinese hamster cells 2
DNA damage and repair −3.2 −4.0
explore cellular mechanisms in PDT with the DDPG/DDPC
liposomal mTHPC derivative Foslipos, using the prostate car-
cinoma cell line PC-3 as model.
Our microscopic studies on the cellular uptake showed
that Foslipos is quickly accumulating in the cytoplasm of
PC-3 cells while always sparing the nucleus. We conclude
that liposomal preparations do not affect the intracellular
distribution since comparable patterns had been reported
for mTHPC in a variety of human cell lines [25—27].
As shown before for PC-3-grafted mice [28], PC-3 cells
are highly responsive for mTHPC-mediated PDT. Under our
experimental conditions we repetitively observed an over
90% reduced cell count 24 h after PDT with Foslipos com-
pared to untreated controls. However, the kinetics of this
reaction were not linear but rather characterized by a two-
step process with an initial death of cells, being already
signiﬁcant a few minutes after light application in PDT (i.e.
at TP0) and a second — stronger — boost occurring more than
5 h later. Likely, the ﬁrst ‘‘hit’’ is due to direct detrimental
actions of short-lived reactive oxygen species (ROS), that
are known to be generated in fractions of seconds after PDT
and apparently kill a portion of cells immediately. However,
the majority of cells seemed to be merely damaged by ROS
and eventually undergo a death process that takes several
Table 7 List of genes involved in apoptosis signaling with expression levels altered at least 2-fold in samples subjected to
Foslipos-mediated PDT versus untreated controls. TP1: 1 h after illumination, TP5: 5 h after illumination.
Gene symbol Description Pathway Fold change TP1 Fold change TP5
BAX BCL2-associated X protein Apoptosis signaling −2.5 −3.5
BCL2L1 BCL2-like 1 Apoptosis signaling −4.1 −7.6
CASP8 Caspase 8, apoptosis-related cysteine peptidase Apoptosis signaling −2.0 −3.4
CASP10 Caspase 10, apoptosis-related cysteine
peptidase
Apoptosis signaling −2.5 −3.9
FASLG Fas ligand (TNF superfamily, member 6) Apoptosis signaling −3.8 −4.5
TNFRSF1A Tumor necrosis factor receptor superfamily,
member 1A
Apoptosis signaling −13.4 −6.4
TNFSF10 Tumor necrosis factor (ligand) superfamily,
member 10
Apoptosis signaling −28.0 −4.3
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hours. Whether the latter is related to apoptosis was not
within the scope of our experiments and will be the focus of
further studies.
To investigate the mechanisms leading to the observed
photodynamic effects in more detail we performed exper-
iments to characterize damaging effects on nucleic acids.
Results for DNA damage, RNA amount and integrity sup-
port our above observation of an acute PDT effect
that can be documented already shortly after light
application.
Since we were unable to localize photosensitizer ﬂuo-
rescence to the cell nucleus, it was surprising that directly
after PDT a signiﬁcant number of DNA strand breaks due
to base loss were already detectable. Based on anisotropy
imaging studies that showed a localization of mTHPC to
the nuclear envelope [29], light activation may have lead
to damage of this membrane compartment, allowing for
an immediate ROS-related injury of (peripherally residing)
DNA. However, results may also be explained by mecha-
nisms similar to those observed in a murine glioma cell
line, where mTHPC entered the nucleus during light applica-
tion [30]. The profound and early DNA damage may account
for instant cell destruction but — if not repaired — may
also result in, e.g. blocked DNA replication eventually lead-
ing to initiation of death cascades. Notably, even within
24 h after PDT no recovery of the number of abasic sites
(compared to TP1) was detected, indicating that no DNA
repair had been initiated. At the RNA level these results
are complemented by the observation that several impor-
tant genes associated with DNA repair mechanisms had been
transcriptionally downregulated or destroyed after PDT with
Foslipos. These include the early DNA damage sensor ATM,
DDB1, that is a subunit of the damage-speciﬁc DNA bind-
ing protein complex, the DNA excision repair endonucleases
ERCC1 and ERCC3, the postreplication DNA repair genes
RAD23A and RAD50, the uracil-DNA glycosylase UNG and the
DNA double strand repair proteins XRCC1 and XRCC2. Fur-
thermore, RNA for PCNA, that is involved in base-excision
repair pathways, was reduced. However, low DNA repair
capacities have dual effects: they confer a cytotoxicity
favorable for PDT by triggering cell death but surviving cells
are prone to mutations with unpredictable consequences.
In worst case this may result in secondary malignancies
after PDT. Our data are in accordance with those in murine
gliobastoma cells where mTHPC-PDT also resulted in an
immediate DNA damage, however, in this study and oth-
ers activation of repair mechanisms after PDT had been
reported [30—33]. Since our data are in contrast to in vitro
studies in human myeloid leukaemia and nasopharyngeal
carcinoma cells where no DNA damage was found after
mTHPC-PDT [34,35], the observed effect may depend on cell
line.
The signiﬁcantly lower readings at TP0 of RNA content
per cell after PDT versus all controls indicate that some RNA
was initially destroyed, — presumably by an acute and direct
effect of ROS on RNA and not by transcriptional regulation.
Not unexpected, the major part of speciﬁc genes investi-
gated here thus displayed lower transcript numbers after
PDT. Since total RNA consists to 90—95% of ribosomal RNA
(rRNA), our data may also point towards an impact of PDT
on the translational machinery itself. Interestingly, illumina-
tion alone (IRR) lead to a signiﬁcant increase of RNA amounts
measured at TP24, so that actually an interaction of effects
elicited by light on the one hand and ROS on the other hand
may take place after PDT.
Our further RNA expression studies focusing on estab-
lished genes involved in stress and toxicity indicated a
very complex molecular response of PC-3 cells to mTHPC-
mediated PDT, including both higher or lower transcript
levels of genes with the potential to either support or
counter-act PDT actions. While a higher gene expression
is due to an upregulation, lower expression scores may be
either a sign of PDT-related RNA destruction or of true down-
regulation. The latter may well be a consequence of the
observed oxidative DNA damage after PDT. However, with
regard to possible damage of rRNA in PDT it is far from clear
whether upregulated transcripts are in fact translated into
proteins.
Our study reveals reduced levels of genes involved in cel-
lular defense mechanisms against oxidative and metabolic
stress. PDT with other photosensitizers are partly in accor-
dance [36,37] and partly in contrast to our data [38,39].
Because CAT and SOD1 have been shown to protect cells
against phototoxic effects of hematophorphyrin derivative
or ALA in vitro [40,41] and inhibition of SODs results in
increased PDT effects [42], we hypothesize that the reduced
ability of the cells to cope with oxidative and metabolic
stress may constitute an important mechanism for PDT
effects with Foslipos. However, as in other studies [43,44],
we found that two antioxidant defense genes (CRYAB and
HMOX1) were strongly upregulated. The small heat shock
protein CRYAB and the heme oxygenase family member
HMOX are known to act as anti-apoptotic molecules that pro-
tect cells against oxidative damage [45]. Together with the
observation that inhibition of HMOX may increase the efﬁ-
cacy of PDT [44,46], we propose that — if translated — high
levels of HMOX or CRYAB may eventually prevent optimal
phototoxic effects.
Expression patterns of heat-shock proteins (HSPs) in our
study turned out to be very complex. Several previous papers
reported the induction of HSP60, HSP70 or HSP90 after PDT
with various photosensitizers [47—52]. However, HSPs con-
sist of large protein families and in our study we found that
expression of members may be downregulated or upregu-
lated after PDT with Foslipos. Upregulation of the HSP40
member DNAJB4 as well as HSP70 members HSPA1A, HSPA1L
and especially HSPA6, that is only induced by severe stress-
stimuli, may mirror the extent of damage in our model but
also indicate the presence of a (partly) preserved stress-
response system. On the other hand it should be noted that
RNA levels of several HSP members investigated here are
downregulated. Thus protective mechanisms by HSPs may
be rather impaired after PDT with Foslipos. Notably, some
of the downregulated HSP70 members belong to essential
house keeping genes.
PDT with Foslipos may not only have direct destructive
effects on cells but may also block proliferation and induce
cell cycle arrest in survivors. Since cell damage is obvi-
ously so profound that repair mechanisms are not operative,
death pathways are eventually activated. As reported in
part previously [53—55], transcripts of cyclin family genes
CCNC, CCND1 and CCNG1 as well as of PCNA, a protein
crucial for DNA replication, were markedly reduced after
PDT in our model thereby possibly leading to a diminished
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proliferative activity. However, the observed downregula-
tion of cyclin-interacting transcription factor E2F1 may also
directly promote cell death, as reported previously for PC-3
cells [56]. The tumor suppressor p53 (TP53) is regarded as a
key factor for the regulation of cell growth and death. Inter-
estingly, we and others [57] found that PDT did not change
the expression of this gene. However, the expression of one
of the main targets of TP53, the cyclin-dependent kinase
inhibitor CDKN1A, was reduced after PDT in our study, fur-
ther supporting an impact of PDT on cell cycle processes.
Our data are in contrast to PDT studies that report an
increase in CDKN1A [58]. Since MDM2, an important inhibit-
ing factor of p53, was reduced in our study, the ratio of
MDM2 to TP53 apparently changed. This may be associated
with the potential of increased p53-related pathways and/or
reduced p53 degradation followed by cell cycle arrest and
apoptosis. Furthermore, we found a strong upregulation of
the bZIP transcription factor DDIT3 — notably independent
of p53 — after PDT. Since DDIT3 had been implicated in
anti-proliferative effects and the induction of apoptosis by
certain anti-cancer agents, including in PC-3 cells [59], the
observed high levels may have also contributed to growth
arrest and apoptotic signaling in our experiment after
PDT.
We here report a marked downregulation of IGFBP6 after
PDT. Being a relatively speciﬁc inhibitor of IGF-II action,
high levels of IGFBP-6 had been found to block prolifera-
tion and increase apoptosis in vitro, including in PC-3 cells
[60,61].
In our study, genes involved in apoptosis signaling all dis-
played reduced transcript numbers. Most of these genes
seem to be damaged early — probably due to direct ROS
effects. TNFRSF1A, that binds CASP8, as well as both the
apoptosis-inducing ligands TNFSF10 and FASLG are almost
completely shut down already at TP1 in our model. The bio-
logical consequences of fewer apoptosis-promoting BAX in
addition to fewer anti-apoptotic BCL2L1 transcripts in PDT
with Foslipos are not clear yet. Of interest is the further
reduction of CASP8 and CASP10 RNA over time that is sug-
gestive of a PDT-driven regulatory process. Since many of
cell death processes are more adequately investigated at
the protein level our data do not generally exclude the acti-
vation of apoptotic pathways in Foslipos-mediated PDT. The
results may rather be another sign of a breakdown in basic
cellular functions.
Taken together, we propose that Foslipos-mediated PDT
in PC-3 cells is characterized by a two-stage process. A sig-
niﬁcant number of cells is disintegrated within minutes,
— a process that is likely driven by direct actions of ROS
on vital biological components. Even in in vitro systems
that ought to contain a homogeneous population of cells
and that uniformly accumulate the photosensitizer, the
majority of cells survive this attack. Of course we can-
not exclude that this is due to our experimental set-up
with, e.g. unequal illumination. However, initially surviving
cells go into growth arrest and display signs of an oxida-
tive stress response, while many transcripts whose proteins
are known to contribute to cellular rescue mechanisms
are reduced. Since this is in parallel to severe damages
of genomic DNA and the translational system, cells are
unable to recover and ultimately die after a delay of several
hours.
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3. Effects of Hypericin and a Chlorin Based Photosensitizer alone or in Combination in 
Squamous Cell Carcinoma Cells in the Dark 
 
The following manuscript is accepted in Photodiagnosis and Photodynamic Therapy Journal. 
 
The contributions of Emina Besic Gyenge to the study: „Dark Activity of Hypericin and a 
Chlorine Based Photosensitizer alone or in Combination in Squamous Cell Carcinoma Cells” 
were the following: 
 
1. Cell culturing  
 
2. Proliferation assay experiment in UMB-SCC 969 cell line figure 1 
 
3. Intracellular accumulation of photosensitizers in UMB-SCC 969 cell line, in particular: 
figure 2.1 (confocal imaging of time dependent accumulation of hypericin, Foslipos® and 
their 1:1 mixture) and figure 2.2 (fluorescence measurements of time dependent accumulation 
of hypericin, Foslipos® and their 1:1 mixture)and figure 3.1 (confocal imaging of time 
dependent elimination of hypericin, Foslipos® and their 1:1 mixture)and figure 3.2 
(fluorescent measurements of time dependent elimination of hypericin, Foslipos® and their 
1:1 mixture) 
 
4. Photosensitizer localisation experiments and confocal imaging in UMB-SCC 969 cell line 
figure 4 
 
5. RNA extraction and RNA integrity number measurements figure 5 (for both cell lines) 
 
6. DNA damage (comet assays) for UMB-SCC 969 cell line figure 6 
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Summary
Introduction:  The  toxic  inﬂuence  of  photosensitizers  in  the  dark  is  poorly  investigated.  In
our study  we  used  the  photosensitizers  liposomal  meso-tetrahydroxyphenyl  chlorin  derivative
(Foslipos®)  and  hypericin  as  well  as  their  1:1  combination  on  two  different  head  and  neck
squamous cell  carcinoma  (HNSCC)  cell  lines  (UMB-SCC  745  and  UMB-SCC  969).
Materials  and  methods:  We  examined  uptake,  efﬂux  and  localization  of  the  photosensitizers
with confocal  microscopy.  Fluorescence  quantiﬁcation  was  measured  with  a  micro-plate  spec-
trometer. Special  interest  was  given  to  effects  on  cell  proliferation  (BrdU  proliferation  assay),
RNA quality  (Bioanalyzer  measurements)  and  DNA  damage  (comet  assays)  in  the  dark.
Results:  Foslipos® uptake  was  linear  over  time  and  its  efﬂux  was  not  achieved  even  after  24  h
while uptake  of  hypericin  reached  a  plateau  after  5  h  and  was  almost  eliminated  after  24  h.
Localization  of  Foslipos® was  organelle-unspeciﬁc.  Hypericin  was  found  mainly  at  membranes
and in  trans-golgi  network.  Foslipos® treated  cells  showed  cell  toxicity  for  the  highest  concen-
tration (10  g/mL).  In  contrast,  hypericin  was  toxic  for  all  concentrations  (10—0.6  g/mL).  The
photosensitizer  combination  was  non-toxic  for  all  concentrations  (10—0.6  g/mL).  No  changes
in RNA  quality  were  monitored.  Initial  DNA  damage  was  found  only  in  hypericin  treated  UMB-SCC
745, which  recovered  after  3  h.  No  signiﬁcant  DNA  damage  was  found  for  UMB-SCC  969.
Conclusion:  Our  data  shows  that  the  combinatorial  application  decrease  photosensitizer  toxic-
ity, which  can  be  advantageous  in  PDT  treatments.
© 2012  Elsevier  B.V.  All  rights  reserved.
∗ Corresponding author. Fax: +41 446355702.
E-mail address: emina.besicgyenge@uzh.ch (E. Besic Gyenge).
1 Contributed equally.
Introduction
Photodynamic  therapy  (PDT)  has  emerged  as  an  alterna-
tive  treatment  modality  for  patients  with  head-and-neck
squamous  cell  carcinoma  (HNSCC)  that  may  supplement
or  even  replace  conventional  therapies  such  as  surgery,
radio-  and/or  chemotherapy  [1,2]. As  with  other  PDT
1572-1000/$ — see front matter © 2012 Elsevier B.V. All rights reserved.
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applications,  patients  had  been  reported  to  beneﬁt
from  the  minimal  invasiveness,  the  biocompatibility  with
other  treatment  modalities,  the  option  for  repeatabil-
ity,  the  absence  of  serious  side  effects,  the  excel-
lent  cosmetic  or  functional  outcome  and  the  fast
recovery  [3,4].
Various  ﬁrst  and  second  generation  photosensitizers  had
been  successfully  explored  for  PDT  of  early  primary,  sec-
ondary  and  recurrent  HNSCC  with  curative  and  palliative
aims  or  as  an  intraoperative  adjuvant,  including  porﬁmer
sodium,  haematoporphyrin  derivative,  talaporﬁn  sodium,
5-aminolevulinic  acid-induced  protoporphyrin  IX,  meso-
tetrahydroxyphenyl  chlorin  (mTHPC),  chlorin  e6  or  hypericin
[1,2].
In  most  cases  the  photosensitizer  is  administered  sys-
temically  and  shows  a  preferential  accumulation  in  tumor
cells  compared  to  healthy  tissue.  The  reason  for  the  lat-
ter  is  only  incompletely  understood,  but  may  be  related
to  e.g.  an  impaired  wall  integrity  of  tumor-supplying  ves-
sels  or  changes  in  the  metabolism  of  cancer  cells  leading
to  higher  photosensitizer  retention.  However,  the  exposi-
tion  by  photosensitizers  of  somatic  cells  is  considerable
in  such  protocols  and  may  eventually  result  in  an  uptake
of  the  photosensitizer  into  various  tissues  of  the  body.
Although  PDT-mediated  cell  death  only  occurs  in  those
photosensitizer-bearing  cells  that  are  illuminated  with  the
appropriate  wavelength,  little  is  known  about  cellular  and
molecular  responses  that  may  occur  after  cellular  interac-
tion  with  photosensitizers  in  the  dark.
Studies  from  our  group  indicated  that  PDT  may  be
improved  if  a  combination  of  photosensitizers  is  applied.
We  reported  on  a  patient  who  showed  unexpected  photo-
toxic  effects  due  to  an  unintended  simultaneous  activation
of  (aminolevulinic  acid-induced)  protoporphyrin  IX  and
hypericin,  that  were  taken  for  the  diagnosis  of  breast  can-
cer  and  as  an  antidepressant,  respectively  [5].  Further
in  vitro  studies  on  keratinocyte  and  endometrial  cancer
cell  lines  conﬁrmed  that  the  combination  of  these  two
photosensitizers  and  white  light  resulted  in  a  synergis-
tic  enhancement  of  PDT  effects  [6,7]. In  addition,  we
recently  demonstrated  that  a  photosensitizer  mixture  of
mTHPC  and  hypericin  may  be  advantageous  for  antimicrobial
PDT  [8].
Currently,  no  studies  are  available  that  deal  with  possi-
ble  beneﬁcial  properties  of  photosensitizer  mixtures  for  PDT
of  malignant  head-and-neck  tumors.  As  a  ﬁrst  step  towards
the  evaluation  of  a  combined  systemic  hypericin/mTHPC-
mediated  PDT  protocol  for  HNSCC  patients,  we  here
investigate  possible  in  vitro  dark  activities  of  these  photo-
sensitizers  alone  and  in  combination.
Materials and methods
Photosensitizers
Foslipos® was  kindly  donated  from  Biolitec  AG,  Jena,
Germany  and  had  a  concentration  of  mTHPC  in  liposomes  of
1.5  mg/mL  (dissolved  in  water).  Hypericin  (1  mg)  was  pur-
chased  from  Invitrogen,  Basel,  Switzerland.  It  was  dissolved
in  1  mL  of  100%  ethanol  (EtOH).
Cell  culture
The  cell  lines  UMB-SCC  745  and  UMB-SCC  969  were  derived
from  oropharynx  and  tonsil  head  and  neck  squamous  cell
carcinomas,  respectively,  and  were  kindly  provided  by  Dr.
Robert  Mandic´,  Department  of  Otolaryngology,  Philips  Uni-
versity,  Marburg,  Germany.
The  cells  were  cultured  under  standard  conditions  (37 ◦C,
5%  CO2, 95%  air  atmosphere)  in  RPMI  growth  medium
(Invitrogen)  supplemented  with  10%  fetal  calf  serum  (FCS,
Sigma—Aldrich,  Buchs,  Switzerland),  1%  4-(2-hydroxyethyl)-
1-piperazineethanesulfonic  acid  (HEPES,  Invitrogen),  1%
Minimum  Essential  Medium  Non  Essential  Amino  Acids  (MEM
NEAA,  Invitrogen)  and  1%  penicillin  and  streptomycin  (Invit-
rogen).
Every  second  day  the  growth  medium  was  replaced.
When  the  cells  reached  conﬂuence,  the  cell  passaging
was  done  with  trypsin  (1×,  Invitrogen),  in  general  every
2—3  days.
Proliferation  assay
The  dark  cytotoxicity  was  evaluated  using  a  commer-
cial  cell  proliferation  assay  (Cell  Proliferation  ELISA,  BrdU
(chemiluminescent),  Roche,  Basel,  Switzerland).  The  cells
were  seeded  in  black  96-well  plates  (2000  cells/well,
Greiner,  Solingen,  Germany)  with  100  L  growth  medium
and  cultured  at  37 ◦C,  5%  CO2 for  24  h.  Next,  the  growth
medium  was  replaced  with  fresh  one  containing  hypericin
or  Foslipos® or  a combination  of  both  at  ﬁnal  concen-
trations  ranging  between  10  g/mL  and  0.6  g/mL.  The
control  samples  were  treated  with  the  same  amount  of
100%  EtOH  as  applied  in  hypericin  and  phototsensitizer
mixture  treated  cells.  After  an  incubation  time  of  5  h,
the  cells  were  washed  with  phosphate  buffered  saline
(PBS,  Oxoid,  Hampshire,  United  Kingdom)  and  incubated
overnight  with  fresh  growth  medium  (200  L/well)  contain-
ing  BrdU-labeling  agent.  Incorporated  BrdU  was  detected
with  an  ELISA  immunoassay  according  to  the  manufacturer’s
protocol.  The  resulting  signal  was  quantiﬁed  by  measur-
ing  the  photons  using  a  micro-plate  spectrometer  with
photomultiplier  technology  (BioTek  Instruments,  Luzern,
Switzerland).
Photosensitizer  intracellular  accumulation
5000  cells/well  were  seeded  in  black  96-well  plates
(Greiner)  and  grown  overnight  at  37 ◦C.  For  the  accu-
mulation  study  photosensitizers  (hypericin  and  Foslipos®,
2.5  g/mL  ﬁnal  concentration)  and  the  photosensitizer  mix-
ture  (1:1  mixture  of  hypericin  and  Foslipos®, 1.25  g/mL
each)  were  incubated  for  several  time  points  (1  and  30  min,
1  h,  3  h,  5  h,  7  h  and  24  h).  Sextuplicates  were  used  for  each
time  point  and  cell  line.
Furthermore,  cells  were  incubated  with  hypericin  or
Foslipos® and  photosensitizer  mixture  (1:1  mixture  of  hyper-
icin  and  Foslipos®),  respectively,  for  5  h.  Subsequently
growth  medium  was  replaced  with  fresh  one  and  left  in  the
incubator  during  different  time  points  (1  min,  1  h,  3  h,  5  h,
7  h  and  24  h).
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For  both  experiments  the  cells  were  washed  three  times
with  PBS  and  ﬂuorescence  was  subsequently  measured
quantitatively  with  a  micro-plate  spectrometer  (Tecan  Inﬁ-
nite  M1000,  Tecan  Group  Ltd.,  Männedorf,  Switzerland).
To  exclude  cross-talks  between  photosensitizers  each
micro-well  plate  was  measured  four  times  with  following
adjustments:  excitation  wavelengths  420  nm  and  554  nm  and
emission  wavelengths  600  nm  and  654  nm.
In  addition  cells  were  seeded  on  poly-L-lysine  (PLL,
0.25  mg/mL,  Sigma—Aldrich)  —  coated  glass  cover  slips
(50,000  cells,  Hecht-Assistant,  Sondheim,  Germany).  The
cells  were  then  incubated  as  reported  above.  For  each
condition  doublets  were  made.  After  treatment  cells  were
washed  with  PBS,  ﬁxed  for  15  min  with  PBS  containing  1%
paraformaldehyde  (PFA,  Sigma—Aldrich)  and  0.33%  saccha-
rose  (Sigma—Aldrich),  permeabilized  with  0.01%  Triton  X-100
(Roche)  for  1.5  min,  nuclei  stained  with  4′-6-diamidino-2-
phenylindole  (DAPI,  1  g/mL,  Roche)  and  ﬁnally  mounted  on
cover  slides  with  Glycer  Gel  (Dako,  Baar,  Switzerland).  The
monitoring  was  carried  out  with  a  confocal  laser  scanning
microscope  (Leica  SP2,  Heerbrugg,  Switzerland).  Excita-
tion  wavelength  for  hypericin  was  594  nm,  for  Foslipos®
and  for  the  photosensitizer  mixture  488  nm.  Emission  wave-
lengths  were  in  the  range  of  640—720  nm  for  Foslipos®, for
hypericin  590—680  nm  and  for  mixture  590—720  nm.  Exci-
tation  wavelength  for  the  visualisation  of  DAPI  was  350  nm
and  for  detection  a  wavelength  range  of  450—500  nm  was
used.
Photosensitizer  localisation  (immunocytochemistry):
Both  cells  lines  were  cultured  on  PLL  coated  cover  slides
and  incubated  for  5  h  with  hypericin,  Foslipos® and  a  1:1
mixture  of  both  at  ﬁnal  concentrations  of  2.5  g/mL.
After  incubation  cells  were  ﬁxed  for  15  min  with  1%  PFA,
permeabilized  with  0.01%  Triton  X-100  (Roche)  for  1.5  min,
then  blocked  for  30  min  at  room  temperature  with  0.1%
bovine  serum  albumin  (BSA,  Calbiochem,  San  Diego,  USA)
and  afterwards  washed  with  PBS.  For  labelling  of  golgi  appa-
ratus  and  trans  golgi  network  mouse  anti-cis  golgi  matrix
protein  130  antibody  (GM130,  1:500,  stock  concentration
0.7  mg/mL,  Abcam,  Cambridge,  United  Kingdom)  and  rabbit
anti-trans  golgi  network  protein  antibody  (TNG46,  1:500,
stock  concentration  0.5  mg/mL,  Abcam),  respectively,  were
used.  Visualisation  of  endoplasmic  reticulum  was  achieved
with  mouse  anti-protein  disulﬁde  isomerase  antibody  (PDI,
1:200,  stock  concentration  1  mg/mL,  Abcam).  Mitochondria
were  stained  with  Mitotracker  Orange  (working  solution
300  nM,  Invitrogen).
The  primary  antibodies  were  incubated  for  2  h  at  room
temperature  or  overnight  at  4 ◦C.  Subsequently  the  samples
were  washed  and  incubated  with  FITC-labelled  donkey  anti-
rabbit  or  anti-mouse  antibodies  respectively  (both  1:500,
Sigma—Aldrich)  together  with  DAPI  (1  g/mL)  for  1  h  at  room
temperature.  After  washing  samples  were  mounted  and
examined  with  confocal  microscopy.  Excitation  and  detec-
tion  wavelengths  for  photosensitizers  and  DAPI  were  chosen
as  described  above.  For  FITC  detection  an  excitation  wave-
length  of  488  nm  was  used  and  emission  was  recorded  in  the
range  of  490—540  nm.
For  all  confocal  studies  control  experiments  were
performed,  cells  were  cultured  as  described,  but
photosensitizer-containing  medium  was  replaced  with
growth  medium.
RNA  quality
Cells  were  grown  in  6-well  plates  (500,000  cells/well;
doublets  for  each  condition,  Greiner)  under  standard  con-
ditions  overnight.  Next,  single  photosensitizers  (hypericin
and  Foslipos®)  and  the  photosensitizer  mixture  (1:1  mix-
ture  of  hypericin  and  Foslipos®)  were  incubated  for  5  h  at
ﬁnal  concentrations  of  2.5  g/mL  (1.25  g/mL  each  in  pho-
tosensitizer  mixture).  Subsequently  photosensitizer  growth
medium  was  replaced  with  fresh  one  without  photosensi-
tizers.  RNA  extraction  was  made  with  NucleoSpin  RNA  II
Kit  (Macherey-Nagel,  Oensingen,  Switzerland)  according  to
the  provided  protocol.  The  cells  were  lysed  with  350  L
lysis  buffer  (RA1)  containing  3.5  L  -mercaptoethanol  and
stored  at  −20 ◦C  until  use.  The  whole  extraction  procedure
was  performed  in  the  dark.  The  ﬁnal  RNA  elution  step  was
done  with  40  L  RNase-free-water.
The  RNA  yield  was  determined  with  a  Nanodrop-
spectrometer  (Thermo  Fisher  Scientiﬁc,  Essex,  United
Kingdom)  and  RNA  quality/integrity  with  a Bioanalyzer  Agi-
lent  2100  (Agilent  Technologies,  Santa  Clara,  USA).  We  used
either  pico-chips  for  RNA  concentrations  between  0.2  and
5  ng/L or  nano-chips  for  concentrations  between  50  and
500  ng/L (both  chips  from  Agilent  Technologies).  Measure-
ments  and  corresponding  analysis  (determination  of  RNA
Integrity  Number,  RIN)  were  acquired  by  the  RIN  algorithm
software  of  the  Bioanalyzer.
DNA  damage  (comet  assays)
500,000  cells/well  were  seeded  in  6  well  culture  plates
(Greiner)  and  grown  overnight.  After  photosensitizer  incu-
bation  (hypericin  and  Foslipos® and  1:1  mixture  of  both,
2.5  g/mL  total  concentration)  for  5  h  comet  assays  [9]
were  performed  directly  (TP  1  =  0  h)  or  3  h (TP  2  =  3  h)  after
removal  of  photosensitizer.  Brieﬂy,  for  the  ﬁrst  microscopy
slide  coating  1%  normal  melting  point  agarose  (Fluka,  St.
Louis,  USA)  was  used.  After  the  photosensitizer  incuba-
tion  the  cells  were  detached  with  cell  stripper  solution
(CELLGRO,  Manassas,  USA)  supplemented  with  0.05%  trypsin
(Invitrogen)  and  subsequently  transferred  to  1%  low  melt-
ing  point  agarose  (LMPA;  Fluka).  After  placing  of  350  L  of
LMPA  cell  solution  on  microscopy  slides  the  samples  were
kept  at  4 ◦C  for  15  min.  The  slides  were  then  placed  in  lysis
buffer  (2.5  M  NaCl,  100  mM  EDTA,  10  mM  Trizma  base,  pH
10)  for  one  hour  and  subsequently  electrophoresis  (10  M
NaOH  and  200  mM  EDTA,  pH  >  13)  was  done  for  30  min  at
24  V/cm.  After  neutralisation  (0,4  M  Tris-buffer,  pH  7,5),
samples  were  stained  with  GelRed  Nucleic  Acid  Staining
(Roche  Diagnostics),  washed  and  mounted  with  cover  slips.
As  a  positive  control  staurosporin  (1  g/mL,  3  h)  treated
cells  were  used.  Examination  was  performed  with  wide  ﬁeld
microscopy  (Leica  LX,  Heerbrugg,  Switzerland).  Statistical
calculations  were  made  with  one  way  Anova  Tukey’s  Multiple
Comparison  Test,  p  <  0.05  was  considered  as  signiﬁcant.
Results
The  effects  of  photosensitizers  on  cell  proliferation  in  the
dark  are  shown  in  Fig.  1A  and  B.  Signiﬁcant  reduction  of
cell  viability  was  found  for  Foslipos® treated  samples  at
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Figure  1  BrdU  proliferation  assays  in  UMB-SCC  745  (in  A)  and  UMB-SCC  969  (in  B)  cells  after  5  h  incubation  of  photosensitizers
(hypericin in  black,  Foslipos® in  red  and  mixture  of  both  in  blue)  at  different  concentrations  ranging  from  0  to  10  g/mL.  The
concentration  of  single  photosensitizer  in  the  mixture  was  always  half  of  the  overall  concentration.  (For  interpretation  of  the
references to  color  in  this  ﬁgure  legend,  the  reader  is  referred  to  the  web  version  of  this  article.)
highest  (10  g/mL)  photosensitizer  concentration  (up  to  60%
of  cell  viability  reduction  for  both  cell  lines).  Concentrations
of  2.5  g/mL  and  5  g/mL  respectively,  induced  up  to  20%
cell  proliferation  increase  compared  to  control  samples  (not
signiﬁcant)  which  were  set  to  100%.  The  concentrations  of
1.25  g/mL  and  0.6  g/mL  did  not  show  signiﬁcant  changes
in  cell  proliferation.  The  hypericin  treated  cells  (in  both
cell  lines)  displayed  signiﬁcant  cell  viability  reduction  for
all  photosensitizer  concentrations.  The  BrdU  assay  results
indicated  almost  linear  cell  toxicity  distribution  for  con-
centrations  between  1.25  and  10  g/mL.  The  highest  cell
viability  reduction  was  detected  for  the  hypericin  concen-
tration  of  10  g/mL  (60%  reduction).  The  concentrations
in  the  range  from  5  to  1.25  g/mL  caused  a  cell  reduc-
tion  between  20  and  36%  (Fig.  1A  and  B).  The  lowest
hypericin  concentration  (0.6  g/mL)  led  to  a  proliferation
reduction  of  42%  for  both  cell  lines.  Despite  the  same
overall  photosensitizer  concentration  in  the  mixture  no  sig-
niﬁcant  reduction  of  cell  proliferation  was  found.  This  was
observed  for  all  applied  photosensitizer  concentrations  from
0.6  g/mL  to  10  g/mL.  Based  on  these  results  a photo-
sensitizer  concentration  of  2.5  g/mL  was  used  for  further
studies.  For  the  mixture  single  photosensitizer  concentra-
tion  was  1.25  g/mL  each.
Subsequently  intracellular  accumulation  of  photosensi-
tizers  (2.5  g/mL)  over  different  time  periods  (0  and  30  min,
1  h,  3  h,  5  h,  7  h  and  24  h)  was  performed.  The  results  of  the
confocal  study  for  0  h,  5  h  and  24  h  for  both  cell  lines  and
all  photosensitizer  treatments  are  depicted  in  Fig.  2.1  and
in  addition  Fig.  2.2  displays  the  quantitative  ﬂuorescence
measurements  (time  points  0  h,  1  h,  3  h,  5  h,  7  h  and  24  h).
Fig.  2.1  shows  confocal  pictures  of  hypericin  uptake  which
clearly  display  increase  of  hypericin  aggregates  after  5  h
in  both  cell  lines.  The  ﬂuorescence  measured  for  hypericin
treated  cells  followed  a  Gaussian  distribution  curve  with  a
maximum  of  intensity  after  5  h  of  incubation  (Fig.  2.2A). The
increase  of  intracellular  ﬂuorescence  over  time  for  Foslipos®
treated  cells  was  continuous.  This  was  visible  from  confocal
pictures  and  quantitative  measurements  (Fig.  2.1  and  2.2B).
The  results  for  the  accumulation  of  the  mixture  were
consistent  with  results  obtained  for  single  photosensitizers
(Fig.  2.1  and  2.2C  respectively).  The  ﬂuorescence  intensity
was  weaker  (Fig.  2.2C) compared  to  single  photosensitizer
measurements  (3.5  times  weaker  for  hypericin  and  2.5  times
for  Foslipos® wavelengths  adjustments).
Results  of  photosensitizer  efﬂux  are  depicted  in
Fig.  3.1  and  3.2.  Again,  the  pictures  in  3.1  show  the
cells  with  corresponding  photosensitizer  after  different  time
points  (0  h,  5  h  and  24  h  after  preceding  5  h  of  incubation).
A  reduction  of  intracellular  amounts  of  hypericin  is  not  visi-
ble  after  5  h  but  almost  complete  cellular  clearance  occurs
within  24  h.  Only  few  hypericin  aggregates  were  detectable
after  this  time.  For  Foslipos® and  mixture,  respectively,
ﬂuorescence  signals  were  visible  even  after  24  h.  The  pho-
tosensitizer  mixture  treated  cells  displayed  higher  amount
of  aggregates  as  found  in  hypericin-only  treated  cells.
The  quantitative  measurements  showed  that  after  24  h  the
hypericin  ﬂuorescence  signal  is  reduced  by  over  95%,  for
Foslipos® a  reduction  of  65%  was  visible  and  ﬁnally  for  mix-
ture  an  over  95%  reduction  in  case  of  hypericin  and  reduction
up  to  65%  in  case  for  Foslipos® was  detected  (Fig.  3.2B). Both
cell  lines  displayed  similar  behaviour.
Further,  we  addressed  our  study  to  intracellular  localisa-
tions  of  photosensitizers  after  5  h  of  incubation.  Hypericin
was  mainly  found  at  cellular  membranes  (outer  cell  mem-
branes  and  nuclear  membranes)  and  the  perinuclear  region.
Well-deﬁned  co-localisation  was  also  found  with  trans  golgi
network  protein  (TGN,  Fig.  4).  Foslipos® did  not  exhibit  any
co-localisation  with  stained  cell  organelles.  The  localisation
of  Foslipos® after  5  h  of  incubation  was  limited  unspeciﬁcally
to  the  cell  cytoplasm.  These  results  were  found  for  both  cell
lines.
The  RNA  quality  measurements  after  5  h  of  photosensi-
tizer  incubation  (2.5  g/mL)  showed  no  inﬂuence  on  RNA
integrity.  The  virtual  Northern  blots  are  depicted  in  Fig.  5.
The  quality  of  RNA  of  photosensitizer  treated  cells  was  the
same  as  for  the  control  samples,  the  RNA  integrity  numbers
(RIN)  ranged  from  10  to  9.8.
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Figure  2  Confocal  laser  microscopy  pictures,  shown  in  2.1,  displaying  accumulation  of  photosensitizer  (hypericin,  Foslipos® and
mixture of  both)  over  different  time  periods  (0  h,  5  h  and  24  h)  in  UMB-SCC  745  and  UMB-SCC  969  respectively.  Nuclei  are  shown
in blue  and  photosensitizers  in  red.  Scale  bars  =  20  m.  The  graphs  in  2.2  are  showing  quantitative  ﬂuorescence  measurements  of
photosensitizer  accumulation  (hypericin  in  A,  Foslipos® in  B  and  mixture  of  both  in  C)  over  time  (0—24  h)  in  UMB-SCC  745  and  UMB-
SCC 969  cells  respectively.  The  ﬂuorescence  of  photosensitizer  mixture  was  measured  once  with  hypericin  adjustments  (excitation
at 554  nm  and  detection  at  600  nm)  shown  in  2.2C  left  and  once  with  Foslipos® adjustments  (excitation  at  420  nm  and  detection  at
654 nm)  shown  in  2.2C  right.  (For  interpretation  of  the  references  to  color  in  this  ﬁgure  legend,  the  reader  is  referred  to  the  web
version of  this  article.)
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Figure  3  Confocal  laser  microscopy  pictures  in  3.1  are  displaying  elimination  of  photosensitizers  (hypericin,  Foslipos® and  mixture
of both,  incubation  time  5  h  correspond  to  0  h  in  the  pictures)  over  different  time  periods  (0  h,  5  h  and  24  h)  in  UMB-SCC  745  and
UMB-SCC 969  respectively.  Nuclei  are  shown  in  blue  and  photosensitizers  in  red.  Scale  bars  =  20  m.  The  graphs  in  3.2  are  showing
quantitative ﬂuorescence  measurement  of  photosensitizer  elimination  (hypericin  in  A,  Foslipos® in  B  and  mixture  of  both  in  C,
incubation time  5  h)  over  time  (0—24  h)  in  UMB-SCC  745  and  UMB-SCC  969  cells  respectively.  The  ﬂuorescence  of  photosensitizer
mixture was  measured  once  with  hypericin  adjustments  (excitation  at  554  nm  and  detection  at  600  nm)  shown  in  3.2C  left  and  once
with Foslipos® adjustments  (excitation  at  420  nm  and  detection  at  654  nm)  shown  in  3.2C  right.  (For  interpretation  of  the  references
to color  in  this  ﬁgure  legend,  the  reader  is  referred  to  the  web  version  of  this  article.)
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Figure  4  Confocal  laser  microscopy  pictures  showing  partial  (in  yellow)  co-localization  of  hypericin  (in  red)  with  transgolgi  network
(TGN, in  green)  in  UMB-SCC  745  and  UMB-SCC  969  respectively.  Foslipos® did  not  display  any  co-localization  with  TGN.  Nuclei  are
shown in  blue  and  photosensitizers  in  red.  Scale  bars  =  10  m.  (For  interpretation  of  the  references  to  color  in  this  ﬁgure  legend,
the reader  is  referred  to  the  web  version  of  this  article.)
The  DNA  damage  assay  was  performed  with  single  cell
electrophoresis  (comet  assay).  Fig.  6A  shows  measurements
of  comet  tail  length  immediately  (TP  1)  and  3  h  (TP  2)
after  previous  photosensitizer  incubation  (5  h)  compared  to
untreated  cells.  The  UMB-SCC  969  did  not  display  any  sig-
niﬁcant  DNA  damage  for  all  applied  treatments.  In  contrast,
the  UMB-SCC  745  cell  line  experienced  signiﬁcant  DNA  dam-
age  for  hypericin  treatment  immediately  after  incubation.
The  comet  tails  were  1.4  fold  longer  then  comet  tails  in
untreated  cells.  After  3  h  post  incubation  of  photosensi-
tizer  (TP  2),  comet  tails  displayed  signiﬁcant  recovery  (half
as  long  comet  tails  as  measured  immediately  after  incuba-
tion)  but  the  damage  was  still  signiﬁcant  if  compared  to
the  untreated  cells.  In  hypericin  treated  samples  we  could
observe  a  2%  of  cell  population  (at  TP  1)  with  very  long
comet  tails  (high  DNA  damage).  This  cell  population  did  not
exhibit  any  recovery  even  after  3  h  (TP  2).  Still,  the  DNA
damage  (comet  tail  length)  caused  with  hypericin  in  com-
parison  to  those  induced  with  staurosporin  (positive  control)
was  in  general  negligibly  small  (Fig.  6B).  The  UMB-SCC  745
cell  line  did  not  exhibit  any  signiﬁcant  comet  tail  change
for  Foslipos® or  photosensitizers  mixture  treatment  for  both
time  points.  Fig.  6B  displays  confocal  pictures  of  untreated
UMB-SCC  745  cells,  hypericin  and  staurosporin  treated  cells.
Discussion
PDT  is  becoming  an  important  alternative  treatment  modal-
ity  for  head  and  neck  squamous  cell  carcinoma  (HNSCC)  [1].
Further,  it  is  reported  that  every  photosensitizer  possesses
certain  beneﬁts  for  its  use  in  PDT  [10,11]  and  according
to  our  previous  studies  [7,8]  using  several  photosensitiz-
ers  simultaneously  could  improve  PDT  outcome.  It  is  very
important  to  elaborate  and  exclude  all  possible  photosensi-
tizer  cross  effects  (chemical  and  intracellular)  in  the  dark
before  investigating  PDT  effects.  In  our  study  we  applied  a
liposomal  mTHPC  derivative  (Foslipos®) and  one  of  the  most
powerful  naturally  occurring  photosensitizers,  hypericin,  on
two  different  HNSCC  cell  lines.
Physicochemical  photosensitizer  properties  play  a  vital
role,  apart  from  solubility  and  biomolecular  (proteins  and
membranes)  interaction  behaviour,  in  cellular  tolerability.
The  photosensitizer  effects  on  cell  viability  in  the  dark  are
poorly  explored.  Hypericin  treated  cells  showed  prolifera-
tion  decrease  for  all  concentrations  in  both  cell  lines.  This
could  be  due  to  the  light  independent  inhibition  of  differ-
ent  enzymes  [12]  such  as  protein  kinase  C,  various  protein
tyrosine  kinases  or  mitochondrial  succinoxidase,  which  play
an  important  role  in  cell  survival,  growth,  proliferation  and
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Figure  5  The  virtual  Northern  blots  displaying  RNA  quality  after  5  h  of  incubation.  In  (A)  are  displayed  results  for  UMB-SCC  745
cells and  in  (B)  for  UMB-SCC  969  cells.  The  RNA  quality  measurements  were  performed  with  Bioanalyzer  Agilent  2100.
death  [13,14].  It  is  reported  that  in  most  cases  these  effects
are  more  prominent  under  light  application  and/or  if  hyper-
icin  is  slightly  chemically  modiﬁed  [15]. In  contrast  to  the
above  mentioned  minor  inhibitions,  Johnson  and  Pardini
[16]  reported  that  hypericin  showed  strong  light  indepen-
dent  inhibitory  activity  against  glutathione  reductase  (IC50
of  about  2  nmol/L),  which  is  an  important  cellular  antiox-
idant.  Low  intracellular  levels  of  antioxidants  can  cause
oxidative  stress  and  may  lead  to  cell  damage.  It  was  also
reported  that  hypericin  has  a  50%  competitive  inhibition  for
several  species  of  cytochrome  P450  [17,18],  whereupon  var-
ious  metabolic  processes  could  be  affected.  Additionally,  it
is  known  that  hypericin  can  cause  reduction  in  intracellular
pH  by  proton  transfer  to  surrounding  molecules  leading  to
pH  dependent  structural  changes  in  proteins  [19]. All  these
ﬁndings  could  account  for  affected  cell  proliferation  in  our
study.  Further  investigations  on  this  topic  were  not  within
the  scope  of  our  study  but  will  be  the  focus  of  subsequent
experiments.  Foslipos® treated  cells  showed  only  signiﬁcant
changes  for  highest  photosensitizer  concentrations  (up  to
45%  viability  decrease  for  10  g/mL).  The  mechanisms  which
affect  cell  viability  are  not  yet  known.  Kiesslich  et  al.  [20]
reported  that  Foslip® (difference  to  Foslipos® 5%  glucose  in
the  solution)  has  a  dark  toxic  effect  in  gall  bladder  cancer
(GBC)  and  bile  duct  cancer  (BDC)  cell  lines  starting  from
20  g/mL  (∼5%  decrease)  to  100  g/mL  (∼85%  decrease)
photosensitizer  concentration.  The  additional  5%  of  glucose
in  Foslip® can  be  excluded  as  a  reason  for  the  proliferation
decrease  in  our  cell  models  because  both  photosensitizer
formulations  were  tested  (data  not  shown).  The  use  of  a
different  cell  model  is  more  likely  as  an  explanation.  In  our
study  the  proliferation  assays  with  photosensitizer  mixture
application  in  the  dark  indicated  that  even  with  the  highest
concentrations  (10  g/mL,  hypericin  and  Foslipos® 5  g/mL
each)  cell  viability  remains  the  same  as  for  control  sam-
ples.  The  decrease  in  cell  proliferation  for  5  g/mL  hypericin
(showed  in  a  proliferation  assay  experiment  for  hypericin
alone)  was  approximately  36%.  The  mechanisms  underlying
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Figure  6  The  relative  (compared  to  control  samples)  fold  change  of  comet  tail  length  of  hypericin,  Foslipos® and  photosensitizer
mixture treated  cells  is  shown  in  (A)  after  TP  1  =  0  h  and  TP  2  =  3  h  (post  previous  5  h  of  incubation)  without  illumination  in  both  cell
lines (UMB-SCC  745  and  UMB-SCC  969).  (B)  Wideﬁeld  ﬂuorescent  microscopy  pictures  of  comet  tails  (in  red)  of  untreated,  hypericin
and staurosporin  treated  UMB-SCC  745  cells.  The  scale  bars  =  10  m.  *p  <  0.001.  (For  interpretation  of  the  references  to  color  in  this
ﬁgure legend,  the  reader  is  referred  to  the  web  version  of  this  article.)
the  improved  tolerability  of  the  photosensitizer  mixture  are
not  clear.  However,  since  hypericin  is  known  to  attach  to
lipoproteins  and  incorporates  into  lipid  membranes  [21], it
cannot  be  excluded  that  in  the  mixture  hypericin  interacts
with  Foslipos® liposomes,  thereby  changing  its  bioactivity.
The  cell  dependent  behaviour  of  photosensitizer  uptake
and  their  efﬂux  were  shown  in  many  studies.  For  example
Kiesslich  et  al.  [22]  investigated  9  different  biliary  cancer
cell  lines  on  uptake,  release  and  phototoxicity  of  mTHPC
and  found  great  variations  in  uptake  between  individual
cell  lines  resulting  in  even  more  pronounced  differences
in  phototoxicity.  Ritz  et  al.  [23]  showed  different  hyper-
icin  uptake  in  12  primary  human  glioma  cell  cultures.  They
assumed  that  the  uptake  was  dependent  on  an  energy
dependent  uptake  process  involving  LDL  receptor-related
proteins.  Photosensitizer-uptake  and  -efﬂux  processes  in
our  study  were  similar  for  both  cell  lines.  Uptake  of
hypericin  followed  a  Gaussian  curve  distribution  with  a  ﬂuo-
rescence  maximum  after  5  h  of  incubation.  The  intracellular
aggregation  of  hypericin  was  visible  in  our  confocal  observa-
tions  and  it  was  increasing  over  incubation  time.  Hypericin
aggregates  (stacked  and  planar  associations)  [24]  are  well
documented  and  examined.  Additionally,  it  is  reported  that
this  leads  to  ﬂuorescence  quenching  which  we  could  observe
in  our  quantitative  ﬂuorescence  measurements.  On  the
one  hand  aggregate  formation  prevents  the  photosensitizer
photodegradation  [25,26]  but  on  the  other  hand  hypericin
diffusion  is  heavily  affected  [27]  and  therewith  also  its
cellular  uptake  in  case  the  aggregation  takes  place  extracel-
lularly  and/or  cellular  efﬂux  in  case  it  occurs  intracellularly.
Confocal  pictures  of  hypericin  intracellular  clearance  dis-
played  that  hypericin  aggregates  are  present  even  after  24  h.
This  can  have  a  negative  effect  on  PDT  outcome  prolong-
ing  photosensitivity  if  applied  in  vivo.  Foslipos® uptake  was
continuous  over  24  h,  corresponding  to  the  results  achieved
in  our  study  with  the  prostate  carcinoma  cell  line  PC-3  [28]
and  many  other  studies  [29]  including  work  of  Kiesslich  et  al.
[20]  who  has  demonstrated  a  continuous  uptake  reaching  a
plateau  of  the  cellular  ﬂuorescence  after  36  h.  The  cellular
efﬂux  of  Foslipos® in  our  cell  models  was  slightly  differ-
ent  to  this  study.  UMB-SCC  745  displayed  45%  and  UMB-SCC
969  25%  of  Foslipos® ﬂuorescence  intracellularly  after  24  h.
The  Foslip® retention  in  GBC  and  BDC  cells  was  very  high
even  after  48  h  (48%  for  GBC  and  beyond  70%  for  BDC  cells)
post  medium  exchange,  which  was  high  enough  even  for
a  suitable  PDT  effect.  The  slow  release  of  mTHPC  and  its
derivatives  from  the  cells  was  reported  in  several  other
studies  [30,31]  and  remains  unclear.  Our  slightly  different
ﬁndings  in  photosensitizer  uptake  and  efﬂux  in  HNSCC  cell
lines  could  be  a  result  of  different  cellular  and  metabolic
processes  and  direct  comparison  to  studies  is  difﬁcult.
Photosensitizer  mixture  uptake  and  efﬂux  studies  on  both
UMB-SCC  cell  lines  were  comparable  to  the  observations
achieved  with  single  photosensitizers.  The  ﬁrst  observed
difference  was  a  higher  amount  of  hypericin  aggregates
after  24  h  in  photosensitizer  efﬂux  experiment  in  comparison
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to  hypericin  alone.  Another  important  observation  is  that
hypericin  ﬂuorescence  intensity  in  the  uptake  study  after  5  h
(shown  in  Fig.  2.2)  was  3.5  times  and  after  24  h  even  5  times
weaker  than  it  theoretically  should  be.  The  higher  amount
of  hypericin  aggregates  and  photosensitizers  near  proxim-
ity  could  eventually  cause  ﬂuorescence  quenching.  Taken
together  these  ﬁndings  indicate  slightly  different  intracel-
lular  behaviour  of  hypericin  if  combined  with  Foslipos® and
further  studies  on  this  topic  are  needed.
Subcellular  localisation  of  photosensitizers  is  very  impor-
tant  for  PDT  outcome  and  it  seems  to  be  photosensitizer
and  cell  line  dependent.  In  our  study,  5  h  post  incubation
hypericin  was  mainly  found  in  membranous  systems  (outer
cellular  membranes,  nuclear  membranes,  trans  golgi  net-
work  and  perinuclearly).  In  many  studies  the  intracellular
localisation  of  hypericin  was  investigated.  A  review  of  Theo-
dossiou  et  al.  [32]  summarised  hypericin  localisation  places
in  several  different  cell  lines  reaching  from  lipid  membranes
and  nucleus  to  various  cell  organelles  like  mitochondria,  ER,
Golgi  apparatus  or  lysosomes.  The  distribution  and  localisa-
tion  of  hypericin  seems  to  be  driven  by  many  factors  like
photosensitizer  concentration,  incubation  time,  cell  lines
and  incubation  parameters  or  presence  of  serum  proteins.
A  direct  data  comparison  with  other  studies  is  therefore
rather  difﬁcult.  Foslipos® did  not  co-localise  with  any  cell
organelle  stain  and  it  remained  diffuse  in  cytoplasm  of  both
UMB-SCC  cell  lines.  These  ﬁndings  are  similar  to  those  found
in  our  previous  study  with  PC-3  cells  [28]  or  in  the  study  of
Kiesslich  et  al.  [22]  where  Foslipos® accumulation  in  GBC  and
BDC  cell  lines  could  not  be  organelle-speciﬁcally  localized.
Also  herein  the  localisation  seems  to  be  dependent  on  the
cell  models  and  incubation  parameters.  In  the  mixture  the
localisation  of  single  photosensitizer  was  due  to  the  over-
lapping  absorption  and  emission  spectral  range  difﬁcult  to
separate  from  each  other,  therefore  well-deﬁned  immuno-
cytochemistry  in  photosensitizer  mixture  treated  cells  was
not  feasible.  However,  in  general  the  observation  of  pho-
tosensitizer  localisation  in  the  mixture  was  not  remarkably
different  compared  to  the  confocal  pictures  made  for  single
photosensitizers  (Fig.  2.1).
Intracellular  accumulation  of  photosensitizers  without
illumination  did  not  show  any  inﬂuence  on  overall  RNA  qual-
ity.  These  results  correspond  to  our  previous  study  with
prostate  carcinoma  cell  line  PC-3  [28]. In  contrast,  transient
DNA  damage  was  detected,  but  only  in  case  of  hypericin
treated  UMB-SCC  745  cells.  Since  UMB-SCC  745  cells  did
not  show  signiﬁcant  differences  in  photosensitizer  uptake,
efﬂux  or  localisation  a  plausible  explanation  for  the  minor
DNA  damage  could  be  individual  cell  line  stress  management
caused  by  hypericin.  The  mechanisms  of  action  stay  unclear.
Nevertheless,  compared  to  staurosporin  samples  hypericin
mediated  DNA  damage  in  UMB-SCC  745  was  on  one  side  very
low  and  on  other  the  cells  recovered  after  3  h  post  photo-
sensitizer  removal.
Conclusions
Our  study  is  the  ﬁrst  showing  that  a  combination  of  pho-
tosensitizers  may  reduce  dark  toxic  effects,  potentially
allowing  for  the  save  application  of  higher  photosensitizer
doses  for  PDT  of  HNSCC.  We  are  aware  that  our  study  design
relies  on  cancer  cell  lines  only  and  that  photosensitizer  bio-
behaviour  of  normal  cells  or  in  patients  may  differ.  However,
our  data  will  set  the  stage  for  further  investigations  on  ben-
eﬁts  of  photosensitizers  in  combinations  in  vitro  and  in  vivo.
Possible  consequences  for  PDT  of  photosensitizer  interac-
tions  in  the  mixture  are  now  the  focus  of  ongoing  studies.
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ABSTRACT
The aim of this study was to elucidate photodynamic therapy
(PDT) effects mediated by hypericin and a liposomal meso-
tetrahydroxyphenyl chlorin (mTHPC) derivative, with focus
on their 1:1 mixture, on head and neck squamous cell carci-
noma cell lines. Absorption, excitation and photobleaching
were monitored using ﬂuorescence spectrometry, showing the
same spectral patterns for the mixture as measured for single
photosensitizers. In the mixture mTHPC showed a prolonged
photo-stability. Singlet oxygen yield for light-activated
mTHPC was ΦD = 0.66, for hypericin ΦD = 0.25 and for the
mixture ΦD = ~0.4. A linear increase of singlet oxygen yield
for mTHPC and the mixture was found, whereas hypericin
achieved saturation after 35 min. Reactive oxygen species ﬂu-
orescence was only visible after hypericin and mixture-
induced PDT. Cell viability was also more affected with these
two treatment options under the selected conditions. Exami-
nation of death pathways showed that hypericin-mediated
cell death was apoptotic, with mTHPC necrotic and the 1:1
mixture showed features of both. Changes in gene expression
after PDT indicated strong up-regulation of selected heat-
shock proteins. The application of photosensitizer mixtures
with the features of reduced dark toxicity and combined
apoptotic and necrotic cell death may be beneﬁcial in clinical
PDT. This will be the focus of our future investigations.
INTRODUCTION
Photodynamic therapy (PDT) relies on the uptake of a nontoxic
photoactivatable drug, the so called “photosensitizer”, into cells.
Upon local illumination the photosensitizer can be activated to
excited triplet state. At this energy level, the photosensitizer is
very unstable and may therefore transfer its energy to molecular
oxygen or biomolecules in its proximity initiating the generation
of singlet oxygen and other reactive oxygen species (ROS; 1),
which can cause damage to important cellular compartments
such as mitochondria. The initial oxidative cellular damage is
occurring at the photosensitizer subcellular localization site due
to the short diffusion radius (10–55 nm) of singlet oxygen and
other ROS. Depending on the localization of the damage differ-
ent cellular mechanisms can be activated and can therewith inﬂu-
ence the fate of cells, leading to apoptosis or necrosis. For this
reason, the localization of the photosensitizer plays a very impor-
tant role in PDT-induced cellular responses.
So far, PDT has been successfully used for the treatment of dif-
ferent types of pre malignant and malignant lesions, not only
including for e.g. actinic keratosis or Barrett esophagus but also
skin tumors such as squamous cell carcinoma in situ (Bowen’s dis-
ease), bladder transitional cell carcinomas, non small cell lung can-
cer and head and neck squamous cell carcinoma (HNSCC; 2, 3).
In contrast to conventional cancer treatments such as surgery,
chemo- or radiotherapy PDT is not or minimally invasive, is
repeatable, has low side effects and excellent functional and
cosmetic outcome (4). In addition, promising results were reported
in treatment of patients with advanced cancer who had failed con-
ventional therapy or were unsuitable for such treatments (5,6).
We recently reported that the combination of two photosensi-
tizers may improve PDT effects. First observations had been
reported in a case study where aminolevulinic acid (ALA) was
administered as a guide for intraoperative diagnosis and recogni-
tion of tumor margins in a breast cancer patient, where hypericin
was simultaneously taken as an antidepressant (7). The unin-
tended activation of (ALA-induced) protoporphyrin IX and
hypericin showed unexpected high phototoxic effects. Further in
vitro studies on keratinocyte and endometrial cancer cell lines
conﬁrmed that the combination of these two photosensitizers and
white light resulted in a synergistic enhancement of PDT effects
(7,8). These remarkable results initiated further studies on possi-
ble applications of photosensitizer combinations on oral patho-
gens. We examined PDT effects of hypericin and a liposomal
meso-tetrahydroxylphenyl chlorin (mTHPC) derivative (Fosli-
pos®) in a 1:1 mixture on Streptococcus mutans and S. sobrinus
(9). We found that these two oral pathogens could be completely
eradicated with the photosensitizer mixture showing high PDT
efﬁcacy despite a low dose of single photosensitizers. In addi-
tion, our previous study on dark toxicity (Besic Gyenge et al.
(2012) Photodiagnosis Photodyn Ther. (In press, DOI: 10.1016/j.
pdpdt.2012.03.006) in HNSCC cell lines showed that application
of hypericin and Foslipos® in combination decreases in vitro
*Corresponding author email: emina.besicgyenge@uzh.ch (Emina Besic Gyenge)
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dark toxicity without inﬂuencing photosensitizer physicochemical
properties or their intracellular behavior.
These results prompted us to further investigate the potential
of photosensitizer mixtures in PDT treatment. In this study, we
extensively explored the effects and consequences of PDT with
Foslipos® and hypericin in combination, using an in vitro
HNSCC model.
MATERIALS AND METHODS
Photosensitizers. In our study, we used two different photosensitizers and
their 1:1 combinations. Foslipos®, which is a liposomal derivative of meso-
tetra(hydroxy)phenyl chlorin (mTHPC) was kindly donated from Biolitec
AG (Jena, Germany). The stock concentration was 1.5 mg mL1
(2.2 mM). Hypericin, a herbal photosensitizer which is the main photoac-
tive constituent from St. Johns wort was purchased from Invitrogen (Basel,
Switzerland). A 1 mg was dissolved in 1 mL 100% ethanol (EtOH;
1.9 mM). For both photosensitizers working solutions (0.3–5 lg mL1)
were prepared in Roswell Park Memorial Institute medium (RPMI) growth
medium (Invitrogen) supplemented with 10% fetal calf serum (FCS; Sigma
–Aldrich, Buchs, Switzerland), 1% 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES; Invitrogen), 1% MEM non essential amino acids
(Invitrogen) and 1% penicillin and streptomycin (Invitrogen).
Cell culture. HNSCC cell lines UMB-SCC 745 and 969 were kindly
provided by Dr. Robert Mandić, Department of Otorhinolaryngology,
Philips University (Marburg, Germany). The UMB-SCC 745 was
derived from the oropharynx tumor of a 48-year-old man and UMB-
SCC 969 from the tonsil tumor of a 67-year-old man respectively. The
cells were cultured under standard conditions (37°C, 5% CO2, 95% air
atmosphere) in RPMI growth medium. Cells were passaged by trypsina-
tion (trypsin 1x; Invitrogen) when reaching conﬂuence, in general every
2–3 days.
Absorption and emission spectra. Absorption and emission spectra of
hypericin and Foslipos® were measured using a ﬂuorescence spectropho-
tometer (Cary Eclipse, Varian, Santa Clara) in 100% EtOH at ﬁnal con-
centrations of 1 lg mL1. In addition, the spectra of the 1:1 combination
of hypericin and Foslipos® were recorded. The excitation wavelengths
were ranging from 200 to 900 nm (zero order excitation). The absorption
and emission spectra were recorded from 300 to 800 nm.
Photobleaching experiments. Freshly prepared solutions of hypericin
and Foslipos® were used for photobleaching experiments. Hypericin was
dissolved in EtOH and Foslipos® was dissolved in double distilled water
to reach ﬁnal concentrations of 2 3 105 M. To investigate the photoble-
aching of the mixture, both solutions were mixed in a 1:1 ratio. In a
50 mL reaction vessel, which was thermostated at 25°C with a water
cooling jacket, the solutions were irradiated under stirring with 10 light
bulbs (Osram Dulux®S 865 white, 9 W per 570 lm, spectrum cf.
Fig. 4D). The lamps were arranged around the photoreactor vessel in a
circular fashion at a distance of 5–6 cm. At given time intervals: 0, 10,
20, 30 and 45 min, 1, 1.5, 2–7 and 21 h 1.5 mL of the solution was col-
lected and analyzed by recording the change of main peaks using a Per-
kin–Elmer Lambda 650S UV/Vis spectrophotometer.
Cell viability assay. Cell viability after PDT was determined with a
colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay (Invitrogen). Cells were seeded on transparent 96-well
plates (5000 cells per well) over night. Photosensitizers and 1:1 combina-
tions of both with ﬁnal concentrations of 2.5 lg mL1 were incubated
for 5 h. Cells were washed and 200 lL per well of growth medium was
added. Cells were illuminated with white light (ﬂuorescent tube SYLVA-
NIA standard F15W/154, daylight) for 1 min (6000 Lx; 250 lW;
32 mW cm2) and then kept in the incubator until the next day. Growth
medium was then replaced with growth medium containing
0.5 mg mL1 MTT dye for 3 h. Afterward, growth medium was
replaced with 100 lL dimethyl sulfoxide (DMSO; Sigma–Aldrich) and
the absorption at 565 nm was measured on a microplate spectrometer
(BioTek Instruments, Luzern, Switzerland). For statistical calculations
one-way ANOVA Tukey’s test and the software GRAPHPAD PRISM
were used.
Singlet oxygen yield measurements. Oxygen luminescence: Absorption
spectra were recorded on a Perkin–Elmer (Lambda 2, Courtaboeuf,
France) UV–visible spectrophotometer. Singlet oxygen spectra were
recorded on a SPEX Fluorolog-3 spectroﬂuorimeter (Jobin Yvon, Longju-
meau, France) equipped with a thermostated cell compartment (25°C),
using a 450 W Xenon lamp. The detection at 1270 nm was done through
a PTI S/N 1565 monochromator, and the emission was monitored using a
liquid nitrogen-cooled Ge-detector model (EO-817L; North Coast Scien-
tiﬁc Co., Santa Rosa, CA). Two excitation wavelengths were chosen,
415 nm for Foslipos® and 590 nm for hypericin. Rose Bengal has been
chosen as a reference solution because of its high 1O2 quantum yield in
EtOH (= 0.68, DO = 0.2 at the excitation wavelength).
First experiment: The detection of singlet oxygen was measured at an
excitation wavelength of 590 nm. The concentration of hypericin and
Foslipos® in the mixture was 1:1. Second experiment: The detection of
singlet oxygen was measured at an excitation wavelength 415 nm as
reported above. The concentration of hypericin and Foslipos® in the mix-
ture was 1:1. Figure in supplementary data (Figure S1).
Singlet oxygen sensor green (SOSG) assay: Stock concentrations of
hypericin and Foslipos® were 5 lg mL1 and concentration of the photo-
sensitizer mixture was 2.5 lg mL1 each in TRIS buffer (20 mM).
A quantity of 50 lL of photosensitizers (end concentration of single
photosensitizers: 2.5 lg mL1; in the mixture: 1.25 lg mL1) and
50 lL of SOSG (Molecular Probes, Eugene, OR; 10 lM in 100% metha-
nol [MeOH]) was placed in one well of a black 96-well plate (Cellstar,
Frickenhausen, Germany). The measurement was performed for 1 h alter-
nately with an illumination for 30 s with white light (ﬂuorescent tube
SYLVANIA standard F15W/154, daylight; 6000 Lx; 250 lW;
32 mW cm2) and ﬂuorescence measurements every 3 s over 3 min on a
microplate spectrometer (BioTek Instruments) at an excitation wavelength
of 504 nm and a detection wavelength of 525 nm.
CM-H2DCFDA ROS measurement. Cells were seeded (50 000 cells
per well) on 8-well ibidi slides (l-slide 8 well, ibiTreat; ibidi GmbH,
Munich, Germany). Incubation with photosensitizers and their mixture
took place on the next day for 5 h at 37°C in the dark (overall concentra-
tion of photosensitizers and their mixture was 2.5 lg mL1). Ibidi slides
were incubated with CM-H2DCFDA (Invitrogen) for 1 h at a ﬁnal con-
centration of 5 lM prior to observation. Growth medium was renewed,
cells were illuminated for 1 min (ﬂuorescent tube SYLVANIA standard
F15W/154, daylight; 6000 Lx; 250 lW; 32 mW cm2) and subsequently
live cell confocal scanning microscopy (SP5 Leica Microsystems Inc.,
Bannockburn, IL) was performed. The experiments were repeated three
times in doublets.
FLICATM assay and Hoechst stain. Caspase activity was monitored
with ﬂuorescein labelled inhibitors of poly-caspases (FLICATM Poly
Caspases Kit; ImmunoChemistry Technologies, Bloomington, MN).
Cells were seeded (50 000 cells per coverslip) on poly-L-lysine (PLL)
coated coverslips (Menzel Gläser, Braunschweig, Germany) and grown
overnight. The next day, cells were incubated with photosensitizers
(2.5 lg mL1) and their mixture (1.25 lg mL1 each photosensitizer)
for 5 h, in the dark at 37°C, growth medium was changed and the cells
were illuminated with white light (ﬂuorescent tube SYLVANIA stan-
dard F15W/154, daylight; 6000 Lx; 250 lW; 32 mW cm2) for 1 min.
Subsequently, the cells were incubated for 1 h with fresh growth med-
ium supplemented with FLICATM (30X ﬁnal concentration) after differ-
ent time intervals post illumination (0 and 30 min, 1, 1.5, 2, 2.5, 3, 3.5
and 4 h). As controls we created samples illuminated, but without
photosensitizers, with photosensitizers, but without illumination and
ﬁnally neither with photosensitizers nor illumination. One hour after
FLICATM incubation, nuclei were stained with Hoechst 33342 staining
medium (1 lg mL1, provided with FLICATM Kit) for 5 min. Then,
the cells were washed twice with wash buffer (FLICATM Kit). To ﬁx
the cells, ﬁxative (FLICATM Kit) was added for 15 min. Examination
was made using a confocal scanning microscope Leica TCS SP5 (Leica
Microsystems Inc.). The ﬂuorescence for FITC was observed using a
bandpass ﬁlter (excitation 488 nm, emission 490–540 nm) and the ﬂuo-
rescence of the Hoechst 33342 stain with a UV-ﬁlter with excitation at
350 nm and emission at 450–500 nm.
Annexin V assay. A quantity of 50 000 cells per well were seeded
on 8-well plates (ibidi GmbH). After 24 h, growth medium was
removed and replaced by single photosensitizer and 1:1 photosensitizer
mixture containing medium (single photosensitizer concentration:
2.5 lg mL1; photosensitizer mixture: 1.25 lg mL1 for each photosen-
sitizer) and incubated for 5 h. Then, growth medium was renewed and
samples were illuminated for 1 min (ﬂuorescent tube SYLVANIA stan-
dard F15W/154, daylight; 6000 Lx; 250 lW; 32 mW cm2). Subse-
quently, growth medium was replaced with Annexin V-Fluos labelling
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reagent (20 lL), propidium iodide (1 lg mL1) and Hoechst 33342
(1 lg mL1) in incubation buffer (10 mM HEPES/NaOH, pH 7.4
[Sigma–Aldrich]; 140 mM NaCl [Sigma–Aldrich]; 5 mM CaCl2 [Sigma–
Aldrich]) according to the manufacturer’s protocol. Cells were observed
using a confocal laser scanning microscope Leica TCS SP5 (Leica
Microsystems Inc.) after 15 min of incubation and examination was ﬁn-
ished 3 h after Annexin V incubation.
Cytochrome C staining. Cells were seeded on round glass cover
slides and treated with photosensitizers as reported above in chapter 2.8.
After illumination (1 min, ﬂuorescent tube SYLVANIA standard F15W/
154, daylight; 6000 Lx; 250 lW; 32 mW cm2) supernatant was
replaced with 1% paraformaldehyde, 0.33% sucrose in PBS for 30 min
at different time points after illumination (0, 1 and 3 h). Afterward, cells
were washed two times with PBS and permeabilized with 0.01% Triton
X-100 (Roche) for 2 min at room temperature. After two washing steps
with PBS cells were blocked with 0.1% bovine serum albumine (BSA;
Calbiochem, San Diego, CA) for 30 min at room temperature. Cell sam-
ples were incubated with sheep anti-cytochrome c (1:1000, stock con-
centration 1.5 mg mL1; Sigma–Aldrich) in 0.1% BSA for 1 h at 37°C.
Samples were washed and incubated with donkey anti-sheep IgG cou-
pled biotin (1:200; Jackson ImmunoResearch, West Grove, PA) in 0.1%
BSA for 1 h at room temperature. Finally, after three washing steps
with PBS cells were incubated with Cy5 coupled streptavidin (1:200,
Jackson ImmunoResearch) and 4′,6-diamidino-2-phenylindole (DAPI,
1 g mL1; Roche) in 0.1% BSA for 1 h at room temperature. Subse-
quently, cells were washed three times in PBS and mounted with Glyc-
erGel mounting medium (Dako, Baar, Switzerland). Samples were
monitored using Leica a confocal scanning microscope TCS SP5 (Leica
Microsystems Inc.).
Live cell imaging. Cells were seeded (50 000 cells per well) on 8-well
plates (ibidi GmbH). After 24 h, growth medium was replaced by med-
ium with single photosensitizers or the 1:1 photosensitizer mixture at
concentrations ranging from 0.3 to 10 lg mL1. Cells were incubated for
5 h. Growth medium was renewed and cells were illuminated for 1 min
with white light (ﬂuorescent tube SYLVANIA standard F15W/154, day-
light; 6000 Lx; 250 lW; 32 mW cm2). After illumination ibidi slides
were monitored with a live cell imaging wide ﬁeld microscope Leica LX
(Leica Microsystems Inc.). The experiments were performed three times
individually each time in doublets. The ibidi slides were screened manu-
ally to ﬁnd appropriate place and differential interference contrast (DIC)
images were recorded every 10 min during 18 h.
Quantitative PCR. Cells were grown in 6-well plates (Corning,
500 000 cells per well; doublets for each condition) under standard con-
ditions overnight. Next, single photosensitizer or photosensitizer mixture
was incubated for 5 h at ﬁnal concentrations of 2.5 lg mL1
(1.25 lg mL1 each in the photosensitizer mixture). Subsequently, the
photosensitizer growth medium was replaced by fresh one without photo-
sensitizer. Samples were illuminated with white light for 1 min (ﬂuores-
cent tube SYLVANIA standard F15W/154, daylight; 6000 Lx; 250 lW;
32 mW cm2). RNA extraction was made using NucleoSpin RNA II Kit
(Macherey-Nagel, Oensingen, Switzerland) according to the provided
protocol. The cells were lysed with 350 lL lysis buffer (RA1) containing
3.5 lL b-mercaptoethanol at different time points (1, 3 and 5 h) and
stored at 20°C until usage. The whole extraction procedure was per-
formed in the dark. The ﬁnal RNA elution step was done with 40 lL
RNase-free-water.
Nanodrop and Bioanalyzer measurements: The RNA yield was deter-
mined using a Nanodrop-spectrometer (Thermo Scientiﬁc, Wilmington,
MA) and RNA quality/integrity with a Bioanalyzer Agilent 2100 (Agilent
Technologies, Santa Clara, CA). We used either pico-chips for RNA con-
centrations between 0.2 and 5 ng lL1 or nano-chips for concentrations
between 50 and 500 ng lL1 (both chips from Agilent Technologies).
Reverse transcriptase (RT) reaction: RT reactions were performed for
each time point and with both cell lines with 100 ng total RNA and the
QuantiTect RT-Kit (Qiagen, Hombrechtikon, Switzerland) according to
the manufacturer’s instructions. The reactions yielded a ﬁnal volume of
20 lL. cDNAs were kept at 20°C. Negative controls included omission
of RT enzyme.
Quantitative polymerase chain reaction (qPCR): The following com-
binations were used: for heat-shock 70 kDa protein 6 (HSPA6): sense
primer (5′-tcatgaagccgagcagtaca-3′), antisense primer (5′-gtttttggcagc-
cactctgt-3′), probe (5′-gctgagga-3′) and for alpha-crystallin B chain
(CRYAB): sense primer (5′-cagctggtttgacactggac-3′) and antisense primer
(5′-gcttcacatccaggttgaca-3′), probe (5′-cctggaga-3′). Primer/probes were
based on the human Universal ProbeLibrary System (Roche) and prim-
ers were synthesized by Microsynth. Protocols for qPCR were performed
in triplicates in each 10 lL: 1X Absolute QPCR low ROX mix
(ABgene), 0.1 lM FAM-labelled Universal ProbeLibrary probe (Roche),
0.4 lM each sense and antisense primer and 1 lL cDNA. qPCR was
run in an Applied Biosystems 7500 Fast Real-time PCR System
(Applied Biosystems) under the following conditions: 15 min at 95°C
and 40 cycles with 15 s at 95°C and 1 min at 60°C. Statistical analyses
were performed using the REST software (http://gene-quantiﬁcation.
com).
RESULTS
Absorption and emission spectra
We determined the absorption and emission spectra of hypericin
and Foslipos® and the mixture of both at a range from 300 to
800 nm (Fig. 1). Major absorption bands for hypericin (Fig. 1A)
were found in the range of 300–350, 450–500 and 550–600 nm.
For Foslipos® absorption maxima (Fig. 1A) were found at 380–
450 nm and around 600 nm. For the mixture the absorption
bands (Fig. 1A) were the summation of hypericin and Foslipos®
bands together. The emission wavelengths for hypericin
(Fig. 1B) were detected in the range from 580 to 650 nm. Fosli-
pos® (Fig. 1B) had one emission maximum at 650 nm. Measure-
ments with the photosensitizer mixture (Fig. 1B) displayed the
summation of hypericin and Foslipos® emission peaks. Taken
together no additional peaks were detected in the mixture; the
peak intensity and the peak patterns remained the same if com-
pared to single photosensitizer measurements.
Singlet oxygen luminescence measurements
Singlet oxygen yield measurements for hypericin, Foslipos® and
their 1:1 mixture were performed using 1O2 luminescence at
1270 nm. The triplet quantum yield for 100% hypericin in EtOH
was ΦD = 0.25 and for 100% Foslipos
® ΦD = 0.66. The triplet
quantum yield for the 1:1 photosensitizer mixture measurements at
590 nm was ΦD = 0.32 ± 5% and for 415 nm ΦD = 0.45 ± 5%
(data shown in Figure S1).
Singlet oxygen measurement with SOSG reagent
The production of singlet oxygen was additionally observed over
1 h with SOSG reagent, which is highly selective for singlet
oxygen. The results are shown in Fig. 2. Singlet oxygen yield
produced with hypericin-PDT achieved a plateau approximately
after 35 min while the singlet oxygen yield produced with Fosli-
pos®-PDT was increasing linearly over time. The accumulation
of singlet oxygen produced with Foslipos® after 1 h was almost
ﬁve times higher than the values recorded for hypericin. The
singlet oxygen yield for the photosensitizer mixture corresponded
approximately to the summation of half of the 1O2 yields of
single photosensitizers.
ROS measurements with CM-H2DCFDA reagent
Besides the singlet oxygen yield measurements we observed the
intracellular production of other ROS such as hydrogen peroxide
H2O2, hydroxyl radicals HO
•, peroxyl radicals ROO• and perox-
ynitrite anions ONOO–. We used the non ﬂuorescent cell-perme-
able indicator CM-H2DCFDA for our live cell experiments
Photochemistry and Photobiology 3
(Fig. 3). This substance becomes ﬂuorescent after cellular oxida-
tion and removal of acetate groups by cellular esterases. The pic-
tures showed that both cell lines accumulated high amounts of
ﬂuorescent CM-H2DCFDA directly after hypericin treatment and
illumination. The maximum ﬂuorescence intensity in hypericin-
treated UMB-SCC 745 cells was found after 2 h. UMB-SCC 969
displayed lower ﬂuorescence intensity but accumulated ﬂuorescent
dye was always detectable during examination. In both cell lines
membrane blebbing and apoptotic bodies were visible (see
Figures S2–S4). After Foslipos® treatment ROS were not detect-
able in UMB-SCC 745 but CM-H2DCFDA ﬂuorescence was visi-
ble in UMB-SCC 969 immediately after illumination albeit in a
weaker manner than observed for hypericin treated UMB-SCC
969 cells. At later time points during the observation Foslipos®-
treated cells did not display ﬂuorescent CM-H2DCFDA. Shrinkage
of cells was observed after 2 h. In case of the treatment with both
photosensitizers maximum CM-H2DCFDA ﬂuorescence for
UMB-SCC 969 was detectable directly after illumination (0 h)
which decreased over time (1 and 2 h). UMB-SCC 745 displayed
stronger ﬂuorescence after 1 h if compared to UMB-SCC 969. The
maximum ﬂuorescence for UMB-SCC 745 was detected between
1 and 2 h. Membrane blebbing, apoptotic bodies and cell shrink-
age was also observable as reported for hypericin-treated cells.
Photosensitizer photobleaching experiments
Singlet oxygen and ROS production is dependent on photosensi-
tizer stability. Photobleaching experiments were performed with
two different light sources. The light source which was used for
all experiments (6000 Lx; 250 lW; 32 mW cm2) did not induce
photobleaching effects (data not shown). Illumination with 10
light bulbs (9 W per 570 lm, light spectra in Fig. 4D) showed that
hypericin was photo-stable even after 23.5 h (Fig. 4A). In con-
trast, Foslipos® was completely photo-bleached after 6 h
(Fig. 4B). In case of the 1:1 mixture of both photosensitizers
hypericin did not show any difference in its photo-stability if com-
pared with the single measurement but we could register less
intense photobleaching for Foslipos®. After 8 h the Foslipos®
peak was still visible. Total photobleaching for the Foslipos® peak
in the photosensitizer mixture was achieved after 21 h (Fig. 4C).
Cell viability assay
MTT assays were performed 1 day after UMB-SCC 745 and
UMB-SCC 969 cells were incubated with hypericin, Foslipos®
and their 1:1 mixture for 5 h and illuminated with white light for
1 min (6000 Lx; 250 lW; 32 mW cm2; Fig. 5). The viability
for hypericin-treated cells was reduced by 96% for UMB-SCC 745
and by 90% for UMB-SCC 969. Cell viability for Foslipos®-trea-
ted cells was reduced by 83% for both cell lines. Photosensitizer
mixture-treated cells displayed a 94% viability reduction for
UMB-SCC 745 and a 90% decrease for UMB-SCC 969. Differ-
ences for individual photosensitizers between both cell lines were
not signiﬁcant. The statistical evaluation (one-way ANOVA
Tukey’s test) showed that the PDT effect in Foslipos®-treated
UMB-SCC 745 cells differs signiﬁcantly to hypericin and photo-
sensitizer mixture-treated cells (Tukey’s Multiple Comparison
Test, P < 0.05 was considered statistically signiﬁcant). Cell viabil-
ity differences between hypericin and photosensitizer mixture trea-
ted UMB-SCC 745 cells were not biologically signiﬁcant. In case
of UMB-SCC 969 cells a signiﬁcant viability difference was only
detectable between hypericin- and Foslipos®-treated cells.
Morphological cell changes after PDT
Morphological cell changes after PDT were monitored with wide
ﬁeld microscopy. In Fig. 6A DIC pictures of UMB-SCC 745
cells and in Fig. 6B DIC pictures of UMB-SCC 969 cells treated
with hypericin, Foslipos® and photosensitizer mixture after
different time periods (0, 3 and 17 h) are shown (see supporting
data). Hypericin-treated cells showed morphological changes
immediately after illumination for both cell lines. Directly after
illumination individual cells started to shrink, membrane
blebbing and membrane vesiculation (microparticle formation)
Figure 1. Absorption (A) and emission (B) spectra of photosensitizers used in the study. Shown in black are hypericin spectra, Foslipos® in red and
mixture of both in dashed-blue.
Figure 2. Singlet oxygen measurements performed with Singlet Oxygen
Sensor Green (SOSG) assays after PDT with Foslipos® (red), hypericin
(black) and the mixture of both photosensitizers (dashed-blue). Photosen-
sitizer concentration was 2.5 lg mL1 for single photosensitizers and in
the mixture 1.25 lg mL1 each. Measurements were performed at an
excitation wavelength of 504 nm and an emission wavelength at 525 nm.
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were visible and ﬁnally cell breakage in smaller pieces (apoptotic
bodies) was monitored (see supplementary data). After 3 h more
than 30% of cells displayed such behavior. The majority of cells
died within 12 h. Foslipos® treated cells showed a different
behavior post illumination if compared to hypericin-treated ones.
Cell contraction, which is an initially visible cell death indicator,
was monitored after 4 h for UMB-SCC 745 and 6 h for UMB-
SCC 969. Few cells (ca 3% of the cell population) showed simi-
lar behavior as described for hypericin-treated cells (membrane
blebbing and vesiculation, apoptotic bodies), but the majority of
cells started to shrink and to detach from the surface. After 12 h
cells were found detached in the growth medium in large cell
Figure 3. Confocal laser scanning microscopy pictures showing intracellular accumulation of CM-H2DCFDA (in green) after PDT in both cell lines at
different time points (0, 1 and 2 h) and photosensitizer treatments (hypericin, Foslipos® and the mixture of both, red ﬂuorescence). Scale bars = 30 lm.
Figure 4. Spectra in (A) are showing photobleaching effect of major hypericin (2 9 105 M) emission peaks in ethanol (time: 0, 5, 15, 30 and 45 min,
1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 and 23.5 h), in (B) photobleaching effects of Foslipos® (2 9 105 M) in water (time: 0, 5, 15, 30 and 60 min, 1.5, 2, 2.5,
3, 4, 5 and 6 h) and in (C) the photobleaching effects of the 1:1 mixture of both photosensitizers (time: 0, 10, 20, 30 and 45 min, 1, 1.5, 2, 3, 4, 5, 6, 7
and 21 h). In (D) shown is spectrum of Osram Dulux S 865 white light. The black arrows show decrease of signal intensity.
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aggregates. Morphological changes for photosensitizer mixture-
treated cells were visible immediately after illumination. Initially,
illuminated cells indicated more resemblance to hypericin-treated
cells than to Foslipos®-treated ones. At later time points (5 h
post illumination) membrane bulging was observable followed
by membrane rupture (data not shown). Cell residues remained
immobile and attached on the slide surface. Both cell lines dis-
played similar behavior.
Cell death pathways
Morphological examinations emphasized that hypericin-treated
cells followed rather a programmed (apoptosis) and Foslipos® an
un-programmed (necrosis) cell death. The photosensitizer mix-
ture-treated cells displayed characteristics of both apoptosis and
necrosis. Active caspases during PDT caused death processes
and were detected by covalent binding of FLICATM agents to
active caspases (Fig. 7, additional ﬁgures in supplementary data:
Figures S2–S4). In UMB-SCC 745 and UMB-SCC 969 cells
treated with hypericin caspases were detected 1 h after illumina-
tion. Over time, cells were shrinking continuously and at late
time points (4 h) cells were round in shape, caspase ﬂuorescence
was only visible in a minority of the present cells and Hoechst
dye did not stain the nuclei very well. Only few cells could be
found on the cover slides. Foslipos®-treated cells ﬁrst displayed
cell shrinkage and detachment from slides. Caspase activity was
not observable in UMB-SCC 745 cells. Still, UMB-SCC 969
cells treated with Foslipos® showed low caspase ﬂuorescence in
a few cells. Aggregates of dead cells (in both cell lines) were
found on slides 4 h post illumination. The nuclei could only
partly be stained using Hoechst dye. The photosensitizer mix-
ture-treated cells displayed caspase activity in UMB-SCC 745
after 2 h. UMB-SCC 969 showed caspase activity only in a few
cells. Four hours after illumination cells (both cell lines) were
shrunken and round, but they did not build cell aggregates as
seen in Foslipos®-treated cells. Also, here nuclei staining could
not be achieved as in untreated cells.
Annexin V assay results obtained for UMB-SCC 745 cells are
shown in Figure 8A (additional ﬁgures in supplementary data:
Figures S2–S4). Hypericin-treated cells showed ﬁrst annexin
staining of cell membranes between 1 and 2 h. Partial propidium
iodide nuclear staining was detectable at later time points (2–3 h).
Annexin V maximum ﬂuorescence was detectable between 2 and
3 h. Membrane blebbing and membrane vesiculations were visi-
ble. For Foslipos®-treated UMB-SCC 745 cells annexin V as well
as nuclear propidium iodide co-staining was detectable between 2
and 3 h. Only a small number of cells (2–3% of the cell popula-
tion) were not stained with propidium iodide. UMB-SCC 745
cells, which were treated with photosensitizer mixture showed
annexin V staining between 2 and 3 h including propidium iodide
co-staining. Figure 8B shows the annexin V assay results
achieved for the UMB-SCC 969 cell line. Annexin V staining for
hypericin-treated cells after 1 h was not pronounced as in UMB-
SCC 745, but after 2 h the staining effect was equally prominent.
Partial propidium iodide nuclear staining was detectable at later
time points (2–3 h). Foslipos®-treated UMB-SCC 969 cells dis-
played comparable results achieved for the UMB-SCC 745 cell
line. Photosensitizer mixture treated UMB-SCC 969 cells at later
time points (2–3 h) displayed more annexin V and propidium
iodide co-staining if compared to UMB-SCC 745 cells.
Cytochrome C after PDT was monitored after three different
time periods (0, 1 and 3 h). Figure 9 (additional ﬁgures in sup-
plementary data: Figures S2–S4) displays cytochrome C staining
for all three photosensitizer treatments over 1 and 3 h. The
UMB-SCC 745 cells displayed well-deﬁned mitochondria stain-
ing for all photosensitizers after 1 h. No cytochrome C release
was observed. After 3 h a partly cytochrome C-release was
observable. Hypericin-treated UMB-SCC 969 cells displayed
already after 1 h cytochrome C-staining in the cytoplasm and
after 3 h cytoplasmic staining was even more prominent. Fosli-
pos®-treated UMB-SCC 969 cells displayed well-deﬁned mito-
chondria staining for all time points. Photosensitizer-mixture
treated UMB-SCC 969 cells displayed similar results as reported
for hypericin treatment in this cell line. Staining in the cytoplasm
was less pronounced, but cytochrome C-release was detectable.
Relative quantiﬁcation of gene expression
Analyses of qPCR data revealed that in controls HSPA6 mRNA
was expressed whereas CRYAB transcripts were barely detectable.
However, after PDT with Foslipos®, hypericin or the mixture, both
genes were highly up-regulated over time in UMB-SCC 745 and
UMB-SCC 969 compared to untreated controls. The detailed
results of qPCR data are presented in Table 1.
DISCUSSION
The use of PDT in cancer treatment gained on importance during
the last decade, however, the urge in improving the efﬁciency of
this treatment modality is still high. For this purpose PDT had been
combined with e.g. hyperthermia (10,11), radiation (12–14) and
chemotherapy (15–17), showing in most cases synergistic or addi-
tive effects. In contrast, little is known about possible advantages
of combining different types of photosensitizers for PDT (7, 8).
In our previous study (Besic Gyenge et al. (2012) Photodiagnosis
Photodyn. Ther. (In press, DOI: 10.1016/j.pdpdt.2012.03.006) we
thus examined possible effects of the combination of hypericin and
Foslipos® on two HNSCC cell lines in the dark. We showed that
Figure 5. Cell viability change (MTT assays) 24 h after photosensitizer
treatment (5 h incubation, 2.5 lg mL1 for single photosensitizer and
1.25 lg mL1 for each photosensitizer in the mixture) and illumination
with white light (1 min, 6000 Lx; 250 lW; 32 mW cm2) on both cell
lines. The samples for each condition were in sextuplicates and the
experiment was performed independently three times. The software used
for statistical analysis (one-way ANOVA Tukey’s test) was GRAPHPAD
PRISM. The statistical signiﬁcance was expressed as P-values
(***P < 0.001 and **P < 0.01).
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applying these photosensitizers in combination is decreasing in
vitro dark toxicity without inﬂuencing their physicochemical prop-
erties or behavior. These promising results prompted us to now
explore possible advantages of a combination of hypericin and
Foslipos® for PDT, using the same HNSCC cell models.
We found that the absorption and emission spectra of the pho-
tosensitizer combination did not show any mutual quenching and
ﬂuorescence interactions, i.e. peak pattern remained unchanged if
compared to single photosensitizer measurements. It is thus pos-
sible to apply illumination conditions established for single
photosensitizers. Since the absorption bands in the photosensi-
tizer mixture were the combination of the bands of single photo-
sensitizers one should keep in mind for later applications that the
light source has to cover the whole range of absorption spectra
for both photosensitizers. For this purpose, the application of
white light or a combination of light-emitting diodes (18,19)
could be very effective and at low costs compared to lasers.
Because PDT effects are highly dependent on the photosensi-
tizer’s singlet oxygen and ROS production efﬁcacy, three differ-
ent assays were performed to elaborate yields in the
photosensitizer mixture compared to single photosensitizers and
to explore possible quenching effects in the mixture. The oxygen
triplet quantum yield measurement for Foslipos® (in EtOH)
yielded in 0.66 which is higher than reported before for mTHPC
A
B
Figure 6. Live cell wide ﬁeld microscopy pictures after PDT in (A) UMB-SCC 745 and (B) UMB-SCC 969. Incubation time of photosensitizers was
5 h (concentration of single photosensitizer was 2.5 lg mL1 and in the mixture 1.25 lg mL1 for each photosensitizer), illumination 1 min with white
light (6000 Lx; 250 lW; 32 mW cm2). Scale bars = 100 lm.
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(ΦD = 0.3) (20), but correlates with measurements of mTHPC
loaded into human serum albumin (HSA) nanoparticles in D2O
(ΦD = 0.65; 21). Hypericin triplet quantum yield in methanol
was found before to be 0.39 (22), in our study we measured it in
EtOH and obtained 0.25. The inconsistencies could be explained
by differences in measurement conditions and purity of the
hypericin extraction. It is known that hypericin triplet state is
susceptible to quenching not only by oxygen but also by its tau-
tomeric form and/or other energy acceptors and donors present
in the solution (23). In addition, formation of hypericin aggre-
gates may lead to a decreased singlet oxygen production (24).
When applying photosensitizers in the mixture it should be con-
sidered that photons are divided between photosensitizers and
the production of singlet oxygen or ROS is highly dependent on
both photosensitizers and their direct biological environment.
Singlet oxygen yield measurements (at 417 and 590 nm) for the
photosensitizer mixture did not display any synergistic effects.
It was higher if compared to the singlet oxygen yield generated
by hypericin, but lower if compared to Foslipos® treatment
alone.
Another approach for singlet oxygen measurement included a
highly 1O2 selective SOSG assay. We found that after 35 min
hypericin-mediated accumulation of singlet oxygen achieved a
plateau whereas in case of Foslipos® a continuous increase was
detected. Achieving a plateau in case of hypericin-mediated 1O2
generation cannot be explained by photobleaching effects
because we could not observe photodegradation with our illumi-
nation conditions (6000 Lx; 250 lW; 32 mW cm2). However,
impurities in the hypericin extract, possible chemical reactions
between hypericin and SOSG agent and/or formation of hyperi-
cin aggregates may have been causative. Because mTHPC is
embedded in liposomes, photosensitizer aggregation or chemical
reactions with SOSG agent are less possible as reported for
mTHPC in solution (25). Singlet oxygen generation and there-
with related Foslipos® fast relaxation to the ground state coupled
with photosensitizer photo-stability may have allowed the contin-
uous SOSG ﬂuorescence increase. Data for the photosensitizer
1:1 mixture were in line with the theoretically expected values,
but, in summary, were better than hypericin alone and worse
than Foslipos® alone.
Microscopic evaluations of CM-H2DCFDA showed that PDT
with hypericin resulted in a generation of ROS whereas for Fosl-
ipos®-treated cells no ROS accumulation could be detected.
However, the latter does not generally exclude ROS production
by Foslipos®-mediated PDT in our models, because the known
fast kinetics of this process (26) may have led to an early disrup-
tion of the plasma membrane and an associated release of detect-
able ROS. Notably, after the treatment with the photosensitizer
mixture ROS ﬂuorescence was less compared to treatment with
hypericin alone, possibly reﬂecting the fact that in the mixture
only half of hypericin molecules are present.
It is reported that the excited state for mTHPC in solution has
an apparent triplet state life time of ca 250 ns in air (27). The
triplet state life time for hypericin was found to be 370 ns (23).
These ﬁndings indicated that as long as the photosensitizer
molecule is not degraded/photobleached it can return to the
ground state and under repeated illumination and available
molecular oxygen singlet oxygen and ROS production can be
Figure 7. Confocal laser scanning microscopy pictures of caspase activity on both cell lines after PDT and illumination (1 min, 6000 Lx; 250 lW;
32 mW cm2). The concentration of single photosensitizer was 2.5 lg mL1 and in the mixture concentration was 1.25 lg mL1 for each photosensi-
tizer. Shown in blue are nuclei, in red photosensitizers and in green caspases. Scale bars = 30 lm.
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expected. Stability of photosensitizers is thus on the one hand
very important for effective PDT, but on the other hand major
drawbacks may occur if applied in vivo (long persistence of skin
photosensitivity) (28).
With our illumination conditions (6000 Lx; 250 lW;
32 mW cm2), no photobleaching of the photosensitizers could
be observed (neither alone nor in the mixture) within a time frame
of 3 h. Many studies showed that light doses and available
A
B
Figure 8. Live cell confocal laser scanning microscopy pictures of annexin V and PI? exposure after PDT on (A) UMB-SCC 745 and (B) UMB-SCC
969 cells at different time points. Incubation time of photosensitizers was 5 h and concentrations were 2.5 lg mL1 for single photosensitizer and
1.25 lg mL1 in the mixture for each photosensitizer. Illumination time was 1 min with 6000 Lx; 250 lW; 32 mW cm2. In green is shown annexin
V, in blue nuclei, in red photosensitizers and in magenta propidium iodide. Scale bars = 30 lm.
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molecular oxygen play a crucial role in photosensitizer photoble-
aching (29). Although higher illumination rates can induce high
photosensitizer photobleaching and hypoxia, it had been reported
that lower ﬂuence-rates give favorable PDT treatment responses
(30). Stability of the photosensitizer may be important for
effective PDT, since undegraded/non bleached photosensitizers
can return to the ground state and may be repetitively activated.
However, to investigate whether or not in the mixture, photo-
sensitizers are subjected to changed bleaching kinetics we used
higher light doses. Compared to photobleaching of single photo-
sensitizers, the mixture displayed a strongly delayed bleaching of
Foslipos®, indicating that in the mixture this photosensitizer may
have a prolonged activity. With lower mTHPC doses in combi-
nation with a greater dose of light strong tumor necrosis during
PDT treatment and only a minor damage to normal tissue was
observed (31). Photobleaching is closely related to singlet oxy-
gen production. The observed lower singlet oxygen yield in the
mixture (compared to Foslipos® alone) may therefore be the
explanation for prolonged photobleaching kinetics. Photosensi-
tizer aggregations or inﬂuence on their photo-physics due to their
near proximity could also have an impact on Foslipos® photoble-
aching behavior.
Under our experimental conditions, number of viable cells were
comparable after PDT with hypericin and the photosensitizer mix-
ture, whereas cell survival was slightly higher after Foslipos®-
induced PDT. A cell viability difference was also detectable
between the two cell lines. The high efﬁciency of PDT with hy-
pericin (32, 33) and mTHPC formulations (32) had been previ-
ously shown. However, direct comparisons between our studies
and other studies are generally difﬁcult due to the use of different
light sources, cell lines and incubation conditions.
Investigated morphologically and with different assays we
found that PDT with our photosensitizers resulted in different
modes of cell death: hypericin-treated cells showed features of
apoptotic cell death, Foslipos®-treated cells displayed characteris-
tics of necrotic cell death and photosensitizer mixture-treated cells
showed a combination of initially apoptotic and later necrotic cell
death features. However, it had been shown in many studies that
Figure 9. Cytochrome C staining in both cell lines over 1 and 3 h. Incubation time of photosensitizers was 5 h and concentrations were 2.5 lg mL1
for single photosensitizer and 1.25 lg mL1 of each photosensitizer in the mixture. Illumination time was 1 min with 6000 Lx; 250 lW; 32 mW cm2.
Shown in yellow is cytochrome C staining and in blue cell nuclei staining (DAPI). Scale bars = 25 lm.
Table 1. Quantitative analysis of real-time polymerase chain reaction 1, 3 and 5 h after PDT with Foslipos® (FOS), hypericin (HYP) and the 1:1 mix-
ture of both photosensitizers (MIX) in UMB-SCC 745 (745) and UMB-SCC 969 (969) cell lines. Relative expression ratios of heat shock 70 kDa pro-
tein 6 (HSPA6) and alpha-crystallin B chain (CRYAB), expressed as fold changes compared to untreated controls (all samples normalized to
glyceraldehyde-3-phosphate dehydrogenase).
Gene Cell line
1 h 3 h 5 h
FOS HYP MIX FOS HYP MIX FOS HYP MIX
HSPA6 745 +1526.3 +779.3 +1585.0 +9311.3 +20790.4 +15678.5 +24849.0 +38007.6 +102273.1
969 +1792.0 +834.8 +777.9 +7305.0 +21081.2 +7847.9 +13252.7 +63861.8 +16459.5
CRYAB 745 +3.2 +1.9 +2.4 +22.6 +36.0 +59.8 +137.4 +74.9 +173.6
969 +6.4 +2.1 +4.5 +29.6 +14.0 +33.4 +72.8 +171.6 +168.6
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the cell death mechanisms in PDT depend on many parameters,
including e.g. photosensitizer concentrations, light doses, cellular
redox systems or cell line (34). The different modes of cell death
in our study may be related to the observed differences in intra-
cellular localization of the two photosensitizers (diffuse distribu-
tion of Foslipos® and membrane-associated localization of
hypericin, Besic Gyenge et al. (2012) Photodiagnosis Photodyn.
Ther. (In press, DOI: 10.1016/j.pdpdt.2012.03.006). Destruction
of organelles may induce release of pro- and anti-apoptotic pro-
teins and in combination with cell speciﬁc redox systems different
death pathway are possible. Interestingly, we could show that
apoptotic death pathways were triggered by different mechanisms
dependent on used cell line. In contrast to UMB-SCC 969 cells,
hypericin-mediated apoptotic pathways for UMB-SCC 745 were
not initiated by cytochrome C release (Figure 9 and supplemen-
tary Figure S2). Provoking certain types of cell death pathways is
important in the clinical context, especially in inducing immune
responses (35; antitumor activity of inﬂammatory cells and
tumor-sensitized immune reactions) and further in vivo studies on
trigger mechanisms in PDT would be an important contribution
to the understanding and application of PDT.
Analyses of our qPCR data revealed that all PDT regimes
induced a pronounced expression of HSP70 and HSP20 family
members HSPA6 and CRYAB respectively. Both were among
the most prominently up-regulated genes in our previous study
on Foslipos®-mediated PDT effects in PC-3 cells (36). We found
that HSPA6 mRNA increased from low (UMB-SCC 745) or
undetectable (UMB-SCC 969) levels in controls to a several
1000-fold up-regulation at 5 h post illumination. HSP70 is
known to be induced by oxidative stress of PDT, as previously
reported for mTHPC, hypericin, Photofrin or ALA-induced pro-
toporphyrin IX in different models (36–42). However, while in
our study the singlet oxygen quantum yield considerably varied
with the photosensitizer, fold changes of HSPA6 mRNA did not
signiﬁcantly differ between hypericin, Foslipos® or the mixture
of both. The functional consequences of high HSPA6 levels in
HNSCC cell lines used are not clear yet. Although we have not
investigated the respective protein in our study, likely, translation
to HSP70B’ (the protein derived from HSPA6) is initiated after
PDT,—especially because (ribosomal) RNA quality does not
seem to be compromised. In the light of our data on PDT-related
highly effective cell killing, we propose that HSP70B’ may
rather play a role in promoting cell death mechanisms than to
prevent them (43). Our results are in contrast to other PDT stud-
ies that reported on cytoprotective effects of HSP70 (42, 44, 45).
However, it should be noted that the data from our group are the
ﬁrst to focus on HSPA6 expression in PDT and that it had been
shown that different HSP70 members have opposing functions
(46). A possible role of up-regulated HSPA6 with regard to anti-
cancer immune activation (39) in our cell lines is investigated in
ongoing studies.
After PDT with hypericin, Foslipos® and the mixture, we also
observed a strong induction of CRYAB expression that compared
to HSPA6, was slightly retarded and failed to reach such extremely
high levels over time. However, CRYAB acts as a chaperone and
its up-regulation may thus be interpreted as an—eventually unsuc-
cessful—cellular rescue response aiming at capturing oxidative
stress-damaged proteins and preventing cell death (47). On the
other hand, it should be kept in mind that alpha-crystallin has the
ability to complex with hypericin in its monomeric form, thereby
extending the lifetime of its triplet excited state (48).
In our previous study, we have shown that the mixture of
Foslipos® and hypericin features a reduced dark toxicity in vitro,
potentially allowing for increased photosensitizer doses in vivo
(Gyenge et al. (2012) Photodiagnosis Photodyn. Ther. (In press,
DOI: 10.1016/j.pdpdt.2012.03.006). We have herein shown that
especially with regard to direct killing effects of tumor cells in
PDT the application of the mixture does not show an apparent
advantage over the use of single photosensitizers. However, the
observed occurrence of a combined apoptotic and necrotic cell
death in PDT with the photosensitizer mixture may be clinically
beneﬁcial in terms of PDT-related activation of the immune
system. This hypothesis is currently under investigation in our
laboratories.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Singlet oxygen quantum yields of hypericin (in
red) and Foslipos® (in blue) at excitation wavelengths of 415 nm
for Foslipos® (with increasing hypericin concentration) and
590 nm for hypericin (with increasing Foslipos® concentration).
Rose Bengal was used as a reference solution.
Figure S2. The ﬁgure is exemplarily illustrating different cell
stainings and morphological changes post PDT mediated by
hypericin treatment in head and neck squamous cell carcinoma
cells. (A) DIC and confocal pictures (CM-H2DCFDA staining)
of UMB-SCC 969 cell line indicating different stages of cell
death (A1: control cells, A2: cells 2 h after illumination and A3:
cells 3 h after illumination). (B) confocal scanning pictures illus-
trating (on top) the cells stained with FLICATM caspases assay
(DAPI in blue, hypericin in red and caspase stain in green)
immediately after illumination and 2 h later (UMB-SCC 969),
(in the middle) annexin V death assay (DAPI in blue, hypericin
in red and annexin V stain in green) after 1 and 3 h post illumi-
nation (UMB-SCC 745) and (on the bottom) cytochrome C stain-
ing (DAPI in blue and cytochrome C in yellow) directly after
illumination and 3 h later (UMB-SCC 969). Scale bars = 30 lm.
Figure S3. The ﬁgure is exemplarily illustrating different cell
stainings and morphological changes post PDT mediated by
Foslipos® treatment in head and neck squamous cell carcinoma
cells. (A) DIC and confocal pictures (CM-H2DCFDA staining)
of UMB-SCC 969 cell line indicating different stages of cell
death (A1: control cells, A2: cells 2 h after illumination and A3:
cells 4 h after illumination). (B) confocal scanning pictures illus-
trating (on top) the cells stained with FLICATM caspases assay
(DAPI in blue, hypericin in red and caspase stain in green)
immediately after illumination and 3 h later (UMB-SCC 969),
(in the middle) annexin V death assay (DAPI in blue, hypericin
in red and annexin V stain in green) after 1 and 3 h post illumi-
nation (UMB-SCC 745)and (on the bottom) cytochrome C stain-
ing (DAPI in blue and cytochrome C in yellow) directly after
illumination and 3 h later (UMB-SCC 969). Scale bars = 30 lm.
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Figure S4. The ﬁgure is exemplarily illustrating different cell
stainings and morphological changes post PDT mediated by mix-
ture of hypericin and Foslipos® treatment. (A) DIC and confocal
pictures (CM-H2DCFDA staining) of UMB-SCC 969 cell line
indicating different stages of cell death (A1: control cells, A2:
cells 2 h after illumination and A3: cells 3 h after illumination).
(B) confocal scanning pictures illustrating (on top) the cells
stained with FLICATM caspases assay (DAPI in blue, hypericin
in red and caspase stain in green) immediately after illumination
and 3 h later (UMB-SCC 745), (in the middle) annexin V death
assay (DAPI in blue, hypericin in red and annexin V stain in
green) after 1 and 3 h post illumination (UMB-SCC 745) and
(on the bottom) cytochrome C staining (DAPI in blue and cyto-
chrome C in yellow) directly after illumination and 3 h later
(UMB-SCC 969). Scale bars = 30 lm.
Movie S1. The live cell monitoring after the hypericin treat-
ment (2.5 lg mL1, 5 h of incubation, 1 min illumination with
6000 Lx; 250 lW; 32 mW cm2). Pictures were made with
wide ﬁeld microscope Leica LX every 10 min during 18 h.
Movie S2. The live cell monitoring after the Foslipos treat-
ment (2.5 lg mL1, 5 h of incubation, 1 min illumination with
6000 Lx; 250 lW; 32 mW cm2). Pictures were made with
wide ﬁeld microscope Leica LX every 10 min during 18 h.
Movie S3. The live cell monitoring after the photosensitizer
mixture treatment (1.25 lg mL1 each photosensitizer, 5 h of
incubation, 1 min illumination with 6000 Lx; 250 lW;
32 mW cm2). Pictures were made with wide ﬁeld microscope
Leica LX every 10 min during 18 h.
Please note: Wiley-Blackwell are not responsible for the con-
tent or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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5. General Discussion 
 
 Photodynamic therapy (PDT) is an emerging treatment modality with a constantly 
growing area of application. The long-term treatment experiences, especially from the 
dermatology field, have shown that there are some advantages in using PDT as opposed to 
conventional therapy. PDT treatment has resulted in excellent functional as well as aesthetic 
outcomes. Furthermore, this therapy may be repeated as often as needed with minimal 
damage to normal tissue structures. PDT also shows promising results in the treatment of 
patients with unsalvageable tumours where other treatments have failed. These treatments are 
in the developmental phase and need further improvement [1].  
The PDT mode of action is known to involve three key factors: a photosensitizer, light and 
molecular oxygen. The development of novel photosensitizers and light delivery systems is an 
ongoing process. In general, the terms of improvement are photosensitizer systemic tolerance, 
good solubility under physiological conditions, high yield of singlet oxygen and ROS, low 
photobleaching and light absorbance preferably in deep red region. Some of the established 
photosensitizers exhibit excellent singlet oxygen and ROS yield and have low photobleaching 
but they may still suffer from systemic intolerance or poor solubility. Therefore, in the last 
few years encapsulation in virus-like nanocarriers, liposome, albumine nanoparticles or 
polymeric micelles has aroused scientific interest [2]. It has been shown that different 
formulation/ encapsulations of existing drugs exhibit not only potent anti-tumour activity, but 
they also display highly reduced side effects. In our work on silica-based nanoparticles with 
[Ru(byp)3]Cl2 core as a fluorescent dye [3] nanoparticle bio-behaviour in HNSCC cell lines 
with the aim of developing novel therapeutic strategies was investigated. In this study the 
interactions of core-shell silica nanoparticles interactions with HNSCC cells and their 
complex internalisation was elucidated. Gaining this information is essential before active 
pharmaceutical agents are encapsulated. 
 
In our work we explored in vitro possibilities for improving the efficiency of PDT. 
Furthermore, we have contributed to the understanding of PDT mechanisms of the two most 
powerful photosensitizers nowadays: a liposomal mTHPC derivative (Foslipos®, a second-
generation photosensitizer) and hypericin, the strongest natural occurring photosensitizer. In 
addition, this is the first study that examined the effects of photosensitizer mixtures in 
treatments of cancer cells and microorganisms in vitro. In the following pages, the most 
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important results gained from the extensive studies conducted, which are described in detail in 
enclosed publications and submitted manuscripts (chapters 2-4 and 7) are discussed.  
 
Physico-chemical properties of photosensitizers 
 
In a first step, the physico-chemical properties of applied photosensitizers were 
examined with a main focus on their mixture. The absorption and emission spectra of the 
photosensitizer combination did not show any cross effects. Peak pattern and intensity 
remained unchanged when compared to single photosensitizer measurements. Three different 
measurement approaches were performed (singlet oxygen luminescence, singlet oxygen 
sensor green and ROS selective CM-H2DCFDA reagents) to elaborate singlet oxygen yields 
and ROS production efficacy and to explore possible quenching effects in the photosensitizer 
mixture.  
The oxygen triplet quantum yield measurements are, in general, dependent on the 
parameters used, such as chosen measurement solution. Results from our study with Foslipos® 
correlated with measurements of Wacker et al. [4] where mTHPC was loaded in HSA 
nanoparticles, but it was higher than reported in the literature where mTHPC [5] was 
measured alone. Hypericin triplet quantum yield was found to be slightly lower than 
previously reported [6]. This difference could be explained by individually measurement 
conditions, hypericin purity and/ or time-dependent formation of hypericin aggregates, which 
has an high impact on its bio-distribution and singlet oxygen production as reported in the 
literature [7]. Singlet oxygen yield measurement at 415 nm and 590 nm did not display any 
cross effects for the photosensitizer mixture.  
Additionally, singlet oxygen measurement was conducted with a highly 1O2 selective 
SOSG reagent. In this measurement hypericin-mediated accumulation of singlet oxygen 
achieved a plateau after 35 minutes. When Foslipos® was applied, a continuous increase of 
fluorescence was detected. Collected data for SOSG assay measurements for the 
photosensitizer mixture were in line with the theoretical values expected. It was assumed that 
in the case of hypericin mediated 1O2 generation achieving the plateau was connected to the 
photosensitizer photobleaching effect. Yet in the measurements obtained in our study, 
photodegradation was not detected when illuminated with used white light. Most likely, 
remains from plant extraction and/ or hypericin aggregation play a crucial role on this effect. 
Furthermore, possible chemical reactions between hypericin and SOSG agent and the 
formation of hypericin aggregates tend to be a more feasible explanation for this observation. 
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It can be assumed that the results of Foslipos® mediated fluorescence generation and 
accumulation may be understood to support results obtained. mTHPC, which is embedded in 
liposomes, most likely prevents the photosensitizer aggregation, and chemical reactions with 
SOSG agent are less possible for mTHPC in solution [8].  
Detection of ROS with CM-H2DCFDA was performed on HNSCC cell lines and it 
showed an accumulation of fluorescent dye in hypericin and the photosensitizer mixture 
treated cells while for Foslipos® treated cells no accumulation was detected. The explanation 
for the lack of accumulation of the fluorescent CM-H2DCFDA form for Foslipos® treated 
cells was found in the deficient cell membrane integrity, which was seen in live cell imaging 
and/ or confocal pictures.  
The experiments on photosensitizer photobleaching with lower light doses indicated 
that no significant photobleaching could be detected. Therefore, higher light doses were 
applied in order to examine the possible cross effects in the photosensitizer mixture. 
Surprisingly, the time for complete Foslipos® bleaching in the mixture was approximately two 
hours longer then for the single photosensitizer. Since in the mixture both photosensitizers 
equally absorbed photons and singlet oxygen production was generated by both 
photosensitizers photobleaching had to be related to these events. Additionally, the 
photosensitizer aggregations or the influence on their photo-physics due to their near 
proximity could also have an impact on their photobleaching behaviour.  
 
Photosensitizer uptake, distribution and localisation studies 
 
After the examination of the chemical properties of the photosensitizer, including the 
generation of singlet oxygen and ROS, photo-stability in solution and possible interactions in 
the mixture, the uptake kinetics on cancer cells and microorganisms were examined 
microscopically and spectroscopically. The performed microscopic uptake studies showed 
quick photosensitizer accumulation in the cells (PC-3 and HNSCC cells) and an even faster 
accumulation in microorganisms (Streptococcus sobrinus, Streptococcus mutans, Candida 
albicans, Aggregibacter aphrophilus, Capnocytophaga ochracea and Fusobacterium 
nucleatum (data not shown)).  
The photosensitizer-uptake and -efflux processes in these studies were similar between cell 
lines. Uptake of Foslipos® in the initial studies for PC-3, and in subsequent studies for 
HNSCC, was continuous over 24 hours, while hypericin treated HNSCC cells followed a 
Gaussian curve distribution with a fluorescence maximum after five hours of incubation. 
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Other studies [9, 10] found great variations in uptake between individual cell lines resulting in 
even more pronounced differences in phototoxicity. Additionally, in accordance with many 
studies, which were done on a variety of human cell lines [11-13], the liposomal preparation 
of mTHPC did not affect the intracellular distribution when compared with mTHPC alone. 
Intracellular clearance results, which were made for HNSCC cells displayed that major 
amount of hypericin was cleared within 24 h with some hypericin aggregates remaining, 
while Foslipos® clearance was much slower. The slow release of mTHPC and its derivatives 
from the cells has been reported in several other studies [14, 15] and the reasons remain 
unclear. The photosensitizer mixture uptake and efflux studies on both UMB-SCC cell lines 
were comparable to the observations achieved with the single photosensitizers. The two 
differences were a higher amount of hypericin aggregates after 24 h in the photosensitizer 
efflux experiment when compared to hypericin alone and lower fluorescence intensity in the 
uptake study after five hours. The higher amount of hypericin aggregates and the 
photosensitizers near proximity could eventually cause fluorescence quenching resulting in 
lower fluorescence intensity. Taken together, these findings indicate slightly different 
intracellular behaviour of hypericin when combined with Foslipos®.  
Interestingly, the uptake studies for microorganisms indicated much faster uptake kinetics. An 
incubation time of 15 minutes was sufficient to achieve total PDT mediated eradication of 
examined pathogens, while the intracellular amount of photosensitizers during this incubation 
time did not affect cells. The short incubation protocols in pathogen treatment are definitely 
safer and more tolerable for surrounding tissue. They may provide a novel therapy modality 
on local infections in oral regions.  
 
The PDT effects are highly dependent on intracellular localization places. Thus 
extensive localization studies were performed in the HNSCC cell- and microorganisms model 
system. The photosensitizer subcellular localization studies in HNSCC cells indicated that 
hypericin was mainly found in membranous systems (outer cellular membranes, nuclear 
membranes, in trans golgi network and perinuclearly), while Foslipos® did not co-localise 
with any cell organelle stain and it remained diffuse in cytoplasm of both UMB-SCC cell 
lines and PC-3 cells. In many studies, such as those of Theodossiou et al. [16] or Kiesslich et 
al. [9] intracellular localisation of photosensitizers was investigated and the results correspond 
partially with the findings in our studies. Microscopic analyses in examined microorganisms 
showed similar distribution picture in gram-positive and gram-negative species. S. sobrinus 
and S. mutans as well as C. albicans, A. aphrophilus, C. ochracea and F. nucleatum (data not 
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shown) accumulated all used photosensitizers intracellularly. The intracellular photosensitizer 
localization seems to be driven by many factors such as photosensitizer concentration, 
incubation time, cell model systems, incubation parameters and/ or environment of the 
photosensitizer (such as presence of serum proteins or other substances). This was clearly 
evident from the study performed on microorganisms where photosensitizers were applied in 
combination with chitosan-thioglycolic acid (TGA), which acted as an enhancer for 
antimicrobial PDT effects. Here, uptake of Foslipos ® was prevented through chitosan-TGA 
incubation for some microorganisms, resulting in a shift from intracellular to extracellular 
Foslipos® localization in gram-negative bacteria. In comparision, C. albicans and S. sobrinus 
did not display this behaviour. The underlying mechanisms are not clear yet but they may be 
related to the known lipid-binding capabilities of chitosan [17] and more probable species-
specific factors such as cell wall structure.  
 
Cell viability studies without illumination 
 
The photosensitizer mechanisms on cell viability in the dark have, up to date, received 
very little scientific investigation, most likely due to their complexity. Our study partially 
examined the said mechanisms. The results demonstrated that Foslipos® treated cells (PC-3 
and HNSCC) displayed a significant proliferation decrease only for highest concentration 
used (10 µg/ mL), while hypericin treatment affected cell viability for all applied 
concentrations. Many studies have reported dark toxicity of Foslipos® [13], but the 
mechanisms which affect cell viability were not further investigated. The cell toxic 
concentrations differ from study to study which might be explained by use of different cell 
models. Hypericin effects in the dark could be a result of the light independent inhibition of  
various enzymes [18] such as protein kinase C, protein tyrosine kinases or mitochondrial 
succinoxidase, all of which play important roles in cell growth, proliferation, survival and 
death [19, 20]. In addition, hypericin showed a strong light independent inhibitory activity 
against glutathione reductase and against several species of cytochrome P450 [21, 22], by 
which various metabolic processes could be affected. Hypericin may also reduce intracellular 
pH by proton transfer to surrounding molecules leading to pH dependent structural changes in 
proteins [23]. Any of those findings could account for affected cell proliferation in our study. 
Surprisingly, the proliferation assays with photosensitizer mixture application in the dark 
indicated that even with the highest concentrations cell viability remained as in the control 
samples. The mechanisms underlying the improved tolerability of the photosensitizer mixture 
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are not clear. However, since hypericin is known to attach to lipoproteins, and is preferably 
incorporated into lipid membranes [24], it cannot be excluded that in the mixture hypericin 
interacts with Foslipos® liposomes, thereby changing its bioactivity.  
Furthermore, the examinations of RNA quality in HNSCC cell lines and in PC-3 cell line 
indicated that the overall RNA quality was not influenced by the intracellular accumulation of 
photosensitizers without illumination. There was not observable difference between the two 
HNSCC cell lines. Contrasting these results, in the case of hypericin treated UMB-SCC 745 
and Foslipos® treated PC-3 cells DNA damage was detected. Since UMB-SCC 745 cells did 
not show significant differences in photosensitizer uptake, efflux or localisation when 
compared to UMB-SCC 969 a plausible explanation for the minor DNA damage could be 
found in the fact that different cell lines were used. 
 
In the study focusing on oral pathogens [25], viability of S. sobrinus in the dark was not found 
to be affected by the photosensitizers used (hypericin, Foslipos® and 1:1 mixture), while S. 
mutans showed high toxic effects when incubated with Foslipos® or the photosensitizer 
mixture. Furthermore, ineffectiveness of hypericin-mediated PDT in S. mutans was observed. 
These results were unexpected since both microorganisms are traditionally grouped in a 
common taxonomic cluster. The highly differing sensitivities of the two Streptococcus species 
may be explained by the differences found in the molecular phylogenetic analyses of glucan-
producing enzymes and superoxide dismutases, indicating that the two bacteria strains are in 
fact genetically separate [26-28]. The mechanisms of these effects are unknown and further 
investigations of the molecular and cellular properties are needed.  
In summary, the results from other studies and our own results on cancer cells (PC-3 
and HNSCC) and oral pathogens indicate how little we actually understand about the factors 
that govern photosensitizer generated cellular and bacterial toxicity in the dark. The complex 
molecular mechanisms behind the photosensitizer dark toxicity remain unclear but further 
investigations will be in the focus of our future studies.  
 
Cell viability studies after illumination 
 
The cell viability results after illumination on all three cell lines and applied 
photosensitizers were decreased significantly when compared to control samples. The initial 
study on PC-3 cells for mTHPC- mediated PDT indicated that kinetics of the reaction were 
characterised by a two-step process with an initial cell death few minutes after light 
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application and a second – a stronger one - five hours later. The first PDT effect is likely due 
to direct reactive oxygen species (ROS) damage. Generation of ROS occurs in fractions of a 
second after PDT and may kill a population of cells immediately. However, damage caused 
by ROS seems to merely affect the majority of the cells which rather undergo death processes 
that takes several hours. Excellent PDT results were achieved also on HNSCC cell lines. 
Noteworthy are effects with low light and low photosensitizer doses in the mixture conditions 
especially when compared with Foslipos® treatment alone. The cell viability difference was 
also detectable between the two cell lines. According to many other studies similar results for 
Foslipos® and hypericin induced PDT were found [29, 30]. Unfortunately the PDT effects of 
the photosensitizer combination were not examined in other studies.  
The PDT treatments of gram-positive and gram-negative bacteria when combined with TGA-
chitosan are very attractive. Our results showed that this treatment modality, with appropriate 
protocols, may result in 100% bacterial death. The advantages of PDT in comparison to 
conventional treatments are its proven efficacy on antibiotic-resistant strains, low potential for 
mutagenicity and photoresistance as well as its broad target spectrum [31]. Interestingly, 
despite the large spectrum of photoactive agents available only a limited number have been 
investigated with regards to their antimicrobial applicability. However, it should be 
emphasised that the application of a mixture of photosensitizer has great potential to target 
complex microbial populations, as such found in most infections.  
 
Cell death and morphological changes after illumination 
 
The monitoring of morphological cellular changes and the examination of cell death 
pathways after light application was extensively examined on HNSCC cell lines. Hypericin 
treated HNSCC cells showed features of apoptotic cell death (cell shrinkage, membrane 
blebbing and vesiculation, formation of apoptotic bodies), while for Foslipos® treated cells 
more necrotic cell death outcome (shrinkage of the cells and detaching from the surface) was 
detected. The photosensitizer mixture treated cells showed initial apoptotic death features and 
at later points in time necrotic cell death features. The cellular death pathways were verified 
with caspases activity assay, annexin V death assay and staining of cytochrome C. Foslipos® 
mediated cell death in both HNSCC cell lines were necrotic by nature. Interestingly, the 
experiments conducted demonstrated that apoptotic death pathways in hypericin-induced PDT 
were triggered by different mechanisms depending on the cell line used. The apoptotic 
pathway for the UMB-SCC 745 cell line was not initiated by cytochrome C release in contrast 
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to UMB-SCC 969 cells. Programmed cell death seems to be complicated but obviously there 
are many alternative possibilities to avoid potential intracellular problems resulting in 
apoptosis. The study by Panzarini et al. showed such a cellular death flexibility [32] by 
demonstrating that rose bengal acetate could trigger apoptosis by at least four different 
pathways during the observed time (0 - 12 h) in HeLa cells. The initial apoptosis pathway was 
the intrinsic pathway, followed by the activation of the extrinisic, caspase-12-dependent and 
caspases-independent pathways. Finally, apoptosis was rapidly followed by autophagy. 
Quality-control mechanism of autophagy served as a necrosis protection and Panzarini et al. 
could predominantly registered apoptosis in HeLa. Necrosis was always negligible in their 
study. In addition to the cell model used, the intracellular photosensitizer localization places, 
photosensitizer concentration and applied light doses contribute significantly to the cell death 
pathways, as reported in many other studies [16, 18, 29, 30, 33-37]. The PDT- mediated cell 
death pathways are complicated and it seems that apoptosis and necrosis co-exist and 
interrelate in different proportions. Cellular death trigger mechanisms in PDT are still under 
investigation. These are very important studies in the clinical context and they will make 
significant contribution to the understanding and application of PDT in vivo.  
 
Molecular mechanisms after illumination 
 
The investigation of affected molecular mechanisms was performed by characterizing 
the damaging effects on nucleic acids which was supported by RNA- integrity and quality 
experiments. Surprisingly, directly after illumination a significant number of DNA strand 
breaks were detected in Foslipos®- treated PC-3 and in hypericin-, Foslipos®- and 
photosensitizer mixture- treated HNSCC cells (data not shown). Anisotropy imaging studies 
of mTHPC [38] showed its localization to the nuclear envelope. In addition, our own 
observations of hypericin’s preferably perinuclearly localization might be the reason for the 
damage of membrane compartments, allowing an immediate ROS-related injury of 
(peripherally residing) DNA. Rousset et al. [39] reported possible nuclear mTHPC entering 
during light application in the murine glioma cell line. This could also be an explanation for 
the DNA damage in our study. The profound and early DNA damage may account for instant 
cell destruction or initiation of death cascades but also to cell mutation – if DNA repair 
capacities are too low – and in surviving cells which may result in secondary malignancies 
after PDT. In our study on PC-3 cells a recovery of a-basic sites (no DNA repair initiation) 
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could not be detected even within 24h after PDT, nor could a recovery of comet tails in the 
single cell electrophoresis study on HNSCC cell lines (data not shown, paper in preparation).  
RNA-integrity and quality experiments show a clear degradation pattern in Foslipos®- treated 
PC-3 cells. The RNA degradation in photosensitizer treated HNSCC cell lines was similar 
between applied photosensitizer conditions (hypericin, Foslipos® and 1:1 mixture) but was 
lower if compared to PC-3 cells (data not shown).   
These results were complemented at the RNA level by the observation of several important 
genes associated with DNA repair mechanisms. The gene expression analyses for PC-3 cells 
were performed with an array system of 84 genes involved in stress-response pathways. The 
gene expression in HNSCC cell lines were observed for 16 specific selected genes (paper in 
preparation). The early DNA damage sensors ATM, DDB1, the excision repair endonucleases 
ERCC1 and 3, the post-replication DNA repair genes RAD23A and 50, the uracil-DNA 
glycosylase UNG and the DNA double strand repair proteins XRCC1 and 2 were 
transcriptionally down-regulated or destroyed after PDT with Foslipos® in PC-3 treated cells. 
Our data are comparable with those in murine glioblastoma cells where mTHPC mediated 
PDT also resulted in an immediate DNA damage. However, in this and other studies, 
activation of repair mechanisms had been reported [39-41]. Since our data are contradictory to 
studies in human myeloid leukaemia and nasopharyngeal carcinoma cells where no DNA 
damage was found after mTHPC-PDT [42, 43], it can be assumed that the observed effects 
might be dependent on cell line used. Molecular response of PC-3 cells to mTHPC- induced 
PDT seems to be very complex. Further RNA expression studies on genes involved in cellular 
stress and defence mechanisms response showed that two antioxidant defence genes (CRYAB 
and HMOX1) were strongly upregulated. The small heat shock protein CRYAB, which was 
between 6 and 7-fold up-regulated also for all the photosensitizer treatments in HNSCC cells 
and the heme oxygenase family member HMOX1 is known to act as a molecular chaperon 
preventing the aggregation of denaturated proteins. Furthermore they interact with 
cytoskeletal components such as microtubules, intermediate filaments and microfilaments in 
response to different stress situations [44] protecting cells from oxidative damage [45]. 
Together with the observation that inhibition of HMOX1 may increase the efficacy of PDT 
[46, 47], it can be suggested that high levels of HMOX1 or CRYAB may eventually prevent 
optimal phototoxic effects.  
Expression of heat shock proteins (HSPs) such as HSP60, HSP70 or HSP90 after PDT with 
various photosensitizers was reported to be up-regulated [48-51]. In our study we found that 
expression of HSPs members may be down- or up-regulated after PDT with Foslipos® in PC-
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3 cells. Up-regulation of the HSP40 member DNAJB4 as well as HSP70 members HSPA1, 
HSPA1L and especially HSPA6 that is only induced by severe stress-stimuli may mirror the 
extent of damage in our model but also may indicate the presence of a (partly) preserved 
stress-response system.  
The heat shock protein gene HSPA6 was as well highly up-regulated after all PDT treatments 
in both HNSCC cell lines. This correlates with different studies on PDT-induced heat shock 
protein expressions [1, 52]. The 70kDa heat shock proteins (molecular chaperons) generally 
have cell protective functions in stressful conditions and additionally they serve as markers 
for elimination by immune system [53]. An increase of intracellular concentration of HSP70 
proteins may enhance the ability of a cell to deal with resulting accumulation of abnormally 
folded proteins after PDT treatment. Interestingly, our results show that not only apoptotic 
(hypericin treated cells) but also necrotic cells (Foslipos® treated cells) and cells displaying 
features of both death pathways (1:1 mixture treated cells) have an up-regulated HSPA6 
expression. The HSPA6 up-regulation in the UMB-SCC 745 and in the UMB-SCC 969 cell 
line was immensely high that the interpretation of the data and drawing conclusions 
concerning possible differences between these two cell lines and different treatments was not 
possible. 
The cell damage after PDT in the PC-3 cell model was obviously so profound that 
repair mechanisms were not functional. Therefore, the possible activation of death pathways 
was examined. It was reported that cyclin family genes which are crucial for DNA replication, 
were markedly reduced after PDT [54, 55]. Findings in our model correspond to these studies. 
The down-regulation of cyclin-interacting transcription factors may lead to a diminished 
proliferative activity or it may directly promote cell death. Interestingly, the expression of the 
tumor suppressor p53 (TP53), a key factor for the regulation of cell growth and death, was not 
affected. This has been reported previously [56]. However, the cyclin-dependent kinase 
inhibitor CDK1A, one of the main targets of TP53, was in contrast to other studies [57] 
reduced after PDT in our study. This result supports the assumption of an impact of PDT on 
cell cycle processes. Additionally, MDM2, an important inhibiting factor of p53, was also 
reduced. This may be associated with the potential of increased p53-related pathway and/ or 
reduced p53 degradation followed by cell cycle arrest and apoptosis. Furthermore, a strong 
up-regulation of bZIP transcription factor DDIT3 was found. DDIT3 had been implicated in 
anti-proliferative effects and the induction of apoptosis by certain anti-cancer agents, 
including PC-3 cells [58]. The high levels may have also contributed to growth arrest and 
apoptotic signalling in the experiments performed.  
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The genes involved in apoptosis signalling in our study either displayed reduced transcript 
numbers, or were almost completely shut down. Most of these genes seemed to be damaged 
early – probably due to direct ROS damage. The biological consequences are not clear yet. In 
general, the observation of various cell death processes seems to be more adequately 
investigated at the protein level. The monitoring of apoptotic pathways in Foslipos®- 
mediated PDT in PC-3 cells was not the scope of our study but the data did not exclude their 
activation as observed in caspases activity assay (FLICA) in HNSCC cell lines. Rather, the 
obtained results in PC-3 cells might be another sign of a breakdown in basic cellular 
functions.  
 
Summary 
 
In summary, our study focusing on PC-3 cells with Foslipos®-mediated PDT is 
characterized by a two-stage process, a combination of acute and delayed lethal effects. The 
first step is most likely driven by the direct actions of ROS on vital biological components 
allowing the temporary cell survival, initiating growth arrest, oxidative stress and rescue 
responses. The second step, a few hours later, was characterized by severe damage of the 
genomic DNA and the translational system which prevented recovery of the cells and lead to 
unavoidable cell death.  
The studies on the HNSCC cell lines demonstrated different death pathways (necrosis and 
apoptosis) which seem to be dependent mainly on the photosensitizer. Further, evidence was 
provided that hypericin could induce two different apoptosis pathways (mitochondrial 
dependent and independent death pathways) relying upon the cell line used. Finally, these 
studies showed that the application of a photosensitizer mixture with lower single 
photosensitizer concentrations had an excellent PDT effect in our cell models.  
Based on these results, the application of photosensitizer mixture could be beneficial not only 
in cancer treatment, but it also could help in the fight against microorganisms. This simple but 
innovative approach could open new treatment possibilities in PDT.  
 
Outlook 
 
In the near future we plan to examine the effects and the mechanisms of 
photosensitizers and their mixture without illumination. Also PDT effects with established 
conditions in HNSCC multicellular spheroids will be examined. The comparison of the data 
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obtained in monolayer could give more detailed insight to PDT understanding, which is 
essential before PDT application in vivo. Additionally, we intend to further investigate on 
antimicrobial PDT and we are planning to combine cancer PDT with hyperthermia, where we 
can enhance PDT effects through additional cellular stress. The initial study is ongoing and 
results are very promising.  
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6. Establishment of Three Dimensional Head and Neck Squamous 
Cell Carcinoma (HNSCC) Cell Culture (Multicellular Spheroids) 
 
6.1 Introduction 
 
Nowadays cell culture models are a very important and indispensable instrument in cancer, 
pharmacological and other experimental biology research. Monolayer or suspension cell 
cultures are known for 70 years and revolutionised the way of molecular research. Cell 
monolayers offer the possibility to simplify complex living systems enormously and therewith 
give insight in basic biological functions such as cellular interactions with drugs or various 
cellular pathways important for cell survival or death. The simplicity of this system is at the 
same time its major disadvantage. Drawing conclusions from work with cell cultures and 
extrapolating them to complex living systems is very challenging and it can lead to inaccurate 
context. Beside that, cell cultures are far away to represent complex and well organised 
appearance of tissue or tumours. In 1970 three dimensional cell cultures, so called 
multicellular spheroids, were introduced by experimental radiotherapists [1]. Since then 
tumour multicellular cultures were used in many different research areas such as 
photodynamic therapy, pharmacological research, hyperthermia and antibody-based 
immunotherapy as well as chemotherapy. This cellular model system made immense 
contribution to our knowledge about cellular responses to many therapeutic approaches [2]. 
Compared to monolayer cultures, 3D cell cultures offer similar conditions and 
microenvironments as found in tumours in vivo. They represent avascular tumour nodules or 
regions of solid tumour more accurately [3]. This cell model is gaining increasing value in 
cancer research as an essential tool for pharmacodynamic and pharmacokinetic predictions 
such as drug transportation, cellular resistance, tumour cell-matrix interactions, differentiation 
and invasion processes.  
Part of our study was to establish HNSCC multicellular spheroids protocol for the application 
of photodynamic therapy in vitro. It is known that photodynamic therapy is dependent on the 
concentration of photosensitizer, molecular oxygen present and light penetration [4], therefore 
multicellular spheroids with their complex morphology appear to be suitable for examination 
of PDT-based mechanisms of action.  
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6.2 Materials and Methods 
 
6.2.1 Cell lines 
 
Monolayer: UMB-SCC 745 and UMB-SCC 969 were kindly provided by Dr. Robert Mandić, 
Department of Otolaryngology, Philipps University, Marburg, Germany. The cells were 
cultured under standard conditions (37°C, 5% CO2, 95% air atmosphere) in RPMI growth 
medium (Invitrogen) supplemented with 10% fetal calf serum (FCS, Sigma-Aldrich, Buchs, 
Switzerland), 1% (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Invitrogen), 
1% Minimum Essential Medium Non Essential Amino Acids (MEM NEAA, Invitrogen) and 
1% penicillin and streptomycin (Invitrogen). Every second day the growth medium was 
replaced. When the cells reached confluence, the cell passaging was done with 1x trypsin ( 
Invitrogen), in general every 2-3 days. 
 
Multicellular spheroids (3D cell culture):  For generation of multicellular spheroids we 
applied a modified and for our cells optimised hanging drop method [5]. The following 
parameters were modified: 
i) volume of agar in 96-well plate 
ii) volume of growth medium per well 
iii) volume of cell suspension drops on the lid 
iv) cell concentration per drop 
v) hanging time 
vi) time dependent development of spheroids in wells  
 
The detailed work is described in Marco Etter’s medical doctoral thesis manuscript.  
 
Briefly, the optimized version: 96-well plates were coated with 60 µl of 1.5% agarose (Sigma-
Aldrich) per well, in RPMI medium without FCS. Then 20 µl drops of UMB-SCC cell 
solution (5000 cells/ 20 µl for UMB-SCC 745 and 10’000 cells/ 20 µl for UMB-SCC 969) 
were placed onto the plate lid, the lid was positioned back to the plate and then kept in the 
incubator (37°C, 5% CO2) overnight. The following day, 80 µl growth medium were added to 
each well; the plates were centrifuged shortly and returned to the incubator. In order to avoid 
vibration, which would have had an influence on the formation of spheroids, the incubator 
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was not opened for the first 48 hours. After this initial time spheroids were stable in their form 
and reached the desired diameter of 150 µm two days later.  
 
6.2.2 Microscopy 
 
Microscopes: The development of multicellular spheroids was monitored with different 
microscopic techniques. Leica LX wide field microscope (Leica Microsystems, Wetzlar, 
Germany) was used for time dependent live cell observation of morphological development of 
spheroids. Transmission electron microscopy (TEM) with Philips CM 100 (Royal Philips 
Electronics, Amsterdam, Netherlands) was used to examine the cell differentiations and 
connections inside of spheroids. Scanning electron microscopy (SEM) with Gemini Zeiss 
SUPRA 50VP (Leica Microsystems) was used for examination of surface area of spheroids.  
 
Preparation Protocols: Two different time-dependent live cell imaging experiments were 
performed. Firstly, development of spheroid over time was monitored. Eight spheroids were 
removed from 96-well plates, washed 2 times with PBS and subsequently placed on 18-well 
ibidi slides (Vitaris, Baar, Switzerland) in PBS and monitored for 20 minutes. Used spheroids 
were discarded after observation and for the subsequent experiment next eight spheroids from 
96-well plates were used. The observation was made every second day until day eleven. 
Secondly, we observed behaviour of multiple spheroids in the same well over 5 h.  
Samples for TEM were high pressure frozen and freeze-substituted (at -90°C, -60°C, -
30°C) in water-free acetone and 2% osmium tetroxide (OsO4). The samples were embedded 
first into 33% Epon (Sigma-Aldrich) followed by 66% for 1,5 hours and finally into 100% 
Epon. The polymerisation was in a 60°C heated oven over night. The 60 nm thick sample 
sections were placed onto 200 mesh grids and contrasted with 2% uranyl acetate (Sigma-
Aldrich) and Reynold’s lead citrate (Sigma-Aldrich).  
SEM samples were performed according to the standard protocol. Briefly, samples were 
fixed for 30 minutes with 2.5% glutaraldehyde and 2% OsO4, PBS and washed with distilled 
water. Subsequently samples were dehydrated in ascending EtOH series (60 %, 70%, 80%, 90 
% and 100 %), critical point dried (CPD O30, Leica) and mounted on 12 mm aluminium 
stubs. Sputter coat for 80 seconds with platinum followed subsequently. Additionally, 
behaviour of spheroids was also monitored with SEM. Several spheroids were left on poly-L-
lysine (PLL) coated slides for 20 minutes. The fixation protocol was as described above.  
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6.3 Results 
 
Live cell imaging: Time dependent development of spheroids in the well was observed over 
11 days. One day after cell suspension drops centrifugation spheroids were perfectly round in 
shape with a diameter between 75 µm and 150 µm. Until the sixth day spheroids did not show 
changes in their shape but only in their dimensions. Grown spheroids displayed a diameter 
from approximately 250 µm - 300 µm. From eighth day detaching of the cells on the surface 
was visible which was on eleventh day very pronounced. Both cell lines displayed similar 
behaviour. In figure 1 time dependent spheroid development of UMB-SCC 745 cell line is 
shown as an example.  
 
 
Figure 1: Live cell imaging pictures of UMB-SCC 745 spheroids after different time periods: in A after two 
days, in B after six days, in C after eight days and in D after eleven days. The differential interference contrast 
(DIC) pictures were made by wide-field Leica LX microscope. Scale bars in A = 50 µm and in B-D = 100 µm.   
 
During live cell imaging we observed very interesting spheroids behaviour. If spheroids are in 
very near proximity to each other they tended to dock to each other and fuse (fig. 2). The 
fusing time was within five hours. Due to the semi-transparency of spheroids dynamic 
movements of the cells inside spheroid were observable. The black spots (probably necrotic 
areas) in spheroids were shifted through whole spheroid over time.  
 
 
Figure 2: Live cell imaging pictures of UMB-SCC 745 spheroids. In picture A DIC picture of zero time point 
(spheroids docking) is shown, in B fusing after 2,5 hours and in C totally fusion after 5 hours. The DIC pictures 
were made by wide-field Leica LX microscope every 10 minutes. Scale bars = 100 µm. 
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SEM imaging: Surface and form of spheroids were examined with SEM. In figure 3 A UMB-
SCC 745 spheroids after 4 days of growth are shown. The spheroids are perfectly round in 
shape and had an even and smooth surface. Figure 3 B is an enlarged section of spheroid 
surface. In this picture tight packed cells with strong pronounced cell-cell contacts are visible. 
The cells on the surface of spheroid build a unifying and tightly connected cell layer. 
 
 
Figure 3: SEM pictures of UMB-SCC 745 spheroids. In picture A are shown two spheroids after 4 days. In 
picture B is shown the surface of spheroids. Nicely visible are single cells and cell-cell contacts. Scale bar in A = 
50 µm in B =10 µm. 
 
As already described spheroids demonstrate highly dynamic behaviour. Living spheroids 
were left on PLL coated cover slides for 20 minutes and then fixed for SEM as reported. In 
figure 4 A a spheroid with round shape and smooth surface at the time point zero is shown. 
Picture 4 B shows spheroids after 20 minutes on PLL coated cover slides. The first 
remarkable observation was rapid spheroid form change. Within 20 minutes spheroid were 
flattened and cells started to develop filopodia extensions on the cover slide surface, which is 
displayed in figure 4 C.  
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Figure 4: SEM pictures of UMB-SCC 745 spheroids on PLL coated cover slides over 20 minutes. In picture A 
spheroid at time point zero is shown, in B after 20 minutes. In C enlarged picture of cell filopodia after 20 
minutes is shown. Scale bars in A and B = 50 µm and in C = 10 µm. 
 
TEM imaging: High pressure frozen spheroid ultra-thin sample sections were used to 
examine structures and cellular organisation inside the spheroids. In figure 5 an overview 
picture of a UMB-SCC 745 spheroid with four pictures of detailed structures (A-D) are 
shown. In the overview picture is visible that the cell density is decreasing towards the 
spheroid centre. The cells display necrotic and autophagic features such as large vacuoles, 
degradation of intracellular content, multilamellar bodies (figure 6) and loss of cell-cell 
contacts. The cells which are near to spheroid surface (fig. 5 B and C) are tightly packed and 
have an extremely pronounced filopodia maze which serves as mechanical cellular anchors 
ensuring cohesion of the cells.  
 
 
Figure 5: TEM pictures of high pressure frozen UMB-SCC 745 spheroid. In the middle an overview picture of a 
spheroid is shown. In A and D cells which display predominantly autophagic features (many vacuoles, 
degradation of cell organelles, multilamellar bodies and loss of cell-cell contacts) are shown. In B and C healthy 
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cells with pronounced filopodia-cell-cell contacts, smooth spheroid surface and healthy cell organelles and 
nuclei are shown. Scale bars for A - D = 5 µm and for overall spheroid picture = 20 µm. 
 
Figure 6 A is a detailed picture of autophagy compartments inside the spheroid and in 6 B 
close-up picture of multilamellar bodies. The self-digestion of cells in nutrient-poor spheroid 
compartments is often found. 
 
 
Figure 6: TEM pictures of multilamellar bodies inside high pressure frozen UMB-SCC 745 spheroid. In A an 
overview picture with several vacuoles with multilamellar bodies and other digested cell compartments is shown. 
In B a detailed picture with multilamellar bodies and glycogen storages is shown. Scale bars in A = 500 nm and 
in B = 100 nm. 
 
In summary, the examination of UMB-SCC 745 multicellular spheroids revealed a complex 
morphological architecture with heterogeneous pathophysiological characteristics similar to 
those found in solid tumours such as three dimensional cell-cell interactions, necrotic and 
autophagic compartments and presence of nutrient gradient.  
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6.4 Discussion and Conclusion 
 
The multicellular spheroids represent an accurate and powerful in vitro model for 
various biological research areas. Until now many different protocols for generation of 3D 
cell cultures were described. Still, there are not many research groups using multicellular 
spheroids for their research. This could be due to the complex multicellular spheroid culture 
technique and multiple possibilities to analyse the treated spheroids. The conventional 
generation of multicellular spheroids is based on cell-cell coupling by resisting cell-surface 
interactions [2]. This is used in variety of methods such as agitation of the cell suspension [3], 
cellular aggregation by sedimentation at concaves, usage of microcapsules with Ca-alginate- 
[6] or alginate-chitosan [7] gel membranes, cell adhesion resistant surfaces such as agarose 
[8] or poly-hydroxyethyl methacrylate [9] or a droplet’s air-liquid interface [5, 10, 11]. The 
major working challenge with multicellular spheroids is lack of fully developed high-
throughput manipulation and analysis methods as available for 2D monolayer cell cultures. 
The monitoring of spheroids with different microscopy methods (widefield microscopy, 
multiphoton confocal microsocopy, SEM and TEM,) are well established and widely used. It 
is possible to monitor viable and intact spheroids as well as high pressure frozen, chemically 
fixed or paraffin-embedded multicellular spheroid cultures. Further more, it is possible to 
perform a broad range of immunocytochemical stainings on ultra-thin cross-sections. 
Performance of assays in intact and viable spheroids in contrast is often limited due to the 
complex spheroid morphology which makes penetration of substances difficult. Nowadays 
cell survival in spheroids is monitored with different approaches such as observation of 
respiratory-, lactate dehydrogenase- or acid phosphatase activity [12-14]. Molecular methods 
such as examination of gene expression response may also be applied to multicellular 
spheroids. However, the requirement of large amount of spheroids for the experimental set-
ups should be taken in account. Nevertheless, it was shown that gene expression patterns are 
much closer related to the in vivo situation than results achieved with 2D monolayer cultures 
[15-17]. 
Two dimensional monolayer cultures are widely used in PDT research but this 
approach is inadequate since oxygen gradient as well as heterogeneous population of cells 
(proliferating, quiescent and hypoxic cells) is lacking. Important parameters for good PDT 
efficacy are photosensitizer intracellular concentration (penetration and accumulation), light 
dose and amount of molecular oxygen present. A three dimensional cell model system with 
radially decreasing oxygen gradient [19] offers an excellent insight in processes induced by 
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oxygen dependent therapies such as PDT. Photosensitizer fluorescence features enable an 
easy monitoring and tracking of photosensitizer distribution and for light dosimetry - which is 
very important for accurate in vivo PDT - a number of different strategies is proposed [18]. In 
our study we established and elaborated an easy and low cost protocol for generation of 
HNSCC spheroids which can be applied to any cell type. Results of our previous studies on 
2D monolayer HNSCC cell cultures will serve as a basis for further research in HNSCC 
multicellular spheroids. 
In summary, multicellular spheroids represent an in vitro system between 2D 
monolayers and tumours in situ. This model closely mimics the situation of micro-
environment in solid tumours and is characterised by complex structural features as well as by 
oxygen, nutrient, pH gradients. Therefore application of different treatments (e.g. drug 
screenings, experimental radiotherapy, antibody-based immunotherapy or photodynamic 
therapy) in 3D cell culture is gaining outstanding importance.  
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7.1 Uptake and fate of surface modified silica nanoparticles in head and 
neck squamous cell carcinoma  
 
The contributions of Emina Besic Gyenge to the study: „Uptake and fate of surface modified 
silica nanoparticles in head and neck squamous cell carcinoma” were the following:  
 
1. Spheroid cell culturing 
 
2. Elaboration of experiment designs 
 
3. Nanoparticle uptake experiments (in both cell lines) and microscopic monitoring, in 
particular: figure 2 (nanoparticle internalisation mode), figure 3 (time dependent uptake of 
Ru@SiO2-OH nanoparticles), figure 4 (time dependent uptake of Ru@SiO2-NH2 
nanoparticles), figure 6 (time dependent uptake of Ru@SiO2-PEG nanoparticles), figure 7 
(time dependent uptake of Ru@SiO2-NH2 nanoparticles in spheroids). 
 
4. Nanoparticle intracellular localisation and distribution (in both cell lines) and microscopic 
monitoring, in particular figure 5 (intracellular localisation of Ru@SiO2-OH and Ru@SiO2-
NH2 nanoparticles), figure 8 (intracellular co-localisation of Ru@SiO2-OH and Ru@SiO2-
NH2 nanoparticles) and figure 10 (Ru@SiO2-NH2 nanoparticles distribution during cell 
division)
 117
___________________________________________________________________________ 
 165
 
RESEARCH Open Access
Uptake and fate of surface modified silica
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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is currently the eighth leading cause of cancer death
worldwide. The often severe side effects, functional impairments and unfavorable cosmetic outcome of conventional
therapies for HNSCC have prompted the quest for novel treatment strategies, including the evaluation of
nanotechnology to improve e.g. drug delivery and cancer imaging. Although silica nanoparticles hold great promise for
biomedical applications, they have not yet been investigated in the context of HNSCC. In the present in-vitro study we
thus analyzed the cytotoxicity, uptake and intracellular fate of 200-300 nm core-shell silica nanoparticles encapsulating
fluorescent dye tris(bipyridine)ruthenium(II) dichloride with hydroxyl-, aminopropyl- or PEGylated surface modifications
(Ru@SiO2-OH, Ru@SiO2-NH2, Ru@SiO2-PEG) in the human HNSCC cell line UMB-SCC 745.
Results: We found that at concentrations of 0.125 mg/ml, none of the nanoparticles used had a statistically
significant effect on proliferation rates of UMB-SCC 745. Confocal and transmission electron microscopy showed an
intracellular appearance of Ru@SiO2-OH and Ru@SiO2-NH2 within 30 min. They were internalized both as single
nanoparticles (presumably via clathrin-coated pits) or in clusters and always localized to cytoplasmic membrane-
bounded vesicles. Immunocytochemical co-localization studies indicated that only a fraction of these nanoparticles
were transferred to early endosomes, while the majority accumulated in large organelles. Ru@SiO2-OH and
Ru@SiO2-NH2 nanoparticles had never been observed to traffic to the lysosomal compartment and were rather
propagated at cell division. Intracellular persistence of Ru@SiO2-OH and Ru@SiO2-NH2 was thus traceable over 5 cell
passages, but did not result in apparent changes in cell morphology and vitality. In contrast to Ru@SiO2-OH and
Ru@SiO2-NH2 uptake of Ru@SiO2-PEG was minimal even after 24 h.
Conclusions: Our study is the first to provide evidence that silica-based nanoparticles may serve as useful tools for
the development of novel treatment options in HNSCC. Their long intracellular persistence could be of advantage
for e.g. chronic therapeutic modalities. However, their complex endocytotic pathways require further investigations.
Keywords: nanoparticles, silica dioxide, surface properties, tumor cell line, uptake, endocytosis, cellular fate
1. Introduction
Head and neck squamous cell carcinoma (HNSCC)
comprise a group of epithelial cancers that arise from e.
g. the lips, the oral or nasal cavity, salivary glands, para-
nasal sinuses, pharynx or larynx [1]. With a worldwide
incidence of more than 600’000 new cases per year,
HNSCC accounts for about 6% of all malignant diseases
diagnosed (http://globocan.iarc.fr). If detected early,
patients have cure rates of about 90%. However, 60% of
patients present with advanced disease or loco-regional
lymph node metastasis at the time of diagnosis and have
a poor prognosis [2,3].
Currently, treatment options for HNSCC patients
include surgery, radiotherapy, chemotherapy or a combi-
nation of them [4,5]. Due to the distinct localization of
these tumors in regions with anatomic structures
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important to e.g. breathing, mastication, swallowing or
phonation, invasive treatment regimes frequently leading
to severe functional impairments - often accompanied
by unfavorable cosmetic outcomes. This is true despite
significant advancements made in the reconstructive
abilities over past two decades. Moreover, radiation may
have long-term effects on surrounding healthy struc-
tures such as parts of the brain, the spinal cord or sali-
vary glands. However, while surgery or radiation therapy
is local, chemotherapy is applied systemically and may
thus result in severe adverse effects e.g. on blood cell
production (anaemia, neutropenia, thrombopenia), the
mucosa (mucositis), the auditory and vestibular system
(ototoxicity) or the kidneys (nephrotoxicity). Despite
this aggressive therapeutic regime, to date many patients
with advanced disease cannot be cured and more then
half of them die within five years [6-8]. HNSCC is thus
currently the eighth leading cause of cancer death
worldwide.
To overcome at least some of the challenges in the
therapy of patients with advanced HNSCC, the applica-
tion of nanoparticles has been evaluated with regard to
their advantages for chemotherapeutic/medicinal, radia-
tion and imaging strategies. Previous data indicates that
cytotoxic drugs such as mitoxantron, cisplatin or pacli-
taxel as well as the photosensitizer 5,10,15,20-tetrakis
(meso-hydroxyphenyl)porphyrin (mTHPP) encapsulated
in superparamagnetic, liposome, albumin or methoxy
poly(ethylene glycol)-poly(lactide-co-glycolide) (MPEG-
PLGA) nanoparticles or polymeric micelles not only
exhibit potent antitumor activity, but also displayed
reduced side effects [9-13]. Furthermore, it has been
reported that beta-emitting radionuclides attached to
liposomes showed promising results when applied intra-
tumorally and gold nanoparticles or nanoparticles with
antisense oligonucleotides against the gene ataxia-telan-
giectasia-mutated (ATM) improved radiosensitivity in
rodent head and neck cancer models [14-16]. In addi-
tion, superior imaging in head and neck cancers resulted
from the use of superparamagnetic iron oxide nanopar-
ticles, gold nanoparticles or gadolinium-labelled phos-
phorescent polymeric nanomicelles [17-22].
In the past years, silica-based nanoparticles have
gained increasing interest for medical applications
because of their biocompatibility, versatility and stability.
Numerous in-vitro and in-vivo studies pointed towards
their great potential for improving the efficacy of thera-
peutic agents in tumor cells by e.g. circumventing solu-
bility and stability problems of certain drugs or enabling
targeted delivery and controlled release strategies
[23-25]. Moreover, silica nanomaterials have been pro-
posed as promising medical tools for biosensing [26,27]
and imaging purposes [28].
However, to our knowledge, silica nanoparticles have
not yet been investigated in the context of head and
neck cancers. In this work, we assess the biological in-
vitro behaviour of core-shell silica based nanoparticles
on the HNSCC cell line UMB-SCC-745 with regard to
their cytotoxicity, uptake, localization and intracellular
fate.
2. Materials and methods
2.1. Synthesis of nanoparticles
Spherical core-shell silica nanoparticles encapsulating
tris(bipyridine)ruthenium(II) dichloride [Ru(bpy)3]Cl2 as
fluorescent dye were produced as described before [29].
The method is based on an oil-in-water microemulsion
of n-hexanol-TritonX100-cyclohexane, [Ru(bpy)3]Cl2,
tetraethyl-orthosilicate (TEOS) and ammonia. The sur-
face chemistry of mono-shell silica nanoparticles was
modified by the addition of a mixture of TEOS and
other organosilanes, such as 3-aminopropyltriethoxysi-
lane (APTES) to generate aminopropyl and hydroxyl
functionalities (Ru@SiO2-NH2 and Ru@SiO2-OH) at the
nanoparticle surface. Similarly, PEGylated [Ru(bpy)3]Cl2-
labeled dual-shell nanoparticles (Ru@SiO2-PEG) have
been synthesized as previously described, using a mix-
ture of TEOS and bis(silylated)polyethylene glycol
(SPEGS) for growth of a PEGylated second shell [30].
All the three types of nanoparticles have been fully char-
acterized, as precedently described and have an average
size ranging between 200 and 300 nm [30]. The surface
charge and the hydrophilic character of nanoparticles
have been explored based on their electrophoretic mobi-
lity in nanopure water at neutral pH (Zetasizer Nano
ZS, Malvern Instruments Ltd., UK).
2.2. Cell Culture
The head and neck squamous carcinoma cell line UMB-
SCC-745 was kindly provided by Dr. Robert Mandić,
Department of Otolaryngology, Philips University, Mar-
burg, Germany. The UMB-SCC-745 was derived from
the tonsil tumor of a 48-year-old man and has a distinct
p53 single point mutation and loss of heterozygosity [31].
Monolayer
UMB-SCC-745 cells were cultured under standard con-
ditions (37°C, 5% CO2, 95% air atmosphere) in growth
medium, i.e. RPMI Medium (Invitrogen, Basel, Switzer-
land) supplemented with 10% fetal calf serum (FCS,
Sigma-Aldrich, Buchs, Switzerland), 1% HEPES (Invitro-
gen), 1% MEM non essential amino acids (Invitrogen)
and 1% penicillin and streptomycin (Invitrogen). The
growth medium was changed every second day. The
passage of the cells was performed by trypsination (tryp-
sin 1×, Invitrogen) when reaching confluence, in general
every 2-3 days.
Besic Gyenge et al. Journal of Nanobiotechnology 2011, 9:32
http://www.jnanobiotechnology.com/content/9/1/32
Page 2 of 14
Multicellular spheroids (3D cell culture)
For generation of multicellular spheroids, we applied a
modified hanging drop method [32]. Briefly, 96-well
plates were coated with 60 μl of 1.5% agarose (Sigma-
Aldrich) per well, in RPMI medium without FCS. Then
20 μl drops of UMB-SCC 745 cell solution (5000 cells/
20 μl) were placed on the plate lid, the lid was posi-
tioned back to the plate and then kept overnight in the
incubator (37°C, 5% CO2). The following day, 80 μl
growth medium was added to the wells, the plates were
shortly centrifuged and returned to the incubator. In
order to avoid vibration, which has an influence on the
formation of spheroids, the incubator should not be
opened for the first 48 hours. After this initial time
spheroids were stable in their form and reached the
desired diameter of 150 μm two days later.
2.3. Proliferation assay
The cytotoxicity of nanoparticles was evaluated using a
commercial cell proliferation assay (Cell Proliferation
ELISA, BrdU, chemiluminescent, Roche, Basel, Switzer-
land). For this experiment the cells were cultured in
black Greiner-96-well plates (2000 cells/well, Cellstar,
Frickenhausen, Germany) with 100 μl growth medium
at 37°C, 5% CO2 for 24 h. Subsequently the growth
medium was replaced with fresh one containing
Ru@SiO2-OH, Ru@SiO2-NH2 or Ru@SiO2-PEG nano-
particles at final concentrations ranging between 0.03
mg/ml - 0.5 mg/ml. Nanoparticles were ultrasonicated
for 2 h before incubation to ensure their homogeneity.
After nanoparticle incubation for 5 h, the cells were
washed with phosphate buffered saline (PBS, Oxoid,
Hampshire, United Kingdom) and incubated overnight
with fresh growth medium containing BrdU-labeling
agent. BrdU, which is incorporated only in viable cells
during DNA synthesis, was detected with an ELISA
immunoassay according to the recommendation of the
manufacturer. The resulting signal was quantified by
measuring the photons using a micro-plate luminometer
with photomultiplier technology (BioTek, Luzern, Swit-
zerland). The relative light units/second (rlu/s) directly
correlates to the amount of DNA synthesis and hereby
to the number of proliferating cells in the respective
microcultures.
2.4. Exposure protocols of nanoparticles
For all experiments, nanoparticles were ultrasonicated
for 2 h directly prior to use in cell culture.
For the uptake study the cells were seeded either on
six-well plates (1’000’000 cells/well) for transmission
electron microscopy (TEM) or on poly-L-lysine (PLL,
0.25 mg/ml, Sigma-Aldrich) -coated glass cover slips
(50’000 cells, Hecht-Assistant, Sondheim, Germany) for
confocal laser scanning microscopy (CLSM). The cells
were then incubated with either Ru@SiO2-OH,
Ru@SiO2-NH2 or Ru@SiO2-PEG nanoparticles (final
concentrations 0.125 mg/ml) for different time periods
(30 min, 1 h, 2 h, 5 h, 7 h, 12 h and 24 h) under cell
culture conditions. After each time point cell aliquots
were used for microscopic monitoring by CLSM and
TEM.
Alternatively, multicellular spheroids were grown for 4
days in 96-well plates and also exposed to Ru@SiO2-OH
and Ru@SiO2-NH2 nanoparticles for 5 h and 24 h,
respectively, at final concentrations of 0.125 mg/ml
under cell culture conditions. The nanoparticle distribu-
tion in spheroids was monitored only by CLSM.
For long-time experiments, cells were grown in six-
well culture plates and incubated under cell culture con-
ditions with Ru@SiO2-OH and Ru@SiO2-NH2 nanopar-
ticles for 5 h (final concentrations 0.125 mg/ml).
Following an extensive washing step with PBS, cells
were directly passaged, re-seeded (500’000 cells/well) in
cell culture plates and kept in culture until confluence
(three days). The growth medium was exchanged every
day. Passaging of the cells was continued until fifth pas-
sage. After each passage aliquots of the cells were used
for evaluation by both CLSM and TEM.
For control experiments, cells or spheroids were cul-
tured as above, but nanoparticle-containing medium
was replaced by growth medium.
Protocols for CLSM (TCS-SP2 and TCS-SP5, Leica,
Heerbrugg, Switzerland): After exposure to nanoparti-
cles and washing steps, cells on cover slips were fixed
for 15 min with PBS containing 1% paraformaldehyde
(PFA, Sigma-Aldrich) and 0.33% saccharose (Sigma-
Aldrich). Visualisation of nuclei were performed by
incubation with 4’-6-diamidion-2-phenylindole (DAPI, 1
μg/ml, Roche) and mounted with GlycerGel mounting
medium (Dako, Baar, Switzerland).
In experiments concerning multicellular spheroids,
nuclei were stained with Hoechst staining dye (1 μg/ml,
Sigma-Aldrich), which was added for the last hour of
incubation. After incubation, the spheroids were col-
lected, washed with PBS, fixed with PBS containing 1%
PFA for 30 minutes, washed again with PBS and then
monitored by confocal microscopy.
[Ru(byp)3]
2+ complexes were excited with a 458 nm
laser and detected in the range of 570 - 650 nm. Visuali-
sation of nuclei (DAPI and Hoechst staining) was
achieved with an excitation wavelength of 350 nm and a
detection wavelength range of 450 - 500 nm.
Protocols for TEM (CM100, TEM, Philips, Guildford,
UK): After nanoparticle incubation and washing steps
cells were fixed with 2.5% glutaraldehyde (GA, Electron
Microscopy Sciences, Hatfield, USA) and 0.8% PFA in
0.05 M dimethylarsenic acid sodium salt trihydrate (Na-
Caco, Merck, Darmstadt, Germany) buffer at 1:9 ratio
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for 30 minutes. The samples were washed once with
0.05 M Na-Caco buffer and then fixed for 1 h with 2%
osmium-tetra-oxide and 3% potassium hexacyano-ferrate
(II) trihydrate (Sigma-Aldrich) at 1:1 ratio. After wash-
ing and centrifugation, cell pellets were transferred to
2.5% bacto agar (Agar Scinetific, Wetzlar, Germany),
dehydrated in 70-100% ethanol and embedded in
embedding medium (Glycidether 100 (Promega); dode-
cenylsuccinic-anhydride (Sigma-Aldrich); nadic methyl
anhydride (Sigma-Aldrich) and N, N-dimethylbenzyla-
min purum (Sigma-Aldrich) as activator) for 24 h at 80°
C. Sections (70 nm) were contrasted with uranyl acetate
dihydrate (Sigma-Aldrich) and lead (II) citrate (Sigma-
Aldrich) for 20 minutes each.
2.5. Immunocytochemistry
UMB-SCC-745 cells cultured on PLL coated cover slides
were incubated for 5 hours with Ru@SiO2-PEG,
Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles at final
concentrations of 0.125 mg/ml. After incubation cells
were fixed for 15 min with 1% PFA in PBS, permeabi-
lized with 0.01% Triton-X 100 (Roche) for 1.5 min,
blocked for 30 min at room temperature with 0.1%
bovine serum albumine (BSA, Calbiochem, San Diego,
USA) and washed with PBS. For labelling of early endo-
somes, rabbit anti-EEA1 antibody (1:300, stock concen-
tration 1.3 mg/ml, Sigma-Aldrich) was used. Rabbit
anti-Rab7 antibody (1:300, stock concentration 1.2 mg/
ml, Sigma-Aldrich) was used to visualize late endosomes
and for labelling of Golgi apparatus mouse anti-GM130
antibody (1:500, stock concentration 0.7 mg/ml, Abcam,
Cambridge, UK) was used. Cells were incubated with
primary antibodies for 2 h at room temperature or over-
night at 4°C, washed and incubated with FITC-labelled
donkey anti-rabbit or anti-mouse antibodies, respectively
(both 1:500, Sigma-Aldrich), together with DAPI (1 μg/
ml) for 1 h at room temperature. Lysosomes and mito-
chondria were visualized with Lysotracker Red and
Mitotracker Orange respectively (working concentration
for both 300 nM, Invitrogen). For examination by
CLSM (Leica), [Ru(byp)3]
2+ complexes and nuclei have
been detected as described above, while for FITC excita-
tion and detection wavelengths of 488 nm and 490-540
nm, respectively, have been used.
3. Results
Electrophoretic mobility of Ru@SiO2-OH particles
revealed a ζ-potential of -40 mV, which is in good
agree, ζ-potentials of +11.3 mV and +4.29 mV have
been obtained, respectively. As a prerequisite for our
studies we first determined optimal concentrations of
the different surface-modified nanoparticles in our in-
vitro model (Figure 1). BrdU proliferation assays indi-
cated for all types of nanoparticles that concentrations
ranging between 0.03 - 0.125 mg/ml had no statistic-
ment with the values measured for bare (non doped)
SiO2 nanoparticles, whereas in the case of amino- and
PEG-modified particlesally significant effect on cell pro-
liferation compared to untreated controls. Ru@SiO2-
PEG had no impact on cell growth even at higher con-
centrations (0.25 - 0.5 mg/ml). However, 0.25 and 0.5
mg/ml of Ru@SiO2-NH2 nanoparticles negatively
affected proliferation rates, leading to an average of 21%
and 31% reduced incorporation of BrdU, respectively.
Ru@SiO2-OH nanoparticles diminished cell proliferation
up to 41% at highest nanoparticle concentrations (0.5
mg/ml), while a reduction below 10% was observed at
0.25 mg/ml. Based on these results we decided to use
concentrations of 0.125 mg/ml for all three Ru@SiO2
nanoparticles for further experiments.
To obtain information about the cellular uptake of
Ru@SiO2-PEG, Ru@SiO2-OH and Ru@SiO2-NH2 we
conducted electron microscopic studies in UMB-SCC
745 cells. Generally, nanoparticle incubation did not
result in an obvious ultrastructural damage compared to
untreated controls. Both Ru@SiO2-OH and Ru@SiO2-
NH2 were detected intracellularly already 30 min after
nanoparticle incubation. In case of single nanoparticles,
internalization involved invaginations of the plasma
membrane that are lined by electron dense material at
the cytoplasmic side. Furthermore, clusters of nanoparti-
cles were internalized by membrane ruffling (Figure 2).
In all cases, nanoparticles were found in membrane-
bounded vesicles within the cytoplasm. Intracellular
amounts of Ru@SiO2-OH and Ru@SiO2-NH2 nanoparti-
cles steadily increased between 30 min and 5 h post
incubation (Figure 3 and 4). However after 24 h, large
vesicles with many nanoparticles were found in favour
of vesicles with single nanoparticles (Figure 5). Despite
multiple washing steps during sample preparation for
TEM, considerable amounts of nanoparticles were
attached to the cell surface at all time points
investigated.
In contrast to the other studied nanoparticles, the
uptake of Ru@SiO2-PEG into UMB-SCC 745 cells was
minimal (Figure 6). Very few Ru@SiO2-PEG nanoparti-
cles were observed after 5 h of incubation and then only
in a minority of cells. Neither an increase in uptake over
time nor an affinity to the outer cell membrane as with
the other nanoparticles could be observed. These data
lead us to exclude Ru@SiO2-PEG from further
experiments.
The uptake of Ru@SiO2-OH and Ru@SiO2-NH2
nanoparticles had been additionally investigated in a 3D
cell culture system (Figure 7). Confocal microscopy
revealed that an intense [Ru(bpy)3]Cl2 fluorescence was
visible after 5 h in the cytoplasm of cells constituting
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the outer layer of spheroids while inner cells were
devoid of such signals.
With the aim to better characterize the intracellular
fate of nanoparticles, immunohistochemical studies with
antibodies against markers of endocytotic pathways were
performed. CLSM analyses showed that at all time
points investigated immunoreactions for Rab7, GP 120,
Mitotracker and Lysotracker were present, but never co-
localized with Ru@SiO2-OH or Ru@SiO2-NH2 nanopar-
ticles. In contrast, a subfraction of EEA1 immunosignals
coexisted with Ru@SiO2-OH and Ru@SiO2-NH2 fluor-
escence after 2 h of incubation, reaching a maximum at
5 h (Figure 8). This observation was slightly more pro-
nounced in Ru@SiO2-OH. However, the majority of [Ru
(bpy)3]Cl2 fluorescent nanoparticles was not located
together with EEA1 immunoreactivity. Co-localization
with EEA1 after 24 h of incubation was negligibly low
for both nanoparticle types, even if it was slightly higher
for Ru@SiO2-OH.
In addition, we investigated the presence of
Ru@SiO2-OH or Ru@SiO2-NH2 nanoparticles over a
time span of 15 days (i.e. over five cell passages) in
UMB-SCC 745 cells (Figure 9). During the whole
experiment no signs of degradation of Ru@SiO2 nano-
particles could be observed. During the first two days
after Ru@SiO2-OH or Ru@SiO2-NH2 incubation all
cells contained large numbers of nanoparticles. How-
ever, at day four, Ru@SiO2-OH nanoparticles were
detected only in about 50% of cells, while Ru@SiO2-
NH2 nanoparticles were still present in more than 70%
of the cell population. Nine days after incubation,
Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles were
visible in less then 30% and about 50% of all cells,
respectively. Generally, we found that during mitosis
nanoparticles were either only propagated to one
daughter cell or distributed between both daughter
cells (Figure 10). At day 12 all cells exhibited a cyto-
plasm free of Ru@SiO2-OH. In contrast, Ru@SiO2-
NH2 nanoparticles were found up to day 15, however,
the detectable amounts were low.
4. Discussion
The large data corpus of recent years provides evidence
that silica nanomaterials may have the potential to
strongly improve cancer treatment and diagnosis. Silica
nanomaterials feature the versatility necessary for
tumor-specific modifications, stability in the often harsh
environments of the body, ease of production and -
more importantly - they are generally regarded as bio-
compatible. However, the latter clearly depends on
many parameters such as particle size, surface modifica-
tion, dose, exposure time or cell type used as model
[33]. With the aim to explore the suitability of silica
nanoparticles for new concepts in the treatment of head
and neck cancers we investigated as a first step the bio-
logical in-vitro behaviour of non-targeted 200-300 nm
core-shell silica nanoparticles with three different sur-
face modifications.
Figure 1 Proliferation effects of different surface modified nanoparticles on UMB-SCC 745. BrdU proliferation assays in UMB-SCC 745 cells
after incubation (5 h) of nanoparticles with different surface modifications (Ru@SiO2-OH, Ru@SiO2-NH2 and Ru@SiO2-PEG) at concentration
ranges of 0-0.5 mg/ml.
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While both Ru@SiO2-OH and Ru@SiO2-NH2 nano-
particles displayed high uptake rates in our model, inter-
nalization of PEGylated silica nanoparticles was almost
completely lacking under the same experimental condi-
tions. Although we observed this effect in the related
HNSCC line UMB-SCC 969 and in the human prostate
carcinoma cell line PC-3 as well (unpublished data),
other studies showed, in contrast to our results, that
PEGylated silica nanoshells are at least able to attach to
the outside of MCF-7 cells [34]. However, PEG is
known for its cell-repelling properties [35-37], but
uptake efficiency may be increased by the addition of
targeting ligands [38]. Since grafting of nanoparticles
with PEG has been reported to be advantageous for in-
vivo applications - basically due to its increased half-live
in circulation - and helpful for targeting, the generation
of optimized Ru@SiO2-PEG may be worthwhile (work
in preparation).
Although the plasma membrane is negatively charged,
the different surface charges of (negatively charged)
Ru@SiO2-OH and (positively charged) Ru@SiO2-NH2
nanoparticles had no considerable influence on cellular
uptake kinetics in our model. This is in contrast to
reports indicating that negatively charged nanomaterials
are less effectively internalized [39]. However, a large
number of studies show that both cationic and anionic
nanoparticles are capable of effectively passing the cell
membrane [39].
Our data indicates that at nanoparticle concentrations
of 0.125 mg/ml and below, no perturbances in cell cycle
progression have been detected under our experimental
conditions. An increase of cancer cell proliferation could
be dangerous and hold dire consequences in clinical set-
tings. This phenomenon has been reported in-vitro for
melanoma cells and mesoporous silica nanoparticles
[40], but has never been observed in our experiments.
Figure 2 Nanoparticle internalisation. Transmission electron microscopy pictures of nanoparticle internalisation in UMB-SCC 745 exemplarily
shown for Ru@SiO2-NH2. Uptake occurred either as single nanoparticle (A, B, scale bars = 100 nm), or nanoparticle clusters (C, D, scale bars =
500 nm).
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However, higher concentrations of Ru@SiO2-OH and
Ru@SiO2-NH2 lead to reduced proliferation rates. While
a slowdown in growth of tumor cells may be generally
regarded as a positive effect in cancer treatment it
should be emphasized that the underlying pathomechan-
isms in HNSCC are not clear yet. Previous in-vitro stu-
dies in other cancer cell lines have shown that
cytotoxicity of silica nanoparticles, in relation to size
and incubation time, may be due to oxidative stress
with lipid peroxidation and membrane damage and/or
an inflammatory response [41,42]. A detailed analysis of
the complex molecular pathways involved is therefore
needed in order to estimate possible (wanted or
unwanted) consequences for future therapeutic strate-
gies. Because of the different experimental design (e.g.
longer incubation times, different particle sizes, other
cell lines) it is impossible to directly compare our cyto-
toxicity data with previous studies. However, head and
neck cancer cells seem to display cell toxic effects at
concentrations comparable to other cancer cells, e.g.
cervical adenocarcinoma cells [43], osteosarcoma cells
[42], lung adenocarcinoma cells [37,41], and gastric and
colon cancer cells [44]. Despite this, nanoparticle con-
centrations have to be carefully adjusted: using the same
nanoparticles and experimental conditions as here, PC-3
human prostate cancer cells displayed a proliferation
stagnation of about 15 days after nanoparticle incuba-
tion, although metabolic rates have been found to be
higher (Besic Gyenge et al., unpublished).
With regard to internalization processes of nanoparti-
cles into cells, phagocytosis, pinocytosis and caveolin- or
clathrin-driven endocytosis have all been proposed and
seem to strongly depend on particle form, size and cell
type used. With our experimental set-up, apparently two
different routes of nanoparticle uptake occur in parallel:
on the one hand, single particles enter HNSCC cells via
Figure 3 Time dependent uptake of Ru@SiO2-OH nanoparticles. Ru@SiO2-OH nanoparticle uptake over 2 h (A and B) and 24 h (C and D) in
UMB- SCC 745. A, C: confocal laser scanning microscopy, showing nuclei in blue and Ru@SiO2-OH nanoparticles in red, scale bars = 20 μm. B, D:
transmission electron microscopy, scale bars = 10 μm.
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Figure 4 Time dependent uptake of Ru@SiO2-NH2 nanoparticles. Ru@SiO2-NH2 nanoparticles uptake over 2 h (A and B) and 24 h (C and D)
in UMB-SCC 745. A, C: confocal laser scanning microscopy, showing nuclei in blue and Ru@SiO2-NH2 nanoparticles in red, scale bars = 20 μm. B,
D: transmission electron microscopy, scale bars = 10 μm.
Figure 5 Intracellular localisation of Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles after 24 h. Transmission electron microscopy showing
intracellular localisation of nanoparticles in UMB-SCC 745 after 24 h of incubation. A) Ru@SiO2-NH2 nanoparticles and B) Ru@SiO2-OH
nanoparticles. Scale bars = 5 μm.
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membrane invaginations that ultrastructurally resemble
clathrin-coated pits. The involvement of clathrin-coated
pits in internalization mechanisms of silica nanoparticles
had also been proposed in several previous in-vitro stu-
dies using specific inhibitors or confocal methods
[45-48]. On the other hand, the observed bulk internali-
zation of nanoparticles is likely related to non-clathrin
mediated endocytosis. The latter process rather displays
features of macropinocytosis, such as membrane ruf-
fling. Notably, the different surface charges of our nano-
particles did not play an apparent role with regard to
the observed uptake mechanisms. Detailed studies are
now needed to further characterize the events taking
place at the plasma membrane upon contact with our
silica nanoparticles. However, the incidence of such dif-
ferent simultaneous endocytosis modes of silica nano-
particles is in accordance with a recent paper, where
also discrete entry pathways have been observed for
single and agglomerated amorphous silica nanoparticles
[48]. Furthermore, in mouse melanoma cells, internali-
zation of latex particles of 200 nm (that corresponds
approx. to the size of our particles) involved clathrin-
coated pits, while latex particles of 500 nm (that corre-
sponds approx. to our nanoparticle clusters) preferen-
tially entered the cells via a clathrin-independent
caveolin-associated pathway [49].
To characterize the intracellular fate of our silica
nanoparticles within HNSCC, we next investigated their
possible delivery into early and late endosomes and lyso-
somes. The localization of Ru@SiO2-OH and Ru@SiO2-
NH2 in early endosomes indicates their processing to
endocytotic pathways, however, a considerable number
of particles obviously used a different route of traffick-
ing, that did not involve EEA1-positive organelles. As
long as these organelles have not been characterized, a
possible role of nanoparticle’s surface charge for
Figure 6 Time dependent uptake of Ru@SiO2-PEG nanoparticles. Ru@SiO2-PEG nanoparticle uptake after 2 h (A and B) and 24 h (C and D)
in UMB-SCC 745. A, C: confocal laser scanning microscopy, showing nuclei in blue and Ru@SiO2-PEG nanoparticles in red, scale bars = 20 μm. B,
D: transmission electron microscopy, scale bars = 10 μm.
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endocytic processes cannot be defined. However, the
acidic pH of early endosomes may explain the slightly
higher frequency of (negatively charged) Ru@SiO2-OH
in EEA1-containing vesicles.
While we cannot exclude that some Ru@SiO2-OH and
Ru@SiO2-NH2 may have been shuttled back to the
plasma membrane for segregation, the majority of nano-
particles remained intracellularly and accumulated in
rather large vesicles 24 h after incubation. We propose
that the latter is related to homotypic vesicle fusion. No
transfer to Golgi apparatus-related pathways has been
detected. More importantly, we found that nanoparticle-
bearing vesicles did neither mature from early endo-
somes into (Rab7-positive) late endosomes nor locate to
lysosomes. While both the known stability of silica-shell
nanoparticles and possible cancer-related changes in
Figure 7 Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticle uptake in multicellular spheroids. Uptake of nanoparticles in UMB-SCC 745
multicellular spheroids after 5 hours. Confocal laser scanning microscopy pictures, showing Ru@SiO2-OH (A) and Ru@SiO2-NH2 (B) in red and cell
nuclei in blue. Scale bars = 100 μm.
Figure 8 Co-localisation of Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles with early endosomes. Confocal laser scanning microscopy
pictures showing a partial co-localisation after 2 h of incubation of Ru@SiO2-OH (A, in red) or Ru@SiO2-NH2 (B, in red) fluorescence with
immunosignals for early endosomes protein 1 (A, B, in green). Cell nuclei are stained in blue. Arrows denote large early endosomes, which
contain high amounts of nanoparticles. Scale bars = 30 μm.
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endosomal sorting mechanisms may have prevented
their targeting to degradation pathways, our data is in
contrast to other studies showing that silica nanoparti-
cles are in fact transferred to lysosomes [46,47,50]. Our
results also differ from those of Rejman et al. [49] where
a size-dependency of endocytotic pathways had been
proposed. In this study, at least smaller latex particles
(200 nm) passaged to late endosomes/lysosomes while
only large particles (500 nm) did not [49]. We therefore
conclude that intracellular fate of nanoparticles not only
depends on their size (or agglomeration status) but pre-
sumably also on cell line.
Although the exact nature of different endocytotic
organelles in our model has to await further
Figure 9 Intracellular long time retention of nanoparticles. Transmission electron microscopy pictures of UMB-SCC 745 after nanoparticle
incubation over a time period of 15 days. A-C) 2, 9 and 12 days after incubation of Ru@SiO2-OH nanoparticles. D-F) 2, 9 and 12 days after
incubation of Ru@SiO2-NH2 nanoparticles. Scale bars for A-E) = 5 μm and for F) = 0.5 μm.
Figure 10 Nanoparticle distribution during cell division. Confocal laser scanning microscopy showing distribution of RuSiO2-NH2
nanoparticles during cell division (third passage) of UMB-SCC 745. A) metaphase and B) telophase, nucleus in blue and nanoparticles in red.
Scale bars = 10 μm.
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characterization, the strictly vesicle-associated occur-
rence of Ru@SiO2-OH and Ru@SiO2-NH2 in HNSCC
may have contributed to their biocompatibility. In
human melanoma cells it had been reported that an
escape of silica nanoparticles to the cytoplasm resulted
in changes of the cytoskeleton as well as of adhesion
and migration properties [51]. Whether the vesicular
enclosure of our nanoparticles is a useful feature in the
case of intracellular drug delivery strategies in HNSCC
remains to be proven.
In addition to their relatively large diameter [52,53],
the absence of free Ru@SiO2-OH and Ru@SiO2-NH2
within the cytoplasm of HNSCC may have been the
reason that nanoparticles never passed the nuclear
membrane. Even though localizations of silica nano-
particles within the nucleus had been observed before
[54], our data is in accordance with results from pre-
vious studies [53,55,56]. Recently, it had been shown
that labeling with fluorophores may affect uptake
kinetics and intracellular pathways of certain probes
[57]. However, due to encapsulation of the dye in our
study, it is unlikely that [Ru(bpy)3]Cl2 may have influ-
enced routes of nanoparticles within cells. Until now,
very little is known about the intracellular long-term
fate of silica nanoparticles and possible consequences
of their persistence in biological systems. In human
lung epithelial cells, Stayton et. al. observed a slow but
active transfer of silica nanoparticles from the cyto-
plasm to the exterior environment [58]. They showed
that during the first 24 h almost 50% of nanoparticles
exited the cells. In contrast, our data implicates that
both internalized Ru@SiO2-OH and Ru@SiO2-NH2
remain within the cell and are apparently distributed
between daughter cells at cell division. During the
course of several passages, initially high nanoparticle
amounts in individual cells become “diluted”, but ultra-
structurally are still found in vesicles. The reason for
the observed differences in long-time persistence of
Ru@SiO2-OH and Ru@SiO2-NH2 are not clear yet, but
may also be related to as yet uncharacterised charge-
dependent effects of nanoparticles on endolysosomal
pathways. However, in addition of not featuring acute
cell toxic effects, the presence of our silica nanoparti-
cles over 15 days caused no visible changes in viability,
proliferation or morphology in HNSCC. Of note, over
the time course studied, ultrastructure of nanoparticles
appears to remain unchanged. However, it cannot be
excluded that discrete processes of nanoparticle degra-
dation occurred. Recently, it had been reported that,
depending on functionalization, integrity of silica nano-
particles may be impaired step-wise over time in simu-
lated body fluid with regard to e.g. surface area, pore
width or pore volume [59,60].
Although the high uptake efficiency of Ru@SiO2-OH
and Ru@SiO2-NH2 in our in-vitro mono-layer model
was promising, optimized conditions are needed in case
of solid HNSCC tumors where conditions of poorer vas-
cularisation may exist. Our results in HNSCC spheroids,
an established minitumor model, show that penetration
depth of Ru@SiO2-OH and Ru@SiO2-NH2 does not
reach beyond the first (outer) cell layer - independent of
nanoparticle surface charge. This observation provides
further evidence that our nanoparticles are not actively
exocytosed. Stayton et. al. showed in-vitro that nanopar-
ticles which were exocytosed in growth medium were
taken up by other cells if not removed from growth
medium [58]. Given that nanoparticles are not trans-
ported transcellularly and apparently are incapable of
passing the intercellular junction complexes, new deliv-
ery strategies have to be developed for multicellular
poorly vascularized cancers.
5. Conclusion
In summary, our study is the first to provide evidence
that core-shell silica nanoparticles may be useful tools
for the development of novel therapeutic strategies with
cancers of the head and neck region. However, before
an encapsulation of pharmaceutical compounds or a
functionalization with targeting and imaging moieties
may be considered, a better understanding of how these
nanoparticles interact with HNSCC cells on contact and
after internalization is needed. Starting from our first
steps towards clarification of endocytic pathways, further
microscopic, immunocytochemical and molecular biolo-
gical studies will elucidate nanoparticle sorting as well
as their further intracellular fate, including possible
degradation processes, or nanoparticle-mediated mole-
cular cell responses.
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Abstract
Objective: Dental caries is one of the most common diseases in Western countries. Its pathoetiology is
multifactorial, however, bacteria including Streptococcus mutans and the closely related Streptococcus sobrinus are
regarded as key factors involved in this process. The fact that therapeutic approaches to eradicate these
microorganisms are still limited prompted us to investigate the treatment potential of photodynamic therapy with
the photoactive compounds hypericin (HYP) and meso-tetra(hydroxyphenyl)chlorin (mTHPC) in vitro.
Material and methods: S. mutans and S. sobrinus were cultivated under standard conditions and incubated with
HYP (Invitrogen, Basel, Switzerland), the liposomal mTHPC derivative Foslipos (FOS, Biolitec, Jena, Germany), or a
mixture of both at concentrations ranging between 0.625 and 10 mg/ml for various time points. Following a thorough
washing step, bacteria were irradiated with a dental polymerization instrument (400–505 nm). All samples were
subjected to serial dilutions and spiral plating on blood agar plates. Viable colony counts were determined after 48 h in
culture. Photosensitizer ﬂuorescence of bacteria was visualized by confocal microscopic techniques.
Results: One hundred percent of S. sobrinus could be killed by a 15min incubation with as little as 2.5mg/ml HYP, 5mg/
ml FOS or a mixture of 1.25mg/ml of each photosensitizer followed by light activation of 120 s. In contrast to
S. sobrinus, S. mutans displayed a signiﬁcant dark toxicity for FOS (10–1.25mg/ml) and no relevant PDT effects using HYP
(10–0.625mg/ml) under these conditions. HYP-mediated PDT effects (10mg/ml) could be enhanced to more than 99.9% by
prolonging photosensitizer incubation to 30min and fractional illumination (2 120 s). Complete eradication of S. mutans
was achieved by incubation for 15min with a mixture of 0.625mg/ml each of FOS and HYP and illumination for 120 s.
Conclusion: For both S. mutans and S. sobrinus, short PDT protocols with FOS and/or HYP could be established
that completely eradicated these cariogenic bacteria in suspension. Our study, however, indicated that careful
optimization of PDT conditions may be necessary for successful treatment of even closely related bacterial species. In
multispecies microbial populations, the application of photosensitizer combinations for PDT may be useful.
& 2009 Elsevier GmbH. All rights reserved.
Keywords: Photodynamic therapy; Bacteria; mTHPC; Hypericin; Gram-positive
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Introduction
The oral cavity harbors a plenitude of microorgan-
isms that together constitute the normal ﬂora. However,
under pathologic conditions this complex system may be
disturbed, eventually contributing to the etiology of
various inﬂammatory diseases that may even spread
outside the cavitas oralis [1].
The most prevalent of microorganism-related oral
diseases is caries. Among the different pathogens
involved, the contribution of the Gram-positive faculta-
tive anaerobic bacteria Streptococcus mutans and the
related Streptococcus sobrinus are thought to play key
roles for the progression of this condition [2].
It is well-known that appropriate oral hygiene
strongly reduces the risk for caries; however, the current
number of affected patients is considerable, creating
substantial health care costs [3]. In most cases, caries
treatment consists of debridement of the oral plaque (i.e.
the bioﬁlm where the cariogenic species reside within an
extracellular polymer matrix) or excavation, disinfection
and sealing of the infected dentin. The limitations of
these non-speciﬁc and invasive treatment options
recently rekindled interest in a method whose basic
effects on microorganisms have been known for 100
years i.e. photodynamic therapy (PDT) [4]. Brieﬂy, PDT
is a non- or minimally invasive treatment method relying
on the ability of a photoactive non-toxic drug (the so-
called photosensitizer) which upon activation with light
rapidly generates free radicals or singlet oxygen that can
oxidize cellular constituents and eventually lead to cell
death [5].
In the past decades, numerous studies have underlined
the potential of PDT to destroy bacteria, protozoa,
fungi and viruses [6]. Although published data on PDT
for oral pathogens are relatively limited and most of the
studies had been performed in vitro, was proposed that
PDT either alone or in combination with other strategies
may be a useful option to treat pathogens involved in
periodontitis [7], peri-implantitis [8], endodontitis [9]
and caries [10].
Of the broad spectrum of photosensitizers available
today, several had been successfully applied for PDT on
the cariogenic bacteria S. mutans and S. sobrinus. These
included tricyclic dyes [11–20] or tetrapyrroles belonging
to the classes of porphyrines [16,20], chlorins [21] and
phthalocyanines [22,23]. However, to the best of our
knowledge, neither meso-tetra(hydroxyphenyl)chlorin
(mTHPC) nor hypericin (HYP) have been tested for
treatment of S. mutans or S. sobrinus by PDT.
mTHPC is currently regarded as one of the most
potent second-generation photosensitizers. While the
vast majority of reports concern its high efﬁciency to
destroy cancer cells [24], effects on bacteria are
anecdotal and only include successful treatment of
methicillin-resistant Staphylococcus aureus with a lipo-
somal mTHPC formulation [25].
Hypericin is a phenanthroperylene quinine pigment
naturally occurring in plants such as St. John’s Wort
(Hypericum species). It is currently among the most
popular drugs against mild depression in complemen-
tary medicine. In addition to its potent photo-damaging
effects on cancer cells [26], several studies have indicated
that HYP is active against various Gram-positive
bacteria [27–29].
In order to gain further insight into the effects and
potential of new photosensitizers for clinical application
the ﬁrst study was used to investigate the antimicrobial
effects on the cariogenic Gram-positive bacteria,
S. mutans and S. sobrinus, of mTHPC and HYP alone
and in combined, in PDT.
Materials and methods
Bacterial culture
S. mutans (OMZ 918) and S. sobrinus (OMZ 176)
were obtained from the culture collection of the Institute
of Oral Biology, University of Zurich, Switzerland and
routinely grown aerobically over night at 37 1C in ﬂuid
universal medium (FUM) as described by Gmu¨r and
Guggenheim [30] until the late log phase.
Photosensitizers
Foslipos (FOS), a novel liposomal uncharged
mTHPC compound was kindly donated by Biolitec,
Jena, Germany. A stock solution (1.5mg/ml) of FOS
was prepared in water. HYP was purchased from
Invitrogen, Basel, Switzerland and dissolved as a stock
at 1mg/ml in ethanol. All photosensitizer stock solu-
tions were kept at 4 1C in the dark and further diluted in
FUM.
Confocal microscopy
After incubation of bacteria in the dark with FOS or
HYP (5 mg/ml) for 5, 15 or 30min, respectively all
samples were ﬁxed by drying on microscopic slides and
mounted in Glycergels (Dako, Glostrup, Denmark).
Analyses were performed with a confocal laser scanning
microscope (TCS SP2 and SP5, Leica, Wetzlar, Ger-
many).
PDT protocols
Planktonic bacteria were centrifuged and FUM was
replaced by FOS (0.625–10mg/ml), HYP (0.625–10mg/ml)
or a 1:1 mixture (MIX) of both (0.625–10 mg/ml each).
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Bacteria were incubated for 1–30min at 37 1C in the
dark, followed by two thorough washing steps in
physiological NaCl solution. Thereafter samples were
exposed at a 3-cm distance to the culture surface to
visible light from a halogen polymerization device
(Optilux500, KerrHawe, Bioggio, Switzerland) for
120 s. According to the speciﬁcations of the manufac-
turer, this lamp has a wavelength range of 400–505 nm
and an intensity of 1070mW/cm2. The light source had
an illuminance of 40,000 lx at the surface and of
21,400 lx at the bottom of the incubation tube. Addi-
tional experiments were performed as a sequential light
application for two times 120 s, with a 30min vortex step
in between.
Numbers of viable colony forming units (CFU) were
obtained after 48 h from serial dilutions of all samples in
FUM and spiral plating on Columbia Blood Agar Base
(Becton, Dickinson and Co., Le Pont de Claix, France)
supplemented with 5% hemolyzed human blood. Con-
trols included the following: bacteria received (1) no
treatment (neither light nor photosensitizer), (2) only
photosensitizers, but no light (‘‘dark toxicity’’) and (3)
no photosensitizer, but light.
Data analyses and statistics
All experiments were at least performed in triplicate.
Data are presented as means with standard deviations of
the mean. Data were normalized against untreated
controls (set to 100%) and expressed as a percentage
of surviving or killed bacteria of these untreated
controls. The t-tests were regarded as signiﬁcant with
p-values r0.05.
Results
Streptococcus sobrinus
Microscopic analyses showed that incubations with
FOS and HYP lead to a pronounced ﬂuorescent signal
at S. sobrinus already after 5min. The ﬂuorescence
intensity was further increased after 15min but did not
appear to be considerably stronger after 30min incuba-
tion (Fig. 1).
Controls indicated that growth of untreated
S. sobrinus was not impaired by irradiation with the
dental polymerization tool. Furthermore, when com-
pared with untreated controls, no signiﬁcant dark toxic
effects were detected after incubations with FOS or
HYP (0.625–10 mg/ml) without light activation. In
untreated controls, an average of 2.16E+8CFU/ml
was obtained.
When irradiated after incubation with photosensitizers,
a strong PDT effect was elicited, resulting in 100%
bacterial death at concentrations between 10 and 2.5mg/ml
HYP or 10 and 5mg/ml FOS, when incubated for 15min
and light activated for 120 s. A reduced bacterial count of
rE+05 was still observed down to 1.25mg/ml FOS or
HYP, respectively (Fig. 2). Generally, PDT with FOS
resulted in higher counts of the CFU (in the order of 10-
fold) compared with PDT with HYP. This observation
was most apparent at low photosensitizer concentrations
and is illustrated in Fig. 2.
Application of MIX for 15min and illumination for
120 s revealed that S. sobrinus could be 100% eradicated
using concentrations between 5 and 1.25 mg/ml of each
of the photosensitizers, while the lower concentrated
mixture (each photosensitizer 0.625 mg/ml) led only to a
1.53E+02-fold reduction of CFU counts (Fig. 3). In
comparative analyses of treatment effects with single
photosensitizers, we found that the bactericidal activity
of the MIX with 1.25 mg/ml of each FOS and HYP was
the same as with 2.5 mg/ml HYP alone (Fig. 2). Neither
PDT with FOS nor HYP at 1.25 mg/ml led to a complete
destruction of S. sobrinus (99.988% and 99.998%,
respectively).
Streptococcus mutans
In S. mutans, we observed a ﬂuorescence pattern in
confocal microscopy that was comparable to that in
S. sobrinus with a maximum signal being reached after
15min incubation with either photosensitizer (Fig. 4).
Controls consisting of illumination only indicated no light
sensitivity of S. mutans. In this bacterial strain, untreated
controls reached a mean of 4.16E+07CFU/ml.
Studies dealing with possible dark toxic effects revealed
that treatment with FOS between 0.625 and 10mg/ml was
already effective in killing 97.500–99.999% of bacteria
without light activation (Fig. 5). Additional treatment
with light further improved destruction of bacteria at all
FOS concentrations investigated, ranging from 100% at
concentrations between 10 and 1.25mg/ml to 99.997% at
the lowest concentration tested (0.625mg/ml) (Fig. 5).
In contrast to FOS, not even the highest concentra-
tions of HYP displayed toxicity in the dark (mean
bacterial survival rate of 88.923% at 10 mg/ml HYP
compared with controls). However, when bacteria were
irradiated (120 s) after incubations with HYP bacterial
survival rates were still high. Even PDT with 10 mg/ml
HYP only resulted in an E+02 reduction in S. mutans,
while with low concentrations (1.25 or 0.625mg/ml)
65.965% or 90.894%, respectively, of bacteria survived
(Fig. 6). Using the highest concentration of HYP
(10mg/ml) in combination with a prolongation of
photosensitizer incubation time to 30min and
sequential light application of 2 120 s, a 99.988%
destruction of bacteria could be achieved (Fig. 6).
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Generally, the 1:1 MIX of photosensitizers displayed
the same dark toxicity as the respective concentrations
of FOS alone. To obtain information about PDT using
the MIX, we focused only on 0.625 mg/ml of each
photosensitizer, since this concentration showed a
signiﬁcant PDT effect for FOS when compared with
its dark toxicity (p=0.0063). While we found that under
the above conditions PDT with the MIX completely
(100%) eradicated S. mutans, PDT with neither FOS
nor HYP alone at concentrations of 0.625 mg/ml was
able to do so (survival rate: 0.002% and 90.89%,
respectively; Fig. 7). The same 100% effect could be
obtained by PDT with 1.25 mg/ml FOS (Fig. 7).
Discussion
PDT is characterized by features that make this
treatment modality especially attractive to combat
microbial pathogens. These include its efﬁcacy on
antibiotic-resistant strains, its broad target spectrum as
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Fig. 1. Streptococcus sobrinus after incubation with Foslipos (a–c) and hypericin (d–f) in the dark. Confocal microscopy was
performed after incubation times of 5min (a,d), 15min (b,e) and 30min (c,f). Images were acquired with a 63 1.4 numerical
aperture (NA) oil immersion objective lens providing an optical section thickness of 200 nm.
Fig. 2. Photodynamic effects in Streptococcus sobrinus. Photo-
sensitizers (Foslipos and/or hypericin) at the concentrations
indicated had been incubated for 15min and light (400–505nm)
was applied for 120 s.
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well as its very low potential for mutagenicity and
photoresistance [6]. However, of the large spectrum of
photoactive agents available to date, only a limited
number have so far been investigated with regard to
their antimicrobial applicability.
To the best of our knowledge, our study is the ﬁrst to
investigate bactericidal PDT effects of mTHPC (FOS)
or HYP on S. sobrinus and S. mutans. However, PDT
data from previous studies in mutans streptococci are
available for a few other photosensitizers, including
toluidine blue O [11,12,14,17,18,20], methylene blue
[16,19], erythrosine [15,16], hematoporphyrin derivative
[16,20], native and lysine-conjugated chlorin e6 [21],
aluminium disulphonated or cationic Zn(II) phthalo-
cyanine [22,23], and Rose Bengal [13]. Our results as
well as the vast majority of the above published data
underlined the usefulness of PDT to destroy mutans
streptococci, supporting the general observation that
Gram-positive bacteria are susceptible to inactivation by
photodynamic procedures [31]. Since many experimen-
tal parameters such as cell culture conditions, photo-
sensitizer concentrations and their incubation times,
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Fig. 3. Photodynamic effects in Streptococcus sobrinus after
15min incubation with varying concentrations of a 1:1 mixture
of the photosensitizers Foslipos and hypericin and illumina-
tion (400–505 nm) for 120 s.
Fig. 4. Streptococcus mutans after incubation with Foslipos (a–c) and hypericin (d–f) in the dark. Confocal microscopy was
performed after incubation times of 5min (a,d), 15min (b,e) and 30min (c,f). Images were acquired with a 63 1.4 NA oil
immersion objective lens providing an optical section thickness of 200 nm.
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light sources, illumination intensities and times, differ
considerable both between studies and our set-up, a
comparison of experiments is only of limited value.
However, when analyzing data or establishing proto-
cols, it should be kept in mind that with respect to the
extremely fast growth of mutans streptococci, PDT
killing rates of bacteria may be statistically signiﬁcant
but clinically insufﬁcient. Our study shows that short
PDT protocols with FOS and HYP can be established
that have the capacity to completely kill these bacteria in
suspension. Among all previously published studies,
only two also used planktonic cultures (S. mutans)
as models, showing that PDT protocols with either
0.5 mg/ml Rose Bengal or 100 mg/ml toluidine blue O
resulted in a complete bacterial eradication [13,18]. All
PDT reports dealing with single- or multispecies oral
bioﬁlms (with mutans streptococci) were only able to
reduce viable bacterial counts [14–17,19,20,23]. It is
well-known that pathogens organized in bioﬁlms are
more resistant towards antimicrobial modalities com-
pared to planktonic cultures. This may also hold true for
our PDT protocols, since preliminary studies with
mutans streptococci grown in sucrose-supplemented
media also displayed a reduced bactericidal efﬁciency.
For the light source in our study we used a halogen
hand-held unit routinely applied for polymerization of
light-cured dental materials. Successful elimination of
bacteria in our setting indicated that it may be an
interesting alternative to the commonly used lasers;
especially since the polymerization tool is safer, cheaper
and readily available in most dentists’ ofﬁces. While for
cancer PDT light sources with longer wavelengths are
preferred because of deeper penetration needs, the
superﬁcial sites of cariogenic bacteria are easily acces-
sible with our device. Its wavelength range (400–505 nm)
is perfectly suitable for activation of FOS, since the
Soret band of this photosensitizer is at 420 nm [32]. The
spectrum of HYP contains a very broad absorption
band near 460 nm but, notably, main peaks are outside
the wavelength range of our lamp [33]. Our study is not
the ﬁrst using non-laser light for PDT [34] and
previously, another brand of hand-held photopolymer-
izer was successfully applied for activation of Rose
Bengal in S. mutans [13].
Fig. 7. Photodynamic effects in Streptococcus mutans. Photo-
sensitizers (Foslipos and/or hypericin) at the concentrations
indicated had been incubated for 15min and light
(400–505 nm) was applied for 120 s.
Fig. 6. Effects of hypericin incubated for either 15 or 30min in
Streptococcus mutans. Bacterial cultures had been either kept
in the dark (no light), or illuminated for 15min (1 light) and
two times 15min with an intermittant vortex step of 30 s
(2 light).
Fig. 5. Incubation of Streptococcus mutans with varying
concentrations of Foslipos for 15min with consecutive light
activation (120 s) or without light activation.
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Both S. mutans and S. sobrinus are traditionally
grouped in a common taxonomic cluster – the mutans
group – based on shared phenotypic reactions. The
strongly different experimental sensitivity of the two
Streptococcus species observed in our study was there-
fore rather unexpected and question the close relation-
ship. Our data support earlier molecular phylogenetic
analyses of glucan-producing enzymes and superoxide
dismutases indicating that the two bacteria are in fact
genetically separate [35–37]. From in-vitro cancer studies
– including our own (unpublished data) – the different
behavior of photosensitizers in related types of tumor
cells is actually well-known, underlining the complexity
of biomechanisms initiated by PDT.
Basically, the observed differences in sensitivity
concerned two parameters: (1) high levels of dark
toxicity of FOS in S. mutans vs. S. sobrinus and (2)
ineffectiveness of HYP-mediated PDT in S. mutans – at
least under the conditions effective in S. sobrinus.
Currently, no comparable data of our mTHPC
formulation are available for other microorganisms. In
ongoing studies we are thus investigating whether
S. mutans has an extremely high tolerance or S. sobrinus
is extraordinarily sensitive towards this compound.
However, we propose that the observed dark toxic
effects of FOS should not impose any clinical treatment
consequences. In contrast, inefﬁciency of HYP-mediated
PDT in S. mutans under the same experimental
conditions as in S. sobrinus would necessitate the
development of protocol modiﬁcations. Since our
microscopic analyses indicated that the ﬂuorescence
signal of HYP was no different morphologically from
that of S. sobrinus we conclude that lack of adherence
and/or uptake was not the underlying problem. Details
of these processes, however, have not been investigated
here. Notably, the light source used in our setting had a
sub-optimal wavelength range for activation of HYP.
The improvement of PDT effects by a fractionated
illumination may indicate that the failure with our
standard protocols is – at least in part – related to this
factor. Our data are in line with earlier studies showing
that HYP-mediated PDT effects can be enhanced by
sequential light application [38]. Another critical factor
may be the known complexity of HYP biological effects
[39]. These appear to involve an array of light-dependent
and -independent mechanisms whose roles may vary
under different circumstances. It had been reported, for
example, that HYP activity may be strongly and
speciﬁcally protein-dependent, resulting in either pro-
motion or inhibition of PDT effects in the presence of
certain highly related isoforms of glutathione S-trans-
ferases [40]. The HYP used in our study was a plant
extract of 99% purity (according to the manufacturer’s
speciﬁcation) and the remaining 1% unspeciﬁed herbal
components may have further contributed to the
observed differences of bioeffects. In none of our
experiments, however, did we observe increased growth
rates after treatment with HYP as reported for S. aureus
[41].
In our study, we also investigated the consequences of a
combined application of FOS and HYP for PDT. While
this is the ﬁrst report on mutans streptococci, combined
photosensitizer approaches have been investigated before
in a limited number of studies. In S. aureus, the
combination of HYP and mTHPC was reported to be
counterproductive since bacterial growth was stimulated
and PDT effects inhibited [41], while in contrast the
combination of mTHPC and a hematoporphyrin deriva-
tive resulted in a superior (additive) PDT effect in this
species [42]. In human endometrial cancer cells, in a breast
cancer patient as well in a mouse mammary cancer model
photosensitizer combinations (5-aminolevulinic) acid/HYP
and Photofrin II/meso-tetra-(4-sulfonatophenyl)-porphine,
respectively) led to an enhanced phototoxicity [43,44]. To
explore possible advantages of an FOS/HYP combination
in our model system, we focused on concentrations for
photosensitizers that – when given alone – were unable to
completely kill S. mutans or S. sobrinus. With both
bacteria investigated here, PDT after a short incubation
with the MIX completely sterilized planktonic cultures,
indicating the high efﬁciency of this treatment procedure.
It is of note that PDT with 1.25mg/ml FOS in S. mutans or
with 2.5mg/ml HYP in S. sobrinus had the same 100%
killing effect as the respective optimal MIX. Therefore, the
effects of low-dose single photosensitizers were enhanced
in the MIX, but no clear advantage towards the
application of the total dose by a single photoactive
compound was evident in our set-up. However, in many
clinical settings, multispecies microbial communities have
to be treated. Given a non-uniform response of these
pathogens towards certain photosensitizing agents (as in
our models of cariogenic bacteria), the application of
mixtures may have distinct advantages by targeting a
whole array of microorganisms in one treatment session.
Conclusions
Our study gives further support to the fact that PDT
with second-generation photosensitizers may be an
effective treatment modality to eradicate cariogenic
pathogens. Short protocols within less than 20min
treatment time may be feasible. However, the differ-
ential results on closely related bacterial species indicate
how little we actually understand about the factors that
govern PDT-generated cell death in bacteria. For the
achievement of clinically relevant effects, great care
must be taken to adjust PDT parameters depending on
speciﬁc microorganisms to be targeted. Future investi-
gations of molecular and cellular events elicited by
photosensitizer incubation and PDT may reveal whether
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reduced doses of photosensitizers applied in a combi-
nated treatment will result in favorable clinical effects,
e.g. with regards to immune responses in vivo. However,
the strength of mixtures of photosensitizers for anti-
microbial PDT may be in their potential to target
complex microbial populations such as in supragingival
plaque.
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Zusammenfassung
Hypericin- und mTHPC-vermittelte photodynamische
Therapie zur Behandlung kariogener Bakterien
Zielsetzung: Karies geho¨rt zu den ha¨uﬁgsten Erkran-
kungen in den westlichen La¨ndern. Wenngleich vermut-
lich multiple Faktoren eine ursa¨chliche Rolle spielen, so
wird doch den verwandten Bakterien Streptococcus
mutans und Streptococcus sobrinus eine Schlu¨sselrolle
fu¨r die Pathoa¨tiologie von Karies zugesprochen. Da
geeignete antibakterielle Behandlungsmo¨glichkeiten zur
Zeit fehlen, haben wir in der vorliegenden Arbeit das
Potential einer photodynamischen Therapie (PDT) mit
den photoaktiven Substanzen Hypericin (HYP) und
meso-Tetra(hydroxyphenyl)chlorin (mTHPC) in vitro
untersucht.
Material und Methoden: S. mutans und S. sobrinus
wurden routinema¨ssig kultiviert und mit HYP (Invitro-
gen, Basel, Schweiz), dem liposomalen mTHPC-Deri-
vativ Foslipos (FOS, Biolitec, Jena, Deutschland) oder
einer Mischung aus beiden mit Konzentrationen von
0.625–10 mg/ml unterschiedlich lang inkubiert. Nach
sorgfa¨ltigen Wasch-Schritten wurden die Bakterien
mit einer zahna¨rztlichen Polymerisationslampe bei
400–505 nm bestrahlt. Die Proben wurden dann seriell
verdu¨nnt und auf Blut-Agar-Platten ausspiralisiert.
U¨berlebende Kolonien wurden nach 48 h ausgeza¨hlt.
Ausserdem wurde die Fluoreszenz der Photosensibilisa-
toren an den Bakterien mit einem Konfokalmikroskop
untersucht.
Ergebnisse: S. sobrinus konnte zu 100% abgeto¨tet werden
durch eine 15-minu¨tige Inkubation mit 2,5mg/ml HYP,
5mg/ml FOS oder einer Mischung von 1.25mg/ml beider
Photosensibilisatoren und anschliebender Lichtaktivierung
fu¨r 120 s. Im Gegensatz zu S. sobrinus zeigte S. mutans
unter diesen Bedingungen eine signiﬁkante Dunkeltoxizita¨t
fu¨r FOS (10–1.25mg/ml) und keine relevanten PDT-
Effekte fu¨r HYP (10–0.625mg/ml). HYP-bedingte PDT-
Effekte (10mg/ml) konnten aber durch Verla¨ngerung der
Inkubationszeit auf 30min und eine fraktionierte Bestrah-
lung (2 120 s) auf mehr als 99.9% erho¨ht werden. Eine
vollsta¨ndige Eliminierung von S. mutans konnte durch eine
15-minu¨tige Behandlung mit einer Mischung von je
0.625mg/ml FOS und HYP und einer Belichtung von
120 s erzielt werden.
Schlussfolgerungen: Sowohl fu¨r S. mutans wie auch fu¨r
S. sobrinus konnten kurze PDT-Protokolle mit FOS
und/oder HYP entwickelt werden, welche zur vollsta¨n-
digen Abto¨tung dieser beiden kariogenen Keime in
Suspension fu¨hrten. Unsere Studie zeigte aber auch, dass
die Behandlung verwandter Keime eine sorgfa¨ltige
Optimierung der PDT-Bedingungen notwendig machen
kann. Die Verwendung von Photosensibilisator-Kombi-
nationen ko¨nnte fu¨r die Therapie von mikrobiellen
Multispezies-Populationen hilfreich sein.
Schlu¨sselwo¨rter: Photodynamische Therapie; Bakterien; mTHPC;
Hypericin; Gram-positiv
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7.3 Combining Chitosan and Photodynamic Effects for the Treatment of 
Oral Microorganisms 
 
The following manuscript is submitted in January 2012 in Journal of Translational Medicine. 
 
The contributions of Emina Besic Gyenge to the study: „Combining Chitosan and 
Photodynamic Effects for the Treatment of Oral Microorganisms” were the following:  
 
1. Student supervision and introduction into the filed of research  
 
2. Collection of microscopic imaging data, in particular: figure 3 (Accumulation of hypericin 
and chitosan-TGA in Candida albicans), figure 5 (Accumulation of hypericin and chitosan-
TGA in Aggregibacter aphrophilus), figure 6 (Accumulation of Foslipos® and chitosan-TGA 
in Aggregibacter aphrophilus), figure 8 (Accumulation of hypericin and chitosan-TGA in 
Capnocytophaga ochracea), figure 9 (Accumulation of Foslipos® and chitosan-TGA in 
Capnocytophaga ochracea), figure 11 (Accumulation of hypericin and chitosan-TGA in 
Streptococcus sobrinus) and figure 12 (Accumulation of Foslipos® and chitosan-TGA in 
Streptococcus sobrinus) 
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Abstract 19 
Photodynamic therapy (PDT) had been proposed as a promising treatment option for oral biofilm-20 
mediated diseases. However, susceptibility of oral microorganisms towards PDT varies among and 21 
within species and depends on the photosensitizer used. We thus investigated whether PDT (using 22 
the meso-tetrahydroxyphenyl-chlorine, mTHPC, derivative Foslipos [FOS] or hypericin [HYP]) in 23 
combination with chitosan-thioglycolic acid (chitosan-TGA) can improve antimicrobial effects on 24 
Candida albicans, Aggregatibacter aphrophilus, Capnocytophaga ochracea and Streptococcus 25 
sobrinus. Using confocal microscopy, chitosan-TGA was found to aggregate bacteria and adhere 26 
extracellularly, while both photosensitizers accumulated within cells. The combination of HYP with 27 
chitosan-TGA did not change these cellular localization patterns. In contrast, FOS distribution was 28 
affected upon addition of chitosan-TGA in bacteria, resulting in a colocalization with chitosan-TGA. 29 
Colony forming assays revealed that chitosan-TGA improved FOS-mediated photodynamic effects in 30 
all species. Chitosan-TGA enhanced photodynamic effects of HYP only in C. albicans and A. 31 
aphrophilus, while in S. sobrinus and C. ochracea this combination impaired the outcome to varying 32 
degrees compared to HYP-PDT alone. Our results indicate that the addition of chitosan-TGA to PDT 33 
protocols may be beneficial for the treatment of multispecies odontogenic infections, but some 34 
photosensitizers (such as mTHPC) may be better suitable for such an approach. 35 
 36 
 37 
 38 
 39 
 40 
 41 
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Introduction 42 
The oral cavity harbors a large population of different microorganisms that form a complex 43 
community under healthy conditions (1). Most of these microorganisms are resident bacteria, that 44 
within multispecies biofilms, colonize the oral surfaces (2, 3). In addition, fungi, protozoa and viruses 45 
have all been isolated (4).  46 
If intact, this endogenous flora constitutes an important part of human health since it helps to 47 
maintain local and systemic immunity, contributes to digestion and prevents growth of harmful 48 
exogenous pathogens. However, the normal microbial environment in the mouth is fragile and its 49 
specific balance may be affected by e.g. poor oral hygiene, diseases or drugs. With these 50 
predisposing conditions, certain oral microorganisms may become pathogenic and/or growth of 51 
some species may be promoted, thereby changing the number and proportion of members of the 52 
healthy flora. Oral and dental infections arising from the endogenous flora of the oral cavity 53 
therefore play an important role in daily clinical practice and the most prevalent odontogenic 54 
diseases, i.e. dental caries and periodontal diseases, are thought to originate from opportunistic 55 
bacteria of dental or oral soft tissue biofilms.  56 
Current treatment of periodontal diseases mostly include one or more of the following: mechanical 57 
debridement of the microbiota with or without surgical intervention, disinfection and/or antibiotics 58 
in certain cases (1). Notably, insufficient treatment of oral infections may not only lead to persistent 59 
local problems, but also bears the risk of systemic spread of bacteria or their products. Although the 60 
causative relations have not been fully understood, it had been proposed that oral infections may 61 
contribute to e.g. endocarditis, diabetes mellitus, stroke, preterm delivery and respiratory disease 62 
(5, 6). However, treatment of odontogenic infections is still challenging due to the sheer number of 63 
the opportunistic pathogens, their high multiplication rates, the complex topography of the oral 64 
cavity, the protective character of biofilms against drugs and the rising bacterial resistance to 65 
antibiotics (1). The search for new treatment modalities is therefore ongoing.  66 
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Numerous studies indicate that photodynamic therapy (PDT) may have significant clinical potential 67 
for local treatment of oral infections. As with other PDT applications, antimicrobial PDT relies on the 68 
activation with light of a photosensitizer and the generation of singlet oxygen and other reactive 69 
oxygen species (ROS) that attack vital components of microorganisms (7). It had been shown in-vitro 70 
and in-vivo that PDT is successful in killing bacteria as well as fungi involved in periodontitis, 71 
endodontitis, periimplantitis, caries and oral mucosal infections (8). The effectiveness of 72 
photodynamic interventions on antibiotic-resistant strains had also been demonstrated for oral 73 
species (9) and beneficial immunomodulatory effects in the context of oral antimicrobial PDT had 74 
been reported (10, 11).   75 
Despite these promising results, it had been observed that certain oral microorganisms - even in 76 
planktonic culture - are insufficiently sensitive or refractory to photodynamic killing. This especially 77 
applies to various gram-negative species and strains or yeasts, that are equipped with cell wall 78 
structures that prevent the binding and/or uptake of some photosensitizers (7, 12).  79 
Among the substances that have recently been proposed to improve the antimicrobial effects of PDT 80 
is chitosan, a natural hydrophilic polysaccharide, produced by partial deacetylation of chitin (13). An 81 
important feature of chitosan and its chemical derivatives is its broad-spectrum antimicrobial 82 
activity. In the context of oral infections, chitosans have been reported to effectively inhibit growth, 83 
viability and/or adhesion of gram-positive, gram-negative bacteria and of fungi (14-24).   84 
With the aim to further improve the efficacy of PDT against oral microorganisms we here explore for 85 
the first time the combination of meso-tetrahydroxyphenyl-chlorine (mTHPC) - or hypericin-86 
mediated PDT with chitosan-thioglycolic acid (chitosan-TGA), a chitosan conjugate with strong 87 
bioadhesive and permeation-enhancing properties (25). 88 
 89 
 90 
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Materials and Methods 91 
Microbial cultures 92 
All microorganisms were obtained from the cell culture collection of the Institute of Oral Biology, 93 
University of Zurich, Switzerland. Streptococcus sobrinus (OMZ 176) and Candida albicans (OMZ 110) 94 
were cultured in fluid universal medium (FUM, (26)) in 10% CO2 at 37°C. Capnocytophaga ochracea 95 
(OMZ 362) and Aggregatibacter aphrophilus (OMZ 359) were cultured anaerobically at 37°C in FUM 96 
or in FUM supplemented with 5% horse serum in case of the Capnocytophaga strain. All 97 
microorganisms were grown until late log phase of growth.   98 
 99 
Preparation of chitosan-TGA 100 
Chitosan (low molecular weight, LMW, 50-190 kDa, >85% deacetylated), thioglycolic acid (TGA, 99+ 101 
%) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (98+ %) were obtained from 102 
Sigma-Aldrich, Buchs, Switzerland and used as received. 103 
Chitosan-TGA was prepared as described previously (27). In short, chitosan (500 mg) was dissolved in 104 
diluted HCl (0.09 M, 50 ml) to obtain a 1 % solution of chitosan hydrochloride.  1-ethyl-3-(3-105 
dimethylaminopropyl)carbodiimide hydrochloride (1.20 g, 6.26 mmol) was dissolved in this solution 106 
under stirring and subsequently thioglycolic acid (0.38 ml, 5.43 mmol) was added. The pH was 107 
adjusted to 5 by addition of NaOH (0.5 M) and the reaction mixture was stirred at room temperature 108 
for 3 h followed by dialysis in cellulose membrane tubings with a molecular cut-off of 12 kDa (5 days, 109 
8 °C). The dialysis media were the following; day 1: HCl (5 mM), day 2 and 3: HCl (5 mmol) containing 110 
1 % NaCl, day 4 and 5: HCl (1 mM). The medium was exchanged twice a day. Afterwards, the product 111 
was lyophilized and stored at 4 °C in the dark. For microbiological experiments, chitosan-TGA was 112 
dissolved in 0.9% NaCl solution and further diluted with FUM.  113 
The zeta potential of chitosan-TGA (0.5 mg/ml) was measured with a Zetasizer Nano ZS90 (Malvern 114 
Instruments, Herrenberg, Germany) in folded capillary cells containing the solution under 115 
investigation.  116 
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Preparation of FITC-chitosan-TGA 117 
Chitosan-TGA (30 mg) was dissolved in 3 ml distilled H2O. To this solution a solution of fluorescein 118 
isothiocyanate (FITC, 3 mg, Sigma) in dry MeOH (4.5 ml) was added yielding a fluorescent orange 119 
mixture, which was stirred for 4 h in the dark at room temperature. Afterwards, the solvent was 120 
reduced to 1 ml under vacuum and an orange solid precipitated upon addition of ethanol. The solid 121 
was washed thoroughly with ethanol until the washing solution showed no fluorescence. The 122 
product was dried under high vacuum and stored in the dark at 4 °C. For microscopy studies, FITC-123 
chitosan-TGA was dissolved in 0.9 % NaCl solution and further diluted with FUM. 124 
 125 
Photosensitizers 126 
The photosensitizer Foslipos (FOS; Biolitec AG, Jena, Germany) consists of meso-tetrahydroxyphenyl-127 
chlorine (mTHPC) encapsulated into dipalmitoylphosphatidylcholine/dipalmitoylphosphatidylglycerol 128 
(DPPC/DPPG) liposomes. Concentration of mTHPC in liposomes was 1.5 mg/ml. A stock solution of 129 
FOS (1.5 mg/ml) was prepared in water. Hypericin (HYP; Invitrogen, Basel, Switzerland) was prepared 130 
as a 1.0 mg/ml stock solution in ethanol. All stock solutions were further diluted in FUM and stored 131 
at 4 °C in the dark. 132 
 133 
UV spectra 134 
Absorption spectra of FOS (3.5 g/ml), HYP (3.4 g/ml) and a mixture of chitosan-TGA (0.75 g/ml) 135 
with either FOS or HYP (3.5 g/ml and 3.4 g/ml final concentration) were measured with a 136 
fluorescence spectrophotometer (Lambda 650 S, Perkin Elmer, Waltham, USA) in water.  137 
 138 
Confocal microscopy 139 
Microorganisms were incubated with either 4 mg/ml FITC-chitosan-TGA, 10 µg/ml FOS or 10 µg/ml 140 
HYP for 30 min in the dark at 37 °C. Alternatively, microorganisms were incubated with a 141 
combination of 4 mg/ml FITC-chitosan-TGA and either 10 µg/ml FOS or 10 µg/ml HYP for 30 min in 142 
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the dark at 37 °C (all final concentrations). Thereafter, samples were washed twice with 0.9% NaCl 143 
solution, dried, fire-fixed and mounted in Glycergel (Dako, Glostrup, Denmark). Imaging was 144 
performed with a confocal laser scanning microscope (TCS SP2 and SP5; Leica, Wetzlar, Germany). 145 
 146 
PDT protocols 147 
Density of planktonically cultured microorganisms was determined spectrophotometrically at 550 148 
nm and adjusted to OD 1.0. Afterwards they were incubated with (1) either chitosan-TGA (4 mg/ml 149 
for C. albicans, A. aphrophilus and C. ochracea and 1 mg/ml for S. sobrinus), HYP (10 µg/ml for C. 150 
albicans and C. ochracea; 2.5 µg/ml for A. aphrophilus; 1.25 µg/ml for S. sobrinus) or FOS (10 µg/ml 151 
for C. albicans and C. ochracea; 2.5 µg/ml for A. aphrophilus; 1.25 µg/ml for S. sobrinus) or (2) 152 
chitosan-TGA (at final concentrations indicated above) together with a photosensitizer (at finals 153 
concentrations indicated above)  for 30 min in the dark at 37° C. The microorganisms were washed 154 
twice with 0.9 % NaCl and samples containing photosensitizers were irradiated with a halogen 155 
polymerization device (Optilux 500, KerrHawe, Bioggio, Switzerland) for 120 s from a distance of 3 156 
cm. The device has a wavelength range between 400 and 505 nm with an irradiation intensity of 157 
1070 mW/cm2. Serial dilutions of all samples in 0.9 % NaCl were spiral plated on Columbia Blood 158 
Agar Base plates supplemented with 5 % human blood. The plates were cultured as indicated above 159 
for 1-2 days and colony forming units (CFU) were counted.  160 
 161 
Data analyses and statistics 162 
Experiments were performed in triplicate and repeated at least twice. Data are given in means of 163 
three to six values with standard deviations of the mean. Values are normalized against the controls 164 
(which was set to 100%) and presented as percentage of surviving microorganisms or microbial 165 
death with respect to untreated controls. 166 
 167 
8 
 
Results 168 
General 169 
Zeta potential measurements of chitosan-TGA revealed a value of 6.8 ± 3.3 mV for a concentration 170 
of 0.5 mg/ml chitosan-TGA at pH 7.5 (fig. 1). Lowering the pH lead to increased zeta potentials (pH 4:  171 
63.2 mV and pH 7: 13.9 mV) while a higher pH reduced zeta potentials (pH 8: 1.8 mV and pH 8.75: -172 
3.4 mV).  173 
Measurement of UV spectra showed that the addition of chitosan-TGA to photosensitizers did not 174 
change the pattern of absorption peaks (fig. 2). At wavelengths of up to 400 nm absorbance was 175 
slightly higher in HYP/chitosan-TGA and FOS/chitosan-TGA mixtures compared to photosensitizers 176 
alone. Peaks of HYP at 547 nm and 594 nm were red-shifted each by 6 nm in the mixture. UV spectra 177 
of FOS/chitosan-TGA and FOS alone were matching. Importantly, all spectra were identical within 178 
the wavelength range of our PDT light source (400-500 nm). 179 
We observed that the combination of chitosan-TGA with FOS initiated the formation of small 180 
aggregates. This was not the case with HYP.  181 
 182 
Candida albicans  183 
Analyses by confocal microscopy showed that HYP is taken up by all C. albicans cells. It was visible as 184 
a strong fluorescent signal throughout the cytoplasm in a granular manner. FOS-related fluorescence  185 
was also detected in all cells, but the signal was very weak. In contrast, signals for chitosan-TGA were 186 
confined to the cell envelope and not found intracellularly. The combination of the photosensitizers 187 
with chitosan-TGA showed the same distributions and intensities as with the substances alone (fig. 3 188 
for HYP and chitosan-TGA).  189 
Results of colony counts are shown in fig. 4. Incubation with chitosan-TGA leads to a 99.977 % 190 
reduced number of C. albicans colonies, compared to controls. Treatment with HYP-PDT resulted in 191 
32.483 % whereas the same treatment with FOS resulted in 95.596 % reduced colony numbers, 192 
respectively. With the combination of chitosan-TGA and HYP-PDT, death of 99.975 % of C. albicans 193 
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colonies was observed, in comparison with controls. Combination of chitosan-TGA with FOS-PDT 194 
could diminish number of colonies by 99.984 %.  195 
 196 
Aggregatibacter aphrophilus  197 
Microscopic images are depicted in figg. 5 and 6. Fluorescence images showed that HYP was 198 
accumulated in all A. aphrophilus cells under our conditions. The same was true for FOS, but its 199 
intracellular fluorescence signal was much stronger than with HYP. Incubation with chitosan-TGA 200 
was followed by a loose aggregation of the majority of A. aphrophilus cells in solution. Chitosan-TGA 201 
was visible only at these bacterial aggregates but not at single bacteria. The cytoplasm of cells 202 
appears to be free of chitosan-TGA signals. Incubation of HYP and chitosan-TGA in combination leads 203 
to similar results as documented for HYP or chitosan-TGA alone: HYP was accumulated in all cells 204 
whereas chitosan-TGA was adhering only to aggregates, omitting single bacteria. In contrast, cells 205 
incubated with FOS and chitosan-TGA in combination displayed a relocation of FOS, so that FOS 206 
colocalized to 100 % extracellularly with chitosan-TGA. As a consequence, FOS when combined with 207 
chitosan-TGA was not accumulated within cells as reported for single FOS incubation.  208 
Data of CFU counts are shown in fig. 7. A. aphrophilus treatment with chitosan-TGA alone caused 209 
bacterial death of 99.001%, compared to controls. With regard to photodynamic effects, we found 210 
that HYP and FOS resulted in 44.831% and 43.321% reduced numbers of colonies, respectively. The 211 
combination of chitosan-TGA with HYP-PDT as well as the combination of chitosan-TGA with FOS-212 
PDT eradicated the bacteria completely.  213 
 214 
Capnocytophaga ochracea  215 
Microscopic analysis (figg. 8 and 9) showed that HYP fluorescence was detected within all C. 216 
ochracea cells. The fluorescence signal of FOS treated cells was also found intracellularly in all 217 
bacteria, but was weaker compared to HYP. As with A. aphrophilus, the incubation of chitosan-TGA 218 
caused bacterial aggregation. FITC-chitosan-TGA was observed at bacterial aggregates only, but not 219 
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at single bacteria. When incubated with HYP and chitosan-TGA together, cells displayed a 220 
fluorescence distribution comparable with the pattern of the substances alone. In contrast, when 221 
bacteria were incubated with FOS and chitosan-TGA simultaneously, FOS fluorescence was found 222 
extracellularly and colocalized at aggregates with chitosan-TGA.  223 
Effects of treatments on CFU counts are illustrated in fig. 10. In C. ochracea chitosan-TGA treatment 224 
killed 80.579 % of cells, compared to controls. Photodynamic treatment with HYP and FOS induced 225 
99.997 % and 73.736 % lower colony numbers, respectively. The combination of HYP-PDT with 226 
chitosan-TGA impaired the effect of HYP-mediated PDT, leading to 95.751 % fewer colonies in 227 
comparison to controls. After treatment with FOS-PDT plus chitosan-TGA 98.582 % less colonies 228 
were observed compared to controls.  229 
Treatment with HYP-PDT in C. ochracea also affected bacterial growth patterns: bacteria were 230 
growing much slower and forming smaller colonies which were very difficult to spot. Only 64 h after 231 
HYP-PDT the bacteria had recovered from treatment and colonies could be reliably identified as 232 
viable. 233 
 234 
Streptococcus sobrinus  235 
Microscopic pictures (figg. 11 and 12) presented fluorescence for both HYP and FOS within the 236 
cytoplasm in a granular manner, but with a stronger signal for HYP compared to FOS. Chitosan-TGA 237 
was found in association with the surface of bacteria and bacterial aggregates. Incubation with 238 
chitosan-TGA plus HYP resulted in the same fluorescence patterns as with single compounds, while 239 
the combination of chitosan-TGA plus FOS indicated that FOS was not only present in cells, but also 240 
colocalized with chitosan-TGA extracellularly.   241 
Fig. 13 shows treatment effects in S. sobrinus. Chitosan-TGA alone caused a 99.548 % bacteriostatic 242 
effect, while HYP and FOS-mediated PDT reduced CFU counts by 99.983 % and 94.594 %, 243 
respectively. When HYP-PDT was combined with chitosan-TGA, colony numbers were reduced by 244 
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99.850 %. Furthermore, FOS-PDT combined with chitosan-TGA lead to a CFU reduction of 99.871 % 245 
in comparison to controls.  246 
 247 
Discussion 248 
PDT has emerged as a promising antimicrobial treatment option, with enormous clinical potential 249 
particularly for the therapy of difficult or (multiply) antibiotic-resistant strains. However, numerous 250 
studies provided evidence that not all microorganisms are equally susceptible to PDT. While gram-251 
positive bacteria have been reported to interact with many different photosensitizers, treatment of 252 
gram-negative bacteria is strongly improved by (or even require) the use of cationic photosensitizers 253 
(12). As described in detail elsewhere, this phenomenon may be linked to the presence of anionic 254 
cell wall components in gram-negative bacteria and fungi (12). 255 
Due to their charge characteristics, some of the photosensitizers with highest singlet oxygen 256 
quantum yields therefore do not qualify for broad-band antimicrobial PDT. Among others this may 257 
apply to neutral mTHPC and anionic hypericin, that we found to both effectively kill gram-positive 258 
mutans and sobrinus streptococci (28), but may be less suitable for gram-negative strains (Besic 259 
Gyenge et al., unpublished). 260 
To overcome these limitations we attempted to combine for the first time mTHPC- or hypericin-261 
mediated PDT with the chitosan derivative, chitosan-TGA, using oral microorganisms as models. 262 
Chitosan, a polycationic biopolymer, is generally known for its strong antimicrobial properties 263 
towards gram-negative strains and fungi (29) and may thus complement the effects of our 264 
photosensitizers in PDT. As a first step we here present our data on CFU counts after treatment, but 265 
at this stage no conclusions with regard to the fundamental biological processes (cell death and/or 266 
growth reduction) can be drawn.  267 
In our study we report for the first time that a short 30 min treatment with chitosan-TGA had a 268 
strong broad-band antimicrobial effect on yeast, as well as on selected oral gram-positive and gram-269 
negative bacteria. With our data we therefore contribute to the growing list of antimicrobially active 270 
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chitosans (30, 31). At 4 mg/ml (i.e. the highest possible concentration due to solubility limits), the 271 
effectiveness of chitosan-TGA was S. sobrinus > C. albicans > A. aphrophilus >> C. ochracea. It should 272 
be noted, that only in S. sobrinus 4 mg/ml chitosan-TGA lead to a complete eradication. Lower 273 
chitosan-TGA concentrations (1 mg/ml) were thus used to better explore in S. sobrinus the combined 274 
effects of chitosan-TGA and PDT.   275 
Previous studies provided evidence that the mechanisms of chitosan action relate to the adherence 276 
of the positively charged free amino groups of chitosans with anionic microbial cell wall components 277 
followed by a fatal disturbance of barrier integrity (29, 32-35). Zeta potential measurements 278 
confirmed the positive charge at physiological pH of our chitosan-TGA preparation, which was 279 
slightly higher than described in the literature (4.3 ± 0.74 mV (36)). 280 
In our study we found that chitosan-TGA induced aggregation of bacteria, especially of the two 281 
gram-negative species. Such a behaviour had been described before for various chitosan derivatives 282 
(15, 37-39) and seems to be associated with detrimental effects on the cell wall (37). Since it is 283 
known for a long time that the formation of biofilms is prevented by bacterial aggregation (40) we 284 
suggest that this effect of chitosan-TGA may be a beneficial feature for therapy of patients.  285 
Presumably due to the cationic nature of chitosan-TGA, our confocal microscopy studies always 286 
revealed a close physical proximity of chitosan-TGA to microbial cells, even after extensive washing 287 
steps. However, while chitosan-TGA clearly attached to the cell envelope of C. albicans, we found 288 
that the majority of A. aphrophilus and C. ochracea and all S. sobrinus appeared to be embedded in 289 
more compact masses of chitosan-TGA. Notably, these differences had no impact on antimicrobial 290 
effects of chitosan-TGA. Taking into account the solely extracellular localization of chitosan-TGA, its 291 
primary targets will be microbial cell wall and/or cytoplasmic membrane components rather than 292 
microbial DNA and transcription factors (29, 35).     293 
Since the microscopic picture of chitosan-TGA fluorescence in C. ocheacea was very similar to the 294 
one in A. aphrophilus, the comparably low efficacy of chitosan-TGA on C. ochracea was unexpected.  295 
We assume that differences may be related to specific characteristics of C. ochracea cell envelope, 296 
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like e.g. those that allow for gliding motility on smooth surfaces (the other microorganisms 297 
investigated here are non-motile). Furthermore, we cannot exclude that the addition of horse serum 298 
to the culture of C. ochracea may have interfered with chitosan-TGA activity. Previous studies have 299 
provided evidence that chitosan may bind to serum proteins with resulting altered transfection 300 
efficacy (41). 301 
Our study confirmed our previous data on bactericidal PDT effects on S. sobrinus with the mTHPC 302 
derivative FOS and HYP (28). Aditionally, we here provide new PDT informations with these 303 
photosensitzers against selected gram-negative bacteria and yeast. In our present study, 304 
photosensitizer concentrations had been choosen that that did not result in complete killing of 305 
microorganisms after light activation. Generally and in contrast to chitosan-TGA, both 306 
photosensitizers penetrated cell walls of all species investigated within 30 min of incubation.  307 
Our study supplied the first data on PDT for A. aphrophilus und C. ochracea. Although gram-negative 308 
bacteria are generally regarded as less sensitive to non-positively charged photosensitizers (12), we 309 
found that both HYP- and FOS-mediated PDT is capable of strongly reducing CFU counts in both 310 
species. As especially evident with C. ochracea, the intensity of confocal fluorescence signals of 311 
photosensitizers correlated with efficiency of PDT (i.e. stronger fluorescence was associated with 312 
lower CFU counts after treatment).  313 
Several papers have underlined the general usefulness of PDT for the treatment of Candida (9, 42). 314 
However, little or no results with regard to HYP (43) or FOS, respectively, are available. In our study 315 
we found that PDT with HYP had only very limited antifungal effect on C. albicans, although this 316 
photosensitizer accumulated at high rates in all cells. In contrast, FOS, that showed a decidedly 317 
weaker intracellular fluorescence than HYP in C. albicans, killed over 95% of cultures. These results 318 
highlight the complexity of PDT processes and indicate that the efficiency of a given photosensitizer 319 
does not necessarily (like in gram-negative bacteria) depend on the cellular fluorescence of 320 
photosensitizers within cells. Since nothing is known about the subcellular localization or molecular 321 
responses within C. albicans, we cannot exclude that the observed differences in PDT effects are 322 
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related to differences in intracellular targets, trafficking pathways or activation of certain signaling 323 
cascades (44). Furthermore, we cannot exclude a self-quenching effect of FOS fluorescence signals, 324 
that have been reported when concentrations of liposomal mTHPC are high (45, 46).   325 
Initial tests confirmed that the combination of FOS or HYP with chitosan-TGA does not change the 326 
spectroscopic properties of photosensitizers at the wavelength range of our light source. Notably, 327 
the Q-band of FOS at 652 nm was also not affected by co-incubation with chitosan-TGA. However, 328 
HYP is often activated at 593 nm and for this peak a red-shift of 6 nm was observed. This data is in 329 
line with a previous study, where interactions of Photogem with chitosan resulted in a red-shift of 330 
the Q-band of Photogem (47).  331 
Our results revealed that the effects of a combined treatment with chitosan-TGA plus PDT may be 332 
photosensitizer and/or species-dependent.  333 
Under our experimental conditions, the admixture of chitosan-TGA to FOS always improved its 334 
photodynamic outcome (as judged from CFU counts and compared to FOS-PDT alone). Furthermore, 335 
this combination was also slightly better than chitosan-TGA alone. The underlying mechanisms are, 336 
however, not clear yet. The agglomeration occurring when chitosan-TGA is mixed with (liposomal) 337 
FOS in solution may be related to the known lipid-binding capabilities of chitosan (48). However, the 338 
observation that FOS uptake was prevented upon chitosan-TGA incubation (resulting in a shift from 339 
intracellular to extracellular FOS localization) in gram-negative bacteria while in C. albicans and S. 340 
sobrinus this was not the case, may indicate that direct interactions between chitosan-TGA and FOS 341 
are not the general driving force of this improvement. Rather, species-specific factors at e.g. the cell 342 
wall may have an impact, but this hypothesis requires further investigations.  343 
The combined protocol of HYP-PDT and chitosan-TGA yielded an incongruent picture. In line with our 344 
above data, the combination of chitosan-TGA and HYP-mediated PDT was also slightly superior to 345 
chitosan-TGA alone. In C. albicans and A. aphrophilus this combination was better, but in C. ochracea 346 
and S. sobrinus worse than PDT with HYP alone. The reason for this difference is currently not 347 
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known, especially since the uptake and intracellular localization of HYP did not appear to be 348 
impaired with chitosan-TGA.  349 
In a recent paper it had been shown that unmodified chitosan (LMW, 75-85% deacetylation) 350 
improved PDT with hematophorphyrin or toluidine blue for treatment of gram-positive 351 
Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes and gram-negative 352 
Pseudomonas aeruginosa and Acinetobacter baumannii, respectively (13). Since in this study, 353 
chitosan itself had no antibacterial effect, the underlying mechanisms are likely to be different to the 354 
ones operative in our setup. Another study found that chitosan particles doped with the 355 
photosensitizer Photogem displayed reduced activity against the gram-positive Staphylococcus 356 
aureus compared to Photogem in solution (47). However, these results were obtained without light 357 
irradiation and had been explained by an interaction of negatively charged groups of Photogem with 358 
positive moieties of chitosan (47).  359 
 360 
Taken together our study provided first evidence that the combination of chitosan-TGA with PDT 361 
(especially using mTHPC) may be suitable for antimicrobial therapy. With such combined protocols 362 
lower doses of photosensitizers may be applicable, thereby reducing both side effects and costs. 363 
Typically, odontogenic infections are polymicrobial, and their treatment may thus benefit from 364 
modalities as proposed here, that affect gram-positive and gram-negative bacteria as well as fungi. 365 
Compared to unmodified chitosans, thiolated chitosans (including chitosan-TGA) feature improved 366 
mucoadhesion as well as better solubility and diffusive permeability (25, 49) and therefore may offer 367 
new options for local PDT treatment of infections within the oral cavity.  368 
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Figure legends 542 
Fig. 1 543 
Measurements of the zeta potential of chitosan-TGA at pH 7.5. 544 
 545 
Fig. 2 546 
Absorption spectra of (a) hypericin (Hyp) and the mixture of hypericin and chitosan-TGA (TGAHyp) 547 
and (b) Foslipos (Fos) and the mixture of Foslipos and chitosan-TGA (TGAFos).   548 
 549 
Fig. 3 550 
Candida albicans incubated with a  combination of hypericin and chitosan-TGA: (a) differential 551 
interference contrast microscopy, (b) chitosan-TGA (green), (c) hypericin (red), (d) overlay.  552 
 553 
Fig. 4 554 
Survival in Candida albicans after treatment with chitosan-TGA (TGA), hypericin (HYP), Foslipos 555 
(FOS), a mixture of hypericin and chitosan-TGA (TGA + HYP) or a mixture of Foslipos and chitosan-556 
TGA (TGA + FOS) in % compared to controls (set as 100%). 557 
 558 
Fig. 5 559 
Aggregatibacter aphrophilus: (a and b) incubation with hypericin only, differential interference 560 
contrast microscopy (a), overlay with hypericin (red, b); (c-f) incubation with a mixture of hypericin 561 
and chitosan-TGA, differential interference contrast microscopy (c), chitosan-TGA (green, d), 562 
hypericin (red, e), overlay (f).   563 
 564 
Fig. 6 565 
Aggregatibacter aphrophilus: (a and b) incubation with Foslipos only, differential interference 566 
contrast microscopy (a), overlay with Foslipos (red, b); (c-f) incubation with a mixture of Foslipos and 567 
24 
 
chitosan-TGA, differential interference contrast microscopy (c), chitosan-TGA (green, d), Foslipos 568 
(red, e), overlay, yellow color indicates colocalization of red and green fluorescence signals (f).   569 
 570 
Fig. 7 571 
Cell death in Aggregatibacter aphrophilus after treatment with chitosan-TGA (TGA), hypericin (HYP), 572 
Foslipos (FOS), a mixture of hypericin and chitosan-TGA (TGA + HYP) or a mixture of Foslipos and 573 
chitosan-TGA (TGA + FOS) in % compared to controls (set as 0%). 574 
 575 
Fig. 8 576 
Capnocytophaga ochracea: (a and b) incubation with hypericin only, differential interference 577 
contrast microscopy (a), overlay with hypericin (red, b); (c-f) incubation with a mixture of hypericin 578 
and chitosan-TGA, differential interference contrast microscopy (c), chitosan-TGA (green, d), 579 
hypericin (red, e), overlay (f).   580 
 581 
Fig. 9 582 
Capnocytophaga ochracea: (a and b) incubation with Foslipos only, differential interference contrast 583 
microscopy (a), overlay with Foslipos (red, b); (c-f) incubation with a mixture of Foslipos and 584 
chitosan-TGA, differential interference contrast microscopy (c), chitosan-TGA (green, d), Foslipos 585 
(red, e), overlay, yellow color indicates colocalization of red and green fluorescence signals (f).   586 
 587 
Fig. 10 588 
Survival in Capnocytophaga ochracea after treatment with chitosan-TGA (TGA), hypericin (HYP), 589 
Foslipos (FOS), a mixture of hypericin and chitosan-TGA (TGA + HYP) or a mixture of Foslipos and 590 
chitosan-TGA (TGA + FOS) in % compared to controls (set as 100%). 591 
 592 
 593 
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Fig. 11 594 
Streptococcus sobrinus: (a-d) incubation with a mixture of hypericin and chitosan-TGA, differential 595 
interference contrast microscopy (a), chitosan-TGA (green, b), hypericin (red, c), overlay (d).    596 
 597 
Fig. 12 598 
Streptococcus sobrinus: (a-d) incubation with a mixture of Foslipos and chitosan-TGA, differential 599 
interference contrast microscopy (a), chitosan-TGA (green, b), Foslipos (red, c), overlay (d).    600 
 601 
Fig. 13 602 
Survival in Streptococcus sobrinus after treatment with chitosan-TGA (TGA), hypericin (HYP), Foslipos 603 
(FOS), a mixture of hypericin and chitosan-TGA (TGA + HYP) or a mixture of Foslipos and chitosan-604 
TGA (TGA + FOS) in % compared to controls (set as 100%). 605 
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a b s t r a c t
We review current clinical applications of photodiagnosis (PD) and photodynamic therapy (PDT) in the
head and neck ﬁeld and highlight the actual status, problems, challenges as well as the future of this
emerging treatment modality.
In recent years literature presented input from many new developments and their applications. This is
due to better awareness and developing knowledge about PD–PDT from the clinical staff, both nurses and
doctors. But it is also a result of improved drug and hardware development such as lasers, LEDs and
related optical devices. Current photo-medical applications in the head and neck region range from diag-
nostics, treatment of premalignant and malignant lesions, aesthetic and cosmetic applications to the ever
expanding anti-microbial applications.
Although treatment of premalignant and early malignant lesions of the oropharyngeal cavity have long
been the favourite lesions to treat with PDT patients with unsalvageable tumors have also been respond-
ing remarkably well to PDT, adding signiﬁcant quality of life.
There is growing interest in anti-microbiological PDT and recent progress has shown that this application
is able to signiﬁcantly reduce the number or even eradicate speciﬁcmicrobial pathogens. Duringmany sur-
gical treatments better control of microbiological activity through PDT may lead to a better outcome.
Despite progressive development in this ﬁeld a few problems remain: prolonged phototoxicity, limited
penetration of the photosensitizer and light, inadequate speciﬁcity, PDT-related pain as well as the lack
of uniformly accepted protocols both for light application as well as photosensitizers. Recent studies have
shown that PDT based pain can be separated fromother forms of pain, offering hope that a speciﬁcmanage-
ment of painwill be possible. If PDTwill become fully accepted by patients and doctorswemust care about
the negative factors such as pain and prolonged phototoxicity.
 2010 Elsevier B.V. All rights reserved.
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1. Introduction
The application of clinical photodiagnosis and photodynamic
therapy (PD and PDT) is constantly growing. Since the earliest re-
ports by von Tappeiner and Jesionek in 1903 and Policard in
1924 [1,2] on the therapeutic use of ﬂuorescent substances, there
have been signiﬁcant developments in the clinical application of
more sophisticated treatment modalities within less than a cen-
tury. The aim of this review is to outline the current spectrum of
applications, limitations as well as future of PDT in the head and
neck region. The broader acceptance of PDT hinges mainly on the
further development of the two basic components namely, the
light source as well as the photoactive dye or photosensitizer. A
basic advantage of PDT is that there is no lifetime limit to the dose
of photosensitizer. Furthermore, the treatment can be repeated as
often as needed and, no known interaction exists between current
chemo- and radiotherapy protocols and PDT. The excellent func-
tional as well as aesthetic outcomes of PDT treatments may be
attributed to the relative limited damage to normal structures like
nerves, collagen ﬁbers and large blood vessels, although the micro-
vasculature is affected leading to severe and persistent tumor hy-
poxia or anoxia [3]. The well known disadvantages are prolonged
photosensitivity, possible poor initial selectivity between tumor
and normal tissue as well as pain.
Some photosensitizers have a long lag time between initial drug
administration and exposure to the therapeutic light source result-
ing in extended total treatment time. There is a signiﬁcant drive to
modify this. With time the drugs have also been modiﬁed to absorb
longer wavelengths improving the depth of penetration in tissues
[4]. A recent drug, chlorine e6 alone and in combination with the
hydrophilic polymer polyvinylpyrrolidone (PVP) have shown prom-
ise in animal and human applications regarding phototoxicity
[48,49].
Broadly the use of PDD and PDT can be grouped in the following
categories for the head and neck area:
– Diagnostic.
– Treatment of premalignant, as well as early malignant lesions in
the head and neck area.
– Treatment of secondary or recurrent squamous cell carcinomas
of the head and neck.
– Esthetic and cosmetic applications.
– Treatment of bacterial, fungal, parasitic as well as viral infec-
tions (photodynamic anti-microbial therapy or for short PACT).
Themain limitations in themore generalized clinical application
of PDT are ﬁrstly the lack of clinical knowledge and especially the
lack of established treatment protocols and possibly the perception
of the application of a technology still verymuch in a developmental
phase. An expanding array of photosensitizers [50] that could either
be administered systemically or as a topical application is available
and may in future enhance the choice of the most appropriate drug
for the particular situation. Light sources needed for the activation
of the photosensitizermay range from pulsed-dye lasers, potassium
titanyl phosphate lasers to neodymium:Yttrium–aluminium-garnet
(Nd:YAG) lasers. Smaller semiconductor diode lasers have become
more popular due to the mobility, price and power advantages [5].
LED lights are becomingmore andmore powerful, with deeper pen-
etration and thuswider application than just superﬁcial tumors. The
use of mobile PDT units may make a considerable difference in the
accessibility of PDT services to communities not close to a hospital
rendering a PDT service [6]. Although thismay be the case, technical
equipment (light source) is needed with the necessary technical
support to be able to effectively run such a service.When reviewing
the literature, there are few standardized protocols to compare re-
sults andmay lead to confusion by the interested practitioner.Much
work is still needed to clearly deﬁne treatment protocols and
develop affordable and easy to use equipment so that PDT may be
used on a daily basis in most centers for a wide variety of clinical
applications.
At present the use of PDT has been approved for use in clinical
treatment in the USA, EU, Canada, Russia and Japan. The FDA
approved the use of PDT in Barret´s esophagitis, obstructive
tracheobroncheal carcinoma using the photosensitizer Porﬁmer
sodium (Photofrin), and the use of 5-aminolevulinic acid, 5-ALA
(Levulan) and 5-ALA in alcohol solution (Kerastick) for actinic
keratosis while verteporfrin (Visudyne) may be applied for macu-
lar degeneration. In addition to the above the EU also approved the
use of meta-tetrahydroxy-phenyl chlorine (mTHPC), also known as
temoporfrin, (Foscan) as photosensitizer for the treatment of
early and palliative cases of head and neck carcinomas. For squa-
mous- and basal cell carcinomas methyl aminolaevulinat (Met-
vix) was approved as photosensitizer prodrug (Biel [8]).
2. Diagnostic: (PDD: photodynamic diagnosis)
Early and accurate detection of oral dysplasia and cancer in pa-
tients would lead to an increase in early diagnosis and an improved
prognosis of many patients. All cells have a degree of ﬂuorescence
when exposed to light which is called auto ﬂuorescence. This ﬂuo-
rescence is a re-emission of light that can be in varying colors and
is attributed to the presence of chromophores (ﬂuorophores) with-
in them. By using ﬂuorescence spectroscopy these substances can
be detected and are thus representative of biochemical changes
within these tissue [7]. Fluorescence can be detected as auto ﬂuo-
rescence when induced by violet light (400 nm) or may be en-
hanced by the topical or even systemic application of 5-ALA. An
increased red and decreased green ﬂuorescence is an accurate pre-
dictor of dysplasia and malignancy. This effect is further enhanced
by the limited ability of cancerous tissue to metabolize iron and
topical application of iron will thus result in an increase of intracel-
lular protophorphyrin IX (PpIX) [7]. Emerging techniques like elas-
tic scattering spectroscopy, Raman spectroscopy as well as the now
often applied ﬂuorescence spectroscopy will have to be compared
to the proven use of toluidine blue as well as to the gold standard,
namely biopsies, to verify their efﬁcacy and accuracy as diagnostic
tools in the early detection of cancer.
In recent times the diagnostic use of 5-ALA in bladder, brain and
breast tumors has been expanding. The photosensitizer can be ta-
ken in orally a few hours before intraoperative localization of the
tumor border. There is hope that breast cancer will be investigated
more intensely with mini-endoscopes equipped with ﬂuorescence
optics, allowing 5-ALA based localization of PpIX within affected
Nomenclature
PDT photodynamic therapy
PDD photodynamic diagnosis
mTHPC meta-tetrahydroxy-phenyl chlorine
PpIX protoporphyrin IX
5-ALA 5-aminolevulinic acid
PACT photodynamic anti-microbial therapy
HpD hematoporphyrin derivative
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mammary ducts. The potential of further diagnostic applications of
orally applied 5-ALA has been demonstrated in the ﬁeld of breast
cancer surgery where both the differentiation of normal from af-
fected tissue could be demonstrated in a clinical setting [46]. Fur-
thermore the use of 5-ALA could be expanded in sentinel node
identiﬁcation [46,47]. The combination of both these techniques
could be worth further investigation in the ﬁeld of head and neck
surgery.
The photosensitizer hypericin, which is a component of St.
John’s Wort, has been identiﬁed as a powerful tumor imaging agent
that may be able to assist in the deﬁnition of tumor margins as well
as diagnosis in deeper lying tumors [14].
3. Treatment of premalignant and early malignant head and
neck lesions
Under the term head and neck cancer malignant lesions we
group lesions of the oral cavity, neck, pharynx, larynx, nasal cavity,
sinus cavities, orbit and all other related structures like the skin.
The most common of these tumors are squamous cell carcinomas
with an incidence ranging from 4% of all malignancies to as high
as 30% in some developing countries.
The term head and neck cancer however does not distinguish
between the origin of the tumor (epithelial or mesenchymal). It
also does not distinguish between the deeper lying tumors for
example the infratemporal fossa and the more superﬁcial tumors
that may be more accessible to treatment. Of course there are dif-
ferences in etiology and treatment outcomes of this wide array of
tumors. There is more and more evidence to suggest that the
prognosis and thus per deﬁnition the tumor biology differs from
site to site and thus should be deﬁned ﬁrst before studies are
undertaken and results published [52]. This may also hold true
for the evaluation of the effectiveness of treatment of PDT in head
and neck cancer.
There is a wide array of photosensitizers available on the mar-
ket. Clear and strict descriptions of clinical applications exist for
each drug, although off-label use is common.
Mainly two products namely porﬁmer sodium (Photofrin) and
haematoporphyrin derivative (HpD/Photofrin) as well as mTHPC
(Foscan) are used for the treatment of head and neck cancer.
mTHPC is a second generation synthetic photosensitizing drug.
There is a delay of 4 days after injecting the drug before activation
with laser which allows accumulation in cancer cells. There may be
pain associated with the administration of the drug. Light sensitiv-
ity lasts for at least 15 days.
Of late the chlorine e6 derivative (Photolon) has been gaining
literature support as a photosensitizer for superﬁcial and deep le-
sions in the head and neck area with the beneﬁt of a shorter period
of post treatment photosensitivity [55].
Systemically administered photosensitizers like mTHPC are reg-
istered for use in premalignant lesions as well as early invasive as
well as otherwise untreatable carcinomas of the oropharyngeal re-
gion. It is also possible to treat very superﬁcial lesions with 5-ALA
that is either topically applied or administered orally [8].
Copper et al. [9] reported on their experience in the treatment
of multiple primary tumors in the head and neck. The authors used
mTHPC mediated PDT for the treatment of multiple primary muco-
sal malignancies in the oral cavity and oropharynx. Of the 27 pa-
tients with 42 tumors the staging ranged from carcinoma in situ
lesions (3 cases), stage I (23 cases), II (15 cases) to stage III (1 case).
Most patients were treated for a single tumor, although three pa-
tients were treated with multiple synchromatous tumors. In 28
of the 42 tumors (67%) treatment was successful with a cure rate
of 85% for stage I or in situ disease versus 38% in the stage II and
III group. Most patients had a good functional outcome and recur-
rent tumors could be treated with conventional single or combined
surgical, radio or chemo-therapy protocols. One patient developed
more serious light exposure complications. This study highlights
the potential beneﬁts as well as the current limitations in treat-
ment of single and multiple primary squamous cell carcinomas
of the oropharyngeal carcinomas. Contrary to conventional chemo-
therapies resistance to PDT has not yet been described [10]. Hop-
per et al. [21] reported on the Phase II trials with m HTC in 2004
and showed good results for early oropharyngeal squamous cell
carcinomas. Understandably better results have been seen with
T1 than in T2 lesions [22].
Porﬁmer sodium (Photofrin) seems to be highly successful
especially in the treatment of T2 and smaller tumors of the larynx
[8]. Other anatomical areas of application are the oral cavity and
oropharynx [20]. This product is a mixture of several porphyrins
from blood and limited absorption of red light with good drug pen-
etration. Light sensitivity for up to six weeks after administration
may diminish the quality of life. Another negative aspect is the rel-
atively poor tumor selectivity.
New generation chlorin based photosensitizers are designed to
overcome problems of the older photosensitizers like poor selectiv-
ity, long administration to exposure time and photosensitivity. A
1:1 mixture comprising of chlorine e6 and polyvinylpyrrolidone
(Fotolon) may also have increasing indications in at least the pho-
todiagnosis and phototreatment applications [23,51]. The mecha-
nism of action seems to be by triggering reactive oxygen species
as well as light dependent cell death via necrosis [53]. Adding the
hydrophilic polymer polyvinylpyrrolidone (PVP) seems to improve
the efﬁcacy of the drug by improving tumor-to-normal tissue ratio.
Penetration after superﬁcial application in an in vivo study was sig-
niﬁcantly improved by this improved formulation [54,55].
The use of a new photosensitizer talaporﬁn sodium (Laserph-
yrin) used with a newly developed ultra mobile semiconductor
low energy PD laser with a wavelength of 664 nm has recently
been reported by Yoshida et al. [24]. This study clearly demon-
strates the importance of adequate intake of the photosensitizer
in this case to a level of above 1 lg/g in the tumor tissue to ensure
an adequate response. Tumor-to-normal tissue ratios ranged from
0.36:1 to 5.69:1 in 9 of 11 patients. Of the 24 patients treated with
T1 and T2 laryngeal, oral and pharyngeal cancer, two presented
with recurrences after a median follow-up period of 20 months.
Another possible photosensitizer that has been tested in an
in vitro study is hypericin. A tumorcidal effect was reached by
exposure times of 5–10 s with a 593 nm laser light and nearly com-
plete squamous cell cancer killing after 120 s of exposure. In vivo
tests in mice conﬁrmed the therapeutic effect of hypericin directly
injected in the tumor [14]. Infrared pulsed laser emissions may be
used to activate the drug and improve tissue penetration of hyper-
icin PDT [19].
Use of 5-ALA is suitable for topical application, but may also be
taken in orally resulting in systemic absorption and reasonable
selectivity. Use is restricted to very superﬁcial lesions like leuko-
plakia or skin lesions like acne vulgaris, sebaceous gland hyperpla-
sia, rosacea and hirsutism, but is not to be used for invasive lesions.
Commercially 5-ALA is marketed known as LevulanKerastick or
as its methylated esther Metvix. After absorbtion, 5-ALA is metab-
olized to another heme precursor, PpIX, which is the actual active
photosensitizer. Peak light absorption is at 635 nm. Normally the
photosensitizer can be activated by a light source 3–4 h after oral
administration of a dose of 10–60 mg/kg. Local application is pos-
sible but technically difﬁcult in the oral area where of carriers in a
cream or gel form has been used [20]. Due to the short half-life,
photosensitivity is normally resolved after a 24 h period. Since ﬁrst
reports on treatment of premalignant lesions with 5-ALA in 1996
there seems to be consistent favorable results in the literature with
100% response rate to less than 50% [20]. There were marked dif-
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ferences in the treatment protocols and that may explain the
widely different outcomes. Recent development of a novel 5-ALA
patch for skin application has simpliﬁed the treatment of skin
lesions as no cream or ointment needs to be applied [56,57].
Successful PDT has also been reported in early oesophageal can-
cer by Maunoury et al. [29]. A response rate of 75% was noted with
the use of porﬁmer sodium as photosensitizer in a group of patients
(n = 24) with early SCC and ADC (T1 or T2). In a larger study Radu
et al. [30] reported their experiences of 101 early squamous cell car-
cinomas in the oral cavity, pharynx, esophagus as well as in the tra-
cheobronchial tree. These tumors were detected as second primary
malignancies in patients with primary head and neck cancer. All
patients had carcinoma in situ or T1 lesions with less than 2 mm
inﬁltration. First generation photosensitizer, haematoporphyrin
derivative (HpD/Photofrin) and Photofrin IIwas used. Complete re-
sponse was seen in 85% of patients with 9 of these recurring after
3–34 months. A permanent eradication was thus seen in 77% of
the tumors without any mortality. No difference was seen in the
response rate of the different treatment sites.
There appears to be a correlation between the ﬂuence rate mea-
sured in mW/cm2 and the type of reaction from tumors. In tumors,
pre-existing hypoxia has been clearly recognized as a barrier to
other oxygen dependent treatment modalities like radiotherapy.
A higher ﬂuence rate as well as higher concentration of photosen-
sitizers often leads to necrosis while a lower ﬂuence rate and pho-
tosensitizer dose may lead to more apoptotic cell death as well as a
cell mediated response. This may be explained by the improved re-
oxygenation ability at a lower ﬂuence rate [25,26]. The lower
ﬂuence rate thus seems to have a much wider inﬂuence than just
direct cell destruction as inﬂammatory cells are more widely
distributed in these circumstances leading to wider and not clearly
deﬁned tumor injury [27,23]. This antitumor immunogenicity with
activation of CD4+ and CD8+ T cell clones with recognition of tu-
mor speciﬁc antigens has been recognized as a factor contributing
to tumor immunity [4].
Hyperbaric oxygen has been proposed as a method to improve
tumor tissue oxygenation and thus improve the response of tu-
mors to PDT [28].
4. Secondary or recurrent squamous cell carcinomas
Major emphasis has been placed on the use of PDT in patients
with secondary or recurrent squamous cell carcinomas of the head
and neck region. PDT has been employed as a palliative treatment
modality where other treatments have failed.
This has been the case in many institutions in countries like
Germany. A recent report by Lorenz and Maier [11] highlights
the possible beneﬁcial effect of PDT in this group of patients. In
the group of 24 patients, 12(50%) reacted favorably with complete
remission and partial remission was seen in 9(37.5%) with three
patients showing no response. The mean duration of overall sur-
vival was 305.7 days and the mean recurrence free survival was
302.7 days. Patients with a complete response had a signiﬁcantly
better mean survival of 414.1 days. In 19% of the patients a signif-
icant improvement of quality of life was measured. Important to
note is that in this group of patients the presence of lymph node
and other distant secondary metastases were excluded before
commencement of treatment. The maximal tumor thickness was
1 cm with the average tumor surface area of 6 cm2.
Debulking of large tumors in a progressive layer by layer
approach has also been proposed by using PDT [12,13]. Another
use of PDT in large tumors is by interstitial photodynamic therapy
(IPDT). In these cases the delivery of light to deeper parts of the
tumor is achieved by placing thin optical light diffusers into the
tumor mass. There is evidence supporting the increased effective-
ness of this therapy due to the improved photo-oxidation and distri-
butionwithin the tumor bed [14]. Currently this treatment ismostly
indicated in cases where no other means of salvage is possible. Lou
et al. [15] reported their experience of 45 patients with end stage
head and neck cancer unsuitable for any other treatment modality.
Signiﬁcant relief in mass effect was noted in 24 patients with 5 dis-
ease free patients after 10–60 months. One patient suffered from a
carotid blowout. The use ofMR imaging guided interstitial photody-
namic laser therapy has been proposed by Jager et al. [16] with the
advantage of being able to deliver an accurate, safe and more uni-
form light delivery in these advanced head and neck tumors [4].
In a large multicentre study [17], 128 patients with advanced,
histological conﬁrmed squamous cell carcinoma and deemed to
be incurable by an interdisciplinary team was included in the
study. Often these patients were extensively pre treated. mTHPC
was used as photosensitizer and delivered at a concentration of
0.15 mg/kg and the surface of the tumor was illuminated on the
fourth day with 652 nm, 20 J/cm2 and with an intensity of
100mW/cm2 resulting in a dose of 20 J/cm2. In 43% the lesions
achieved 100% tumor mass reduction on at least one occasion
during follow-up with a median duration of the response of
117 days with 35% completely cleared 1 year after treatment.
Two important subgroups with better responses were identiﬁed,
namely those who had lesions of 10 mm thickness or less and
those where illumination of the whole surface could be achieved.
Despite the above 29% of tumors thicker than 10 mm achieved
an overall tumor response. Median survival in patients having a
100% tumor response was 426 days compared to 212 days in the
partial responders group. The cost effectiveness of PDT using
mTHPC has been conﬁrmed when compared with four cycles of
palliative chemotherapy [18].
5. Cosmetic applications
Cosmetic applications of PDT are rapidly expanding. This espe-
cially applies to the use of 5-ALA in a wide range of skin conditions.
Besides the FDA approved use for treatment of premalignant and
malignant skin conditions off-label uses for photorejuvination,
treatment of sebaceous gland hyperplasia, rosacea and hirsutism
is now recognized [31]. Use of PDT in the treatment of acne vulga-
ris has also in recent times attracted much interest. Many protocols
have been suggested without one to have been proven to be the
best. Use of 5-ALA is clearly effective; however the side effect pro-
ﬁle has been excessive [32]. 5-ALA or its derivatives normally
comes in a cream base and light can be applied at around 30 min
or as late as 4 h after application. Longer time interval allows for
increased drug penetration and may be further increased by degre-
asing the skin with acetone before 5-ALA application. Recently a
self-adhesive 5-ALA patch for the treatment of actinic keratoses
has been developed [33]. Use of a 532 nm diode laser leads to
the possibility to also treat pigmented lesions as lentigines, kera-
toses and ephelides (freckles) by attacking the underlying abnor-
mal vasculature. Bowen’s disease is also shown to react well to
treatment [5,34]. Rhinophyma as well as sebaceous gland hyper-
plasia may also successfully be treated by 5-ALA PDT [5].
When cells rapidly proliferate or have a high metabolic turn-
over they convert more 5-ALA to PpIX, increasing the effect of
PDT in these areas with resultant reduction of skin hyper pig-
mentation. 5-ALA-PDT has shown to be effective in the treat-
ment of patients with actinic damage and an improvement in
overall cosmesis [32].
During and after treatment patients may experience discomfort
as well as in some cases even intense pain. Swelling as well as ery-
thema may persist for the period of 24 h after activation. With pro-
tocols intended to increase the penetration and effect of the PDT
there are obvious increased symptoms involved [35]. Multiple
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short incubation time (<1 h) treatments results in improved acne
reduction and and decrease in edema, crusting, dyspigmentation
and thus improved patient compliance [31].
Recently, it had been shown that different clinicopathologic fea-
tures of head and neck basal cell carcinoma may also lead to differ-
ent response rates [36]. In this study the response rate was 100%
for ulcerative, 90% for nodular, 62% for superﬁcial, 14% for pig-
mented forms. This shows the added consideration that has to be
taken to improve outcomes in PDT.
6. Treatment of infections in the head and neck region
PACT (Photodynamic anti-microbial chemotherapy) has shown
activity against bacteria, fungi, viruses and protozoa. The broad
spectrum of action including the efﬁcient inactivation of antibi-
otic-resistant strains seems to be a major beneﬁt. Resistance seems
not to be a major factor as the active singlet oxygen and free rad-
icals may interact with several metabolic pathways [37,38]. HPD,
toluidine blue, methylene blue as well as poly-L-lysine-chlorin(e6)
conjugate have all been mentioned as promising candidates for use
in this potential application [20]. Dental practice bioﬁlms have
been shown to be sensitive in varying degrees to PACT. The poten-
tial use of this application in the treatment of common periodonti-
tis, peri-implantitis, caries and in the sterilization of the root canal
in endodontic treatment is signiﬁcant. Erythrosine seems to be
more effective than others in eradicating Streptococcus mutans
[39]. Further potential applications in this ﬁeld are virtually limit-
less. However, investigations in our laboratories recently indicated
that the sensitivity even of closely related oral bacteria to various
photosensitizers and PACT may be quite different (Besic Gyenge
et al., submitted for publication). We therefore propose that for
the treatment of multispecies pathogen populations the applica-
tion of photosensitizer combinations for PACT may be useful.
7. Complications
Some of the potential complications of PDT have been discussed
already. A recent report by Procianoy et al. [40] highlighted the po-
tential caution one has to take in patients suffering fromXeroderma
pigmentosum, a down regulation of DNA repair mechanism disor-
der. In this case there was clear aggravation of the malignant pro-
cess after PDT. A potential further suppression of the DNA repair
process was postulated as possible explanation of this event. Recent
in vitro investigations of our own group using prostate cancer cells
as model system also revealed a down regulation of several genes
associated with DNA repair mechanisms after mTHPC-mediated
PDT (Rossi et al., in preparation). Pain management problems have
regularly been reported and remain a challenge. Remifentanil is of-
ten used to cover the peri-operative intense treatment pain prob-
lems. In opiate tolerant patients clonidine may be a useful
adjunct. Speciﬁc anaesthetic challenges have been identiﬁed, espe-
cially regarding the protection of patients against undue light expo-
sure and ensuring a safe anaesthesia to patients requiring such a
service [41]. Skin protection by the use of textiles or cream is vitally
important in the perioperative period of potential phototoxicity.
8. The future of PDT
Much of the future of PDT depends on the ease of use, cost
effectiveness as well as the treatment outcomes and quality of life
compared to conventional treatments.
One of the major problems in head and neck surgery is the dif-
ﬁculty in predicting the responders from the non responders. This
concerns especially the early carcinomas. One possible reason for
the rate of non responders is the under staging of the tumors
[30], especially in areas where ultrasound diagnostics may be dif-
ﬁcult. Clearly one cannot only rely on the biopsy specimen as it
may not be representative of the whole tumor. For oncological
safety reasons one would like to include a margin of healthy tissue
and this has to be taken into account in the planning phase of PDT,
especially regarding the deepest part of tumor inﬁltration.
Future increased use of PDT can be expected especially with
development of photosensitizers with high absorption at longer
wavelengths leading to deeper penetration and thus the possibility
to treat larger tumor volumes. Selective absorption is another key
issue that can still improve considerably along with the problem-
atic post treatment photosensitivity by decreasing the half-life of
such developed drugs. Liposomal mTHPC may play such a role in
the future. Currently this drug has been limited to the successful
use in the treatment of feline squamous cell carcinoma [42].
In dire need is the scientiﬁc establishment of treatment proto-
cols. The wide differentiation of photosensitizer concentrations,
lighting protocols regarding both total dose as well as ﬂuence rates
may lead to a multiple of unsuccessful treatments before a partic-
ular unit can establish a clinically proven protocol. One of the
emerging ﬁelds of application is PDT targeting. Photosensitizers
can be locked onto a delivery vehicle for instance a molecule with
high afﬁnity for the target. This will lead to more selective treat-
ment of the target area [43].
Of course the reverse may also be possible where photosensitiz-
ers can be used to deliver bioactive molecules including genes, into
cells [44].
Quantum dots have also recently come to our attention [45].
These products can be used as photosensitizers in PDT. One major
potential beneﬁt in the use of quantum dots is their tunable optical
properties and surface chemistries resulting in the possible use to
sensitize other PDT agents or even molecular oxygen through an
energy transfer process.
In a different class of application of photodynamic interaction is
the uncaging of drugs or other biologic agents. The encaged
structure is internalized by the target cell and upon photo activation,
the capsule disrupted and the biologic active agent released [43].
9. Summary
Photodynamic therapy in the head and neck region is still being
regarded as an emerging treatment modality. This is probably due
to the lack of established treatment protocols as well as the major
changes and dynamics in the ﬁelds of lighting and photosensitizers
which may result in initial poor results. With traditional treatment
modalities surgeons regard incomplete response as a treatment
failure. Although to a certain extent it also holds true for PDT
one mostly still has another opportunity for further retreatment
or change to another treatment modality like surgery or radio-
chemotherapy.
When evaluating the literature many of the problems that have
been retarding growth in the PDT ﬁeld has been or is being ad-
dressed by further development of photosensitizers and light
sources. On the horizon there is hope for much improved tumor
selectivity by the way of attachment of photosensitizers to nano
particles with the ability to ﬁx to speciﬁc marker molecules.
So it would seem as if PDT in the head and neck ﬁeld is indeed
promising and rapidly expanding to a ﬂexible treatment modality
with signiﬁcant added beneﬁts to our patients.
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